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Summary
A large body of work generated using mouse models indicates that the immune system has 
the capacity to recognise and eliminate tumour cells. However, it has been suggested that a 
population of T cells, named CD4+Foxp3+ regulatory T cells (Treg), hamper effective anti­
tumour immunity. A substantial enrichment of Tregs is observed within carcinogen 
(methylcholanthrene, MCA) induced murine tumours. Furthermore, depletion of Tregs in 
mice given MCA significantly reduces tumour induction.
To investigate the role of Tregs in anti-tumour immunity a detailed characterisation of 
tumour-infiltrating lymphocytes (TIL) from MCA induced tumours was performed. These 
experiments showed that control of tumour growth following Treg cell depletion is dependent 
on CD8+ cells. The ratio of Tregs to conventional CD4+ T (Tconv) cells and particularly 
CD8+ T cells altered within the tumour to favour immune suppression. Furthermore, tumour- 
infiltrating Tregs displayed a phenotype associated with immunosuppression whereas only a 
small fraction of tumour-infiltrating Tconv and CD8+ T cells appeared activated. Together 
these findings support the hypothesis that Tregs accumulate within tumours and gain control 
of T cells preventing anti-tumour immunity.
Evidence exists to suggest that soluble factors subvert anti-tumour immunity by converting 
tumour-infiltrating Tconv cells into Tregs. To address this issue, the T cell receptor (TCR) 
repertoires of Tregs and Tconv cells within the MCA induced tumours were analysed. The 
TCR repertoires of Treg and Tconv cells were found to be largely distinct suggesting that 
conversion between these two T cell populations does not readily occur. However, it was 
found that tumour specific proliferation and survival of Treg cells may instead account for 
their accumulation in tumours. These studies indicate that identification of factors causing 
preferential proliferation and survival of Treg cells in tumours may enable the inhibition of 
their suppressive effects. The findings of this thesis are important for the rational design of 
cancer immunotherapeutic strategies.
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Chapter 1 -  Introduction
1.1 Tumour development
1.1.1 Tumourigenesis
The development of cancer in humans is a multistep process that usually occurs over many 
decades. This process is the result of an accumulation of numerous mutational and epigenetic 
changes that drives the progressive transformation of normal cells into malignant neoplastic 
derivatives. It is widely believed that during tumourigenesis most, if not all, types of cancers 
must attain a catalogue of fundamental alterations termed “acquired capabilities” (Hanahan 
and Weinberg 2000, Hahn and Weinberg 2002). These are required for the neoplasm to evade 
programmed cell death (apoptosis), develop angiogenic ability, resist anti-growth signals, 
generate mitogenic signals, replicate limitlessly, and invade neighbouring tissue / metastasise 
(Figure 1.1).
1.1.2 Cancer immunosurveillance
The role of the immune system in tumour development has been ardently debated for many 
decades (reviewed in Dunn et al. 2002). In 1909, Paul Erhlich was amongst the first to 
propose that the host immune response could protect from neoplastic disease. However, it 
was not until the second half of the 20th century that this hypothesis was extensively 
investigated. Following the development of inbred strains of mice, and thus the ability to 
successfully carry out graft transfers between syngeneic mice, it was possible to test whether 
tumour tissue was more immunogenic than normal tissue. Indeed, it was ultimately shown 
that mice could be immunised against syngeneic implants of tumours demonstrating the
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Figure 1.1. Acquired capabilities required for tumour development.
It is currently believed that most if not all tumours have acquired a number of capabilities to 
become tumourigenic. Six of these acquired capabilities (evading apoptosis, self sufficiency 
in growth signals, insensitivity to anti-growth signals, limitless replication potential, tissue 
invasion and metastasis, and sustained angiogenesis) are commonly considered as hallmarks 
of cancer. An accumulation of evidence now suggests that another capability could be 
included in this list: the ability to overcome effective anti-tumour immunity. [Adapted from 
The Hallmarks of Cancer Cell, Volume 100, Issue 1, Pages 57-70]
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principle that tumours possessed tumour-specific antigens which could induce robust immune 
responses (reviewed in Old and Boyse 1964, Klein 1966). During the emergence of these and 
other findings Macfarlane Burnet formally proposed the concept of “immunological 
surveillance” of cancers, whereby the immune system is able to recognise and eliminate or 
inactivate potentially dangerous mutant cells that arise in the host (Burnet 1970, 1957). Since 
then, an extensive body of evidence from mouse studies and clinical observations has 
developed which strongly supports the notion that a process of cancer immunosurveillance 
functions to protect the host from the development of cancer.
Much of the evidence to support cancer immunosurveillance has come from studying tumour 
occurrence in various strains of genetically altered, immune deficient rodents (particularly 
mice; Dunn et al. 2002, 2004, and discussed below). For these studies many different models 
of tumour occurrence have been used. These include spontaneous tumour development in 
wild type animals, spontaneous tumour development in animals genetically predisposed to 
tumour formation (such as p53'7' mice), tumour induction by chemical carcinogens and 
growth of transplantable tumour cell lines in recipient mice. The most commonly used model 
of tumour formation for studying cancer immune surveillance is chemical induction with the 
carcinogen 3-methylcholanthrene (MCA).
1.1.2.1 Methylcholanthrene induced tumour development
The induction of tumours by methylcholanthrene has been extensively used to study 
carcinogenesis and particularly tumour immunosurveillance, in vivo (reviewed in Schreiber 
and Podack 2009). Typically experimental mice are injected with 50-400jng of 
methylcholanthrene subcutaneously or intra-muscularly and after 100-200 days the mice
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develop palpable fibrosarcomas at the injection site (van den Broek et al. 1996, 2000a, 
Smyth, Crowe and Godfrey 2001, Takeda et al. 2002, Qin et al. 2002). Methylcholanthrene is 
a polycyclic aromatic hydrocarbon (PAH) (reviewed in DiGiovanni 1992). PAHs are organic 
compounds found in environmental pollutants and appear to contribute to cancer in humans 
(reviewed in Boffetta, Jourenkova and Gustavsson 1997). The process of toxification and 
detoxification of PAHs such as methylcholanthrene is complex requiring multiple enzymes 
such as cytochrome P450 for activation (reviewed in DiGiovanni 1992). Resulting 
metabolites are believed to cause damage to the nucleotide base structure of DNA at random 
sites within the genome of somatic cells.
In experimental mice the local response following MCA insult resembles that of a wound 
healing process (Blankenstein and Qin 2003). Extensive cell death and inflammation occurs. 
Fibroblasts accumulate at the injection site surrounding the MCA fibres. These fibroblasts 
secrete extracellular matrix, encapsulating the MCA, causing fibrosis and detoxifying the 
MCA. However, during this effort to protect the host from MCA the fibroblasts are exposed 
to the genotoxicity of MCA and often become transformed, potentially cancerous cells. 
Presumably these mutated cells become tumours if and when sufficient oncogenic mutations 
have occurred. Examples of the mutations noted in MCA induced tumours include mutations 
in protooncogenes like ras and tumour suppressor genes like p53 (Halevy et al. 1991, 
Watanabe et al. 1999).
Using the model of MCA induced tumours to study tumour development offers many
advantages over other models. For example, for tumours to establish in experimental mice
injected with MCA the mutated cells must first overcome all the biological obstacles
necessary for tumour development whereas transplantable cell lines have already established
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these “acquired capabilities” prior to injection. However, the obvious advantages of 
transplantable cell lines, that is, that they are easier and quicker experimentally, make them 
popular. In contrast monitoring for development of spontaneous tumours can be a slow 
process, ultimately leading to increased mouse housing costs and less flexibility in 
experimental set ups. Furthermore, in contrast to spontaneous tumours, with MCA, tumour 
occurrence is restricted to a particular, easy to monitor site (the injection site).
1.1.2.2 Susceptibility o f immuno-compromised mice to tumour development
Many components of the immune system have been implicated in having a role in the 
development of tumours (reviewed in Dunn et al. 2002, 2004). The susceptibility of immuno­
compromised (often “knockout”) mice to tumour development has particularly helped to 
identify specific cell types or molecules of the immune system which may be involved in 
tumour immunity. Cells of the adaptive arm of the immune system appear important, 
suggesting the recognition of tumour specific antigens. Mice lacking RAG-2 (or RAG-1) are 
unable to rearrange their antigen-receptor genes and as a result the development of T cells, B 
cells and NKT cells is arrested leaving RAG'7' mice without mature lymphocytes (Shinkai et 
al. 1992). Experiments performed by Shankaran et al., (2001) showed that RAG'7' mice 
developed spontaneous tumours more readily than wild type (WT) controls. Furthermore, 
RAG'7' mice were also found to be highly susceptible to MCA induced tumour development 
(Shankaran et al. 2001, Smyth et al. 2001). Similarly, Jal8'7' mice lack Val4Jal8 expressing 
invariant NKT cells and have been shown to develop MCA-induced sarcomas at two to three 
times higher frequency than WT controls (Cui et al. 1997, Smyth et al. 2000a). Innate 
immune cells, such as NK cells and y8 T cells, may also contribute to tumour immunity in 
response to stress or danger signals induced in the tumour microenvironment. Depletion of
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NK cells with either anti-NKl.l or anti-asialo-GMl monoclonal antibodies can increase 
MCA susceptibility (Smyth et al. 2001). Also, TCRy'7' (which lack y8 T cells) are more 
susceptible to MCA induced tumour formation compared to control mice (Girardi et al. 2001, 
Gao et al. 2003). Together these data suggest that lymphocytes are important for protecting 
mice against chemically induced and spontaneous tumours.
Many of the effector molecules utilised by cells of the immune system appear to mediate 
tumour suppression. For example, mice deficient of the IFNy receptor 1 or IFNy are more 
prone to MCA-induced sarcomas (Street, Cretney and Smyth 2001, Shankaran et al. 2001, 
Kaplan et al. 1998). Likewise, mice lacking IFNy are also more susceptible to spontaneous 
lymphomas and lung adenocarcinomas (Street et al. 2002). Another important immune factor 
implicated in tumour immunity is the cytolytic molecule perforin. Mice deficient of perforin 
were found to be more prone to MCA induced tumour development as well as spontaneous 
disseminated lymphomas (van den Broek et al. 1996, Smyth et al. 2000b, Street et al. 2001). 
Finally, there is also evidence to suggest that enhancing immune system activity can reduce 
tumour development. For example, Noguchi et al., (1996) demonstrated that treatment of 
mice with the powerful T and NK cell-stimulatory cytokine, IL-12 significantly delayed 
tumour appearance and ultimately reduced tumour incidence.
1.1.3 Evidence for cancer immunosurveillance in humans.
There is also evidence to support the existence of an immunosurveillance process in humans 
(reviewed in Dunn et al. 2002, 2004). Three main lines of evidence exist: immuno­
compromised humans are more susceptible to cancer; there is a strong correlation between
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the infiltration of immune cells and patient prognosis; cancer patients can develop 
spontaneous immune responses to tumours.
1.1.3.1 Susceptibility o f immuno-compromised humans to cancer
Studies show that individuals with congenital or acquired immune deficiencies are more 
susceptible to tumours of viral origin such as Kaposi’s sarcoma, non-Hodgkin’s lymphoma 
and cancers of the anal and urogenital tract (Gatti and Good 1971, Penn 2000, Boshoff and 
Weiss 2002). However, a true indicator of a tumour immunosurveillance process in humans 
would be to observe an increased incidence of tumours of non-viral origin in these 
individuals. Unfortunately, this is confounded by the fact that these people are far more 
susceptible to lethal viruses and pathogens as well as tumours of viral origin thus not 
allowing the opportunity for the development of spontaneous tumours. Nevertheless, in 
support of the immunosurveillance notion, a number of studies have shown that transplant 
recipients on immunosuppressive drugs display a higher incidence of non viral cancers 
compared to age matched controls (Birkeland et al. 1995, Penn 1996, Pham et al. 1995). It is 
worth noting that not all studies have found this to be the case but an overall examination of 
epidemiological data does suggest an increase in (non viral) tumour incidence in patients 
receiving immunosuppression. The reasons for the increased incidence appear to be two fold. 
Firstly, these patients have an increased susceptibility to developing tumours de novo, 
presumably as a result of reduced recognition or elimination of aberrant cells. However, it has 
also been observed in a number of cases that the transplantation of an organ, accompanied by 
an immunosuppressive regime, has allowed for the outgrowth of an occult tumour previously 
kept dormant by the donor’s intact immune system. A recent example reported the transfer of
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a fatal melanoma transferred in a donated kidney 16 years after the donor had melanoma 
surgery (MacKie, Reid and Junor 2003).
1.1.3.2 Correlation between the presence o f tumour infiltrating immune cells and patient 
prognosis
Another indicator that the immune response influences the behaviour of human tumours is 
the strong correlation between the presence of immune cells infiltrating tumours and 
increased patient survival (reviewed in Dunn et al. 2004). The infiltration of effector T cells 
has been associated with a better prognosis in patients with melanoma (Clark et al. 1989, 
Clemente et al. 1996, Mihm, Clemente and Cascinelli 1996), ovarian carcinoma (Zhang et al. 
2003), colorectal cancer (Naito et al. 1998, Ohtani 2007) and oesophageal carcinoma 
(Schumacher et al. 2001). Similarly the presence of NK cells correlated with the survival of 
patients with gastric carcinoma (Ishigami et al. 2000), squamous cell lung carcinoma 
(Villegas et al. 2002) and colorectal cancer (Coca et al. 1997). One of the most convincing 
studies to date, demonstrated that the type, density and location of immune cells in colorectal 
tumours was a better predictor of patient prognosis than the histopathological methods 
current used for staging cancers (Galon et al. 2006).
1.1.3.3 Spontaneous development o f immune responses to tumours
Another factor that suggests the immune system can influence tumour growth in humans is
the spontaneous development of immune responses to tumours in patients. A large range of
immunogenic human tumour antigens has now been identified. Exemplifying this, the human
cancer immunone database (CIDB) has been established for cataloguing these human tumour
antigens and now contains well over 1000 entries. These antigens have been identified by the
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characterisation of tumour specific antibodies or T cells isolated from cancer patients. The 
serological expression cloning technique (SEREX) developed by Pfreundschuh and 
colleagues (Sahin et al. 1995) has significantly helped to expand the list of antigens 
recognised by the humoural immune response in humans. A second example of spontaneous 
immune responses to tumour antigens in humans is that seen in paraneoplastic neurologic 
disorder/degeneration (PND). This autoimmune disorder is thought to be caused by the 
formation of an antitumour immune response that cross reacts with cells of the nervous 
system (reviewed in Albert and Darnell 2004). Most commonly associated with tumours of 
the breast, lung and ovary, PND patients harbour high titers of antibodies against neuronal 
antigens that are present both in the neuronal cells affected and the accompanying tumour. 
Interestingly, patients with PND often present with neurodegenerative symptoms and at the 
time are unaware they have cancer, yet with time are found to harbour small tumours. Thus it 
appears that an immune response to neuronal antigens expressed by the tumour cells 
recognise and suppress the growth of the malignancy. This phenomenon becomes apparent in 
patients with PND when the immune response also recognises neuronal cells expressing the 
same antigens leading to autoimmunity and neurological symptoms. A number of recent 
papers have demonstrated that PND patients possess CD8+ CTLs specific for neuronal 
antigens such as CDR2 and HuD, and that these T cells can kill target cells in vitro 
(Santomasso et al. 2007, Roberts et al. 2009). However, it is worth noting that although 
patients with PND generally have a more benign cancer course than patients without PND, 
only 10% of PND patients appear tumour free thus the anti-tumour immune response in these 
patients is, at best, incomplete.
Finally, there is also evidence showing that cells of the innate immune arm can specifically
recognise tumours in human patients. One primary example of this involves the proteins
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MICA/B (MHC class I chain-related proteins A and B) which have been found to be 
expressed on many, but not all, human tumours (Groh et al. 1999, Vetter et al. 2002, Jinushi 
et al. 2003). These proteins act as ligands for two receptors expressed on cells of the innate 
immune system: NKG2D on NK cells and most human y8 T cells and the T cell receptor on 
V81 y8 T cells. It has been demonstrated, in vitro, that tumour cells expressing NKG2D 
ligands can be killed by NK cells and y8 T cells and that this killing required the activity of 
the NKG2D receptor and/or the y8 TCR. Two independent studies also showed there is a 
strong correlation between the expression of MICA/B on tumours and a) tumour infiltration 
by V81 y8 T cells (Salih, Rammensee and Steinle 2002) and b) NKG2D on tumour 
infiltrating lymphocytes (Groh et al. 1999).
In summary, it is clear that many patients can develop immune responses that recognise the 
tumours they bear. These spontaneous immune responses of the innate and adaptive immune 
system observed in cancer patients shed light on the possible mechanisms used by the 
immune system to recognise tumours and support the idea of immunosurveillance in humans. 
However, in cancer patients the immune responses observed are clearly unsuccessful as the 
process of immune surveillance has failed to eliminate the tumour. Thus, the existence of 
cancer immunosurveillance in humans remains likely but unproven.
1.1.4 Cancer immunoediting
Despite evidence that a plethora of immune effector functions contribute to tumour 
immunosurveillance, tumours do arise in immunocompetent “normal” hosts. This clinical 
reality may initially seem paradoxical to the immunosurveillance theory. However, it has 
been suggested that the immune system actually has a dual effect in tumour development.
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Not only does it eliminate aberrant, potentially cancerous cells but the same immune pressure 
may ultimately promote the outgrowth of poorly immunogenic tumour cell variants. This 
hypothesis has been termed cancer immunoediting (reviewed in Dunn et al. 2002, 2004, 
Smyth, Dunn and Schreiber 2006).
Evidence to support this extended theory comes from observations that tumours derived from 
immuno-compromised mice are more likely to be rejected when transferred to 
immunocompetent hosts. This suggests that the immune system can influence the 
immunogenicity of developing tumours. For example, Shankaran et al., (2001) found that 
MCA tumours established in the absence of T cells are more immunogenic that those 
originating in an intact immune system. Specifically they found that tumours developed from 
RAG-2'7" mice and WT mice have the same ability to establish themselves and showed 
similar growth kinetics when transplanted into RAG-2'7' recipients. Conversely, the majority 
(8 of 20) of RAG-2"7' tumours were rejected when transplanted into immuno-competent WT 
mice. Similar findings have been made using tumours developed in nude, SCID, NKT cell 
deficient and perforin knockout mice (Svane et al. 1996, Engel et al. 1997, Smyth et al. 
2000a, Street et al. 2002). Thus tumours derived in hosts with an intact immune system are 
less immunogenic than tumours derived from mice without a complete immune system. 
Together this suggests that the immune environment in which a tumour grows sculpts the 
developing tumour, favouring the outgrowth of less immunogenic forms.
Cancer immunoediting is proposed to occur in three sequential phases -  elimination,
equilibrium and escape (Figure 1.2). The elimination phase represents the immune
surveillance of tumours described above. However, cells that manage to evade elimination
enter a period of equilibrium. This is a period of dynamic interaction between the host
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Figure 1.2. The 3 E’s of cancer immunoediting.
Cancer immunoediting is proposed to occur in three phases. The first phase (A) is analogous to classical cancer 
immunosurveillance whereby occult cells are recognised and eliminated by innate and adaptive immune responses. A period of 
equilibrium (B) may also be entered through cycles of genetic instability and immune selection where cancer cell growth and 
immune deletion are at equilibrium. This period, which may last many years in humans, could ultimately result in deletion of all 
pre-cancerous cells or the escape of variants which have managed to avoid detection and/or elimination by the immune system. 
The escape phase (C) describes the uncontrolled growth of cancer cells leading to a palpable tumour. Th = T helper cell; CTL = 
cytotoxic T cell; NK = NK cell; y5T = gammadelta T cell; Treg= regulatory T cell; flashes represent aberrant cells. Adapted from 
Tumour microenvironments, the immune system and cancer survival. Strausberg, 2005. Genome Biology, 6(3) p211.
immune system and the tumour, resulting in an apparent dormancy where tumour expansion 
is kept in check. This phase may last up to several years in humans and can lead to three 
possible outcomes: eventual elimination of the tumour, permanent maintenance in 
equilibrium, or tumour escape, where tumour cell variants emerge from the equilibrium phase 
and present as clinically detectable, progressively growing tumours. Perhaps the most 
compelling evidence for the existence of an equilibrium phase in tumour development was 
provided in a recent report from Robert Schreiber’s laboratory (Koebel et al. 2007). Using 
chemically induced (MCA) murine tumours, this report demonstrated that tumour cells can 
exist in an occult state where they are kept in check by the immune system and that these 
cells can become edited and spontaneously escape immune control. In immunocompetent 
hosts tumour escape represents the outgrowth of a tumour that is able to either resist immune 
detection, resist elimination by the immune system, or induce immune suppression and thus 
tolerance of the tumour. Thus overcoming the host immune defences may represent an 
additional barrier for a tumour to overcome (Figure 1.1).
1.1.5 Escape mechanisms
Tumour escape is the process wherein the immunologically sculpted tumour expands in an 
uncontrolled manner in the immunocompetent host (Dunn et al. 2002). During the 
equilibrium phase, through a process akin to Darwinian selection, tumour variants emerge 
with mutations providing them with increased resistance to immune attack. Ultimately, 
enough genetic or epigenetic changes occur in the tumour cells leading to variants that have 
acquired insensitively to immune detection and/or elimination. Since both innate and adaptive 
immunity have been shown to be important for tumour control, it is likely that escape variants
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have acquired mechanisms to overcome both arms of the immune system. For this, individual 
tumour cells may have obtained multiple mechanisms for immune evasion.
Several mechanisms of immune escape have been demonstrated in tumours. At the tumour 
cell level, alterations in the recognition of tumour cells have been shown. Tumour cells can 
lose the expression of antigen or downregulate MHC molecules which present antigen to 
immune cells (reviewed in Campoli and Ferrone 2008). It is known that tumour cells can 
shed NKG2D ligands (such as MICA) releasing soluble ligands which may attenuate the 
function of NKG2D on host immune cells (Groh et al. 2002). Furthermore, Kaplan et al., 
(1998) demonstrated that insensitivity to IFNy can affect tumour immunogenicity in mice and 
that certain types of human tumours are insensitive to IFNy. IFNy insensitivity may prevent 
both immune detection and/or destruction. Evasion of immune destruction may also occur 
through generation of defects in death receptor signalling, for example TRAIL (Takeda et al. 
2001). Another example of evasion of immune destruction is the expression of anti-apoptotic 
factors, a major capability demonstrated in many tumours (reviewed in Lowe and Lin 2000, 
Kim, Emi and Tanabe 2006a).
Tumour immune escape may also occur through the generation of immunosuppressive
cytokines. The tumour microenvironment is thought to be an immunosuppressed
environment. This is demonstrated by early experiments performed in Robert North’s group
displaying concomitant immunity (Berendt and North 1980, North and Bursuker 1984). This
is the apparently paradoxical immune status where tumour rejection at a secondary tumour
site coincides with tumour growth at the primary site. These experiments suggest that an
immunosuppressive environment is established at the primary site which prevents the
immunity present within the mice as clearly displayed by the rejection of the tumour at the
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secondary site. This immunosuppressive environment may be established by the expression 
of immunosuppressive cytokines, such as IL-10 and TGFp, from tumour cells or other cells 
within the tumour environment. An example of another cell type found within the tumour 
environment which may produce immunosuppressive cytokines is regulatory T cells 
(Sakaguchi et al. 2001). These cells are found in numerous types of murine and human 
tumours and were also shown by Robert North’s group to cause the loss of concomitant 
immunity to tumours (North and Bursuker 1984). These cells may inhibit immune responses 
to tumours by the production of immunosuppressive cytokines such as IL-10 and TGFp but 
have also been shown to have other mechanisms of immune suppressive activity (these will 
be discussed in detail below).
1.1.6 Cancer and inflammation
There is also evidence to show that the immune system not only has anti-tumour effects but 
to the contrary it may promote tumour development. Another pioneer in medical science, 
Rudolf Virchow, is attributed with being the first to suggest that inflammation supports 
cancer (reviewed in Balkwill and Mantovani 2001). In 1863, Virchow noted that neoplastic 
tissues are often infiltrated by leukocytes and suggested that this infiltrate reflected the origin 
of cancer at sites of inflammation. There is now increasing evidence to suggest that 
inflammation can indeed promote tumour development. Indeed, there is sufficient evidence 
for it to be proposed that an inflammatory environment represents an alternative 7th hallmark 
of cancer (Colotta et al. 2009). Proinflammatory cytokines such as IL-1, IL-6 and in 
particular TNFa have been shown to be present in many tumours and are associated with 
tumour progression. These and many other cytokines/chemokines are induced by hypoxia, a 
major physiological difference between normal and malignant tissue. The inflammatory
24
infiltrate in tumours can comprise primarily of macrophage secreting factors promoting 
tumour cell growth/survival, angiogenesis and metastasis. Furthermore, tumour associated 
dendritic cells are usually of an immature phenotype with defective ability to stimulate T 
cells. Interestingly, inhibition of the inflammatory cytokine TNFa with the drug etanercept 
showed possible clinical activity in a clinical trial with ovarian carcinoma patients 
(Madhusudan et al. 2005) and the use of non-steroidal anti-inflammatory drugs (NSAIDS) 
has been shown to reduce cancer risk (Thun et al. 1993, Langman et al. 2000, Steinbach et al. 
2000).
1.2. Regulatory T cells
1.2.1 Preventing autoimmunity
The immune system has evolved to protect the host by combating invading pathogens. Cells 
of the adaptive immune system, namely T and B cells, contribute to this process and are able 
to recognise a plethora of antigens. During development in the thymus (T cells) and bone 
marrow (B cells) lymphocytes that recognise self antigens (autoreactive) are eliminated by a 
process called clonal deletion (Janeway et al. 2001). However, this process is not completely 
efficient and self-reactive lymphocytes can be detected in the periphery of normal 
individuals. Despite this, in healthy individuals these potentially hazardous lymphocytes 
appear to be maintained in an inactive state. It is now recognised that regulatory T cells 
(Treg) are a cardinal cell type involved in preventing autoimmunity. However, their 
establishment to such distinction has been onerous (reviewed in Germain 2008).
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1.2.2 Historical perspective of Tregs
In the early 1970s evidence began to emerge showing that T cells were not only able to elicit 
positive effects on immune responses but were also capable of limiting immune responses 
(Baker et al. 1970, Okumura and Tada 1971, Droege 1971, Gershon and Kondo 1971). These 
negatively acting cells were dubbed suppressor T cells and were suggested to be a specialised 
subset of T cells (Vadas et al. 1976, Cantor, Shen and Boyse 1976, Okumura et al. 1977). 
Suppressor T cells were intensely studied by researchers during the 1970s and early 1980s 
becoming an accepted part of immunology. However, as techniques in molecular biology 
improved, a succession of flawed and negative studies on suppressor T cells led to a complete 
lack of confidence in the suppressor T cell field. Publication of papers in the area declined 
and funding for research into suppressor T cells was severely restricted ultimately leading to 
a loss of momentum in suppressor T cell research.
The renaissance in the suppressor T cell field took off following the publication of work from 
Shimon Sachaguchi’s lab in 1995 which identified CD25 as a marker for these cells 
(Sakaguchi et al. 1995). This article demonstrated that the inoculation of athymic nude mice 
with spleen and lymph node cell suspensions depleted of CD25+ cells caused severe multi­
organ autoimmunity within 2 weeks and even death in 30% of the mice within 3 weeks. 
These data added to recent findings suggesting that a subset of T cells with certain 
activation/memory cell markers could protect from autoimmune disease in mice (Powrie and 
Mason 1990, Powrie et al. 1993). Further studies supported the existence of suppressor T 
cells, now more commonly known as regulatory T cells, by showing that CD4+CD25+ cells 
could limit TCR induced expansion of CD4 and CD8 T cells in vitro (Thornton and Shevach 
1998). These experiments were promptly repeated using human CD4+CD25+ cells providing
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evidence for regulatory T cell activity within the human immune system (Stephens et al. 
2001, Ng et al. 2001, Taams et al. 2001).
A further advancement in the field of regulatory T cells was the discovery that the 
transcription factor Foxp3 played a critical role in the development and/or function of Tregs 
(Hori, Nomura and Sakaguchi 2003, Fontenot, Gavin and Rudensky 2003) and that Foxp3 
expression could be a useful marker for distinguishing these cells (Fontenot et al. 2005c; 
discussed below). Perhaps the most persuasive evidence that Foxp3+ cells were important for 
maintaining immune homeostasis was the dramatic autoimmune phenotype observed from 
the lack of functional Foxp3 in scurfy mice and humans with IPEX (Wildin et al. 2001, 
Bennett et al. 2001, Brunkow et al. 2001, Khattri et al. 2003).
1.2.3 Generation of Tregs
CD4+CD25+Foxp3+ Tregs make up about 5-10% of the CD4 T cell population in naive mice 
and around 1% of all CD4+ T cells in normal humans. It is widely thought that the majority of 
Tregs are generated in the thymus as part of normal T cell development as a consequence of 
recognition of self antigen. These thymically generated Tregs are termed naturally occurring 
Treg (nTreg). Tregs may also be generated in the peripheiy as a consequence of activation of 
mature precursor T cells (reviewed in Bluestone and Abbas 2003). Distinguishing these cells 
from nTregs, these peripherally generated Tregs have been termed adaptive or induced Tregs.
1.23.1 Thymic production o f nTregs
Evidence from studies in mice suggests that nTregs emerge from the thymus as a functionally
mature and distinct T cell subpopulation (reviewed in Sakaguchi 2004). Firstly, it has been
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shown that both nTregs in the periphery and CD4+CD25+CD8' thymocytes express Foxp3 
(Hori et al. 2003, Fontenot et al. 2003). Secondly, a lack of Foxp3 abrogates both populations 
(Fontenot et al. 2003). Furthermore, both peripheral CD4+CD25+ Tregs and 
CD4+CD25+CD8' thymocytes are phenotypically and functionally the same. That is, they 
constitutively express CTLA-4 (Annunziato et al. 2002) and GITR (Shimizu et al. 2002), are 
anergic in vitro and have similar suppressive activities in vitro (Itoh et al. 1999).
It also appears, at least in rodents, that the thymic production of nTregs is temporally distinct 
to other T cells. Experiments initially suggesting this date back to the late 1960s when 
Nishizuka and Sakakura (1969) noticed that thymectomy of neonatal mice 3 days after birth 
resulted in the development of autoimmunity, in particular destruction of the ovaries. Later 
studies suggested that this was the result of a lack of suppressor (regulatory) T cells (Asano et 
al. 1996). More recently, a study using mice expressing the fluorescent marker GFP in 
Foxp3+ cells supported these early findings (Fontenot et al. 2005a). The study showed that 
the percentage of CD4+CD8' thymocytes expressing Foxp3 slowly rose from <0.1% at 12 
hours post birth to -4% 21 days after birth. However, in concurrence with the day 3 
thymectomy data, the increase is not steady and a significant increase in the percentage of 
CD4+CD8' thymocytes expressing Foxp3 occurs between days 3 and 4 post birth.
The mechanism that leads to the development Tregs in the thymus is not well understood. In
particular, the role of the T cell receptor (TCR) specificity in directing thymic precursors to
become conventional T cells (Tconv) or Tregs remain unclear. Many studies, often using
TCR transgenic mice, have suggested that the thymic development of Treg requires unique
TCR interactions with self-peptide MHC complexes expressed on thymic stromal cells (Itoh
et al. 1999, Jordan et al. 2001, Kawahata et al. 2002, Bensinger et al. 2001). Together these
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studies indicate that, compared to the thymic selection of conventional T cells, the 
development of Tregs is facilitated by relatively high TCR avidity interactions with self­
peptide MHC complexes. Nonetheless this avidity must not be so high as to lead to their 
deletion. These findings also form the basis of an opinion that Tregs predominantly recognise 
self antigens (discussed below).
Interactions via accessory molecules may also be important in the thymic development of 
Tregs. For example, mice deficient of CD28, B7, CD40, or mice treated with CTLA-4-Ig 
contain fewer Tregs (Salomon et al. 2000, Kumanogoh et al. 2001). These accessory 
molecules may contribute by increasing the avidity of the interaction between the thymic 
precursor and stromal cell. These interactions may also be important for the peripheral 
maintenance of Treg.
1.2.3.2 Peripherally induced, adaptive Tregs
In mice, Tregs can also be generated from mature T cell populations in the periphery {in vivo) 
under certain conditions of antigenic stimulation (Kretschmer et al. 2005, Apostolou and von 
Boehmer 2004, Thorstenson and Khoruts 2001) or following the adoptive transfer of non- 
regulatory T cells (Curotto de Lafaille et al. 2004). It is also possible to induce the up- 
regulation of Foxp3 and a suppressive phenotype ex vivo in mouse and human T cells by 
activation of mature T cells usually in the presence of immunosuppressive cytokines such as 
IL-10 and TGFp (Levings, Sangregorio and Roncarolo 2001, Yamagiwa et al. 2001, Barrat et 
al. 2002, Chen et al. 2003, Walker et al. 2003b, Fantini et al. 2004). These Tregs have been 
termed induced or adaptive Tregs (reviewed in Curotto de Lafaille and Lafaille 2009). Like 
all T cells, adaptive Tregs are proposed to initially originate in the thymus but are derived
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from classical T cell subsets or from natural Tregs. Specifically, the distinction between 
adaptive Tregs and naturally occurring Tregs is the requirement of adaptive Tregs for further 
differentiation of a T cell subset post thymic development into a Treg phenotype as a 
consequence of exposure to antigen in a particular immunological context (Bluestone and 
Abbas 2003, Curotto de Lafaille and Lafaille 2009).
Despite the evidence that Treg induction can occur in vitro and to some extent in vivo, the 
relevance of Treg induction in the peripheiy under normal physiological conditions remains 
unclear. Perhaps the best example of Treg induction is in the establishment of oral tolerance. 
Both Coombes et al., (2007) and Sun et al., (2007) showed that tolerance to a harmless non­
self antigen (OVA) involved the induction of Tregs in gut-associated lymphoid tissue 
(GALT). Further evidence for induction of Tregs in the periphery comes from the induction 
of tolerance to transplants (Cobbold et al. 2004) and gut and respiratory mucosa (Curotto de 
Lafaille et al. 2008). Many of the findings have lead to the suggestion that adaptive Tregs 
may possess a TCR repertoire that is directed primarily towards foreign antigens (Bluestone 
and Abbas 2003, Curotto de Lafaille and Lafaille 2009). However, it is not specifically 
known what factors may drive the differentiation of mature T cells into Tregs versus T 
effectors in the periphery. Due to the apparent differences in the differentiation requirements, 
the TCR repertoires and the occurrence of natural and adaptive Tregs, it has been proposed 
that the physiological roles of adaptive and naturally occurring Tregs may be different and 
dependant on the immunological context (Bluestone and Abbas 2003, Curotto de Lafaille and 
Lafaille 2009). It has been proposed that, naturally occurring Tregs, which have suppressive 
activity from inception, function to suppress autoreactive T cells typically in non­
inflammatory settings. Conversely, adaptive Tregs arise in an inflammatory context (such as
30
that caused by infection or inflammatory bowel disease) in order to limit self damaging 
inflammatory reactions.
Evidence to support the peripheral generation of Tregs in humans came from a recent report 
by Vukmanovic-Stejic and colleagues (2006). They showed that Tregs have a high rate of 
turnover in vivo, and are susceptible to apoptosis and senescence yet do not diminish 
throughout life. These data suggest that it is unlikely Tregs are exclusively generated as a 
separate lineage from the thymus which is subject to involution at puberty. Instead their 
studies suggested that antigen specific Tregs were continuously derived from the memory 
CD4+ T cell pool. However, a report since then has shown that the TCR repertoires of Treg 
and Tconv are generally non-overlapping and that only a minority of Treg cells can develop 
from FoxP3“CD4+ non-Treg cells in vivo (Miyara et al. 2009). Thus the existence of natural 
and adaptive Tregs in humans (and mice) is plausible but the in vivo relevance of peripheral 
conversion has not yet been demonstrated.
1.2.4 Treg markers
A deficiency of reliable markers for identifying Tregs has been a hindrance on the analysis of 
Treg since their discovery. Indeed, a wholly reliable surface marker for Tregs still remains 
sought after. In 1995 Sakaguchi’s lab published a landmark paper which identified that a 
small subset of CD4+ T cells that co-expressed CD25 were important for maintaining 
immunological tolerance (Sakaguchi et al. 1995). In these studies it was shown that depletion 
of CD4+CD25+ cells from the T cell pool resulted in widespread autoimmunity when the 
remaining CD4+CD25' cells were transferred into recipient mice. These observations were 
soon supported by the in vitro demonstration that CD4+CD25+ cells were able to suppress T
cell responses (Thornton and Shevach 1998). Soon after, human CD4+CD25+ T cells were 
found to have similar regulatory properties (Stephens et al. 2001, Ng et al. 2001, Taams et al. 
2001). However, the use of CD25 as a marker for Tregs is imperfect because it is also 
transiently expressed on activated non-regulatory cells. Of particular nuisance to researchers, 
CD25 is expressed on activated CD4+ T cells but it is also found on other cell types following 
activation including CD8+ T cells and B cells (Muraguchi et al. 1985, Lowenthal et al. 1985).
As mentioned earlier, at present the best marker for regulatory T cells, especially in mice, is
the transcription factor Foxp3 (Forkhead box protein 3). The importance of this transcription
factor for maintaining immune homeostasis is clearly demonstrated in mice and humans
lacking functional Foxp3. A mutation in the Foxp3 gene in Scurfy mice causes them to
develop severe autoimmunity due to a resultant deficiency in Treg (Brunkow et al. 2001,
Khattri et al. 2003). Similarly, humans with the IPEX (immune dysregulation,
polyendocrinopathy, enteropathy, X-linked) syndrome carry a mutation in Foxp3 which
results in a lack of Tregs and severe multiorgan autoimmunity (Bennett et al. 2001, Wildin et
al. 2001). It was also shown that ectopic expression of Foxp3 in non-regulatory T cells could
confer a suppressive phenotype (Hori et al. 2003, Fontenot et al. 2003). Collectively, these
data and others (Gavin et al. 2007, Kim, Rasmussen and Rudensky 2007, Lin et al. 2007),
clearly show that Foxp3 expression is important for the development and maintenance
(Williams and Rudensky 2007) of Tregs in mice and in humans. However, despite premature
suggestions on the contrary (Fontenot et al. 2005c), it is now recognised that Foxp3
expression alone is not sufficient for commitment to the Treg lineage. In humans it has been
found that Foxp3 is up-regulated, albeit transiently, in activated T cells and may also be
expressed by tumour cells (Ebert et al. 2008, Morgan et al. 2005, Karanikas et al. 2008). In
mice Foxp3 does hitherto appear to be Treg specific. However, recent studies using extensive
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microarray analysis have identified an expression signature for naturally occurring Tregs 
(Sugimoto et al. 2006, Hill et al. 2007). When this was compared to Treg-like cells generated 
under certain conditions they showed that Foxp3 expression alone does not induce a full Treg 
genotype (Hill et al. 2007). This supports reports that Foxp3 is necessary for Treg effector 
function but not lineage commitment (Lin et al. 2007).
The correlation between CD25 and Foxp3 expression in T cells is not uniform. In normal 
mice around 10% of Foxp3+ Treg cells do not express CD25. Similarly, around 10% of 
CD25+ T cells do not express Foxp3. It is believed that these CD4+CD25+Foxp3' cells are 
activated T cells and not Tregs. The correlation of expression of CD25 and Foxp3 in humans 
is more complicated (Roncador et al. 2005). CD25 expression appears to fall into three 
levels; high, intermediate and low/no expression (Baecher-Allan et al. 2001, 2005). Almost 
all CD4+CD25hl T cells express Foxp3, whereas variable percentages of CD4+CD25int T cells 
express Foxp3, usually at lower levels also. Typically, Foxp3 expression is not found in 
CD4+CD25l0/‘ human cells.
Despite its benefits over CD25 as a marker for Tregs a major drawback of Foxp3 as a marker 
for Tregs is its intracellular location. This makes it inaccessible for antibody staining of live, 
unfixed cells. Thus cell sorting, depletion or selection of Tregs based on Foxp3 expression is 
not possible with live T cells from humans or unmanipulated mice. This means that CD25 is 
still quite commonly used to identify Tregs, especially in humans. Recent findings from 
Shimon Sakaguchi’s lab (Miyara et al. 2009) suggest that three functionally distinct 
populations of CD4+Foxp3+ cells exist in humans and that these populations can be 
distinguished based on their expression levels of CD45RA and CD25. Those that were
CD45RA+CD25,nt expressed low levels of Foxp3 and were considered resting Tregs.
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CD45RA'CD25mt cells also expressed low Foxp3 levels and were found to be cytokine 
secreting but non-suppressive. Finally, a subset of cells expressing CD45RA*CD25hl were 
found to express high Foxp3 levels and were found to be terminally differentiated activated 
Tregs. Interestingly, the proportions of these subpopulations were found to vary under 
physiological and disease conditions.
1.2.5 Mechanisms of suppression mediated by Treg
The mechanisms by which Treg suppress immune responses are not yet fully understood. 
Tregs have been shown to suppress using many different mechanisms (reviewed in Vignali, 
Collison and Workman 2008). A table summarising the various markers and molecules 
expressed by Tregs is given below (Table 1.1). These can be categorised into four functional 
groups: suppression by secreting inhibitory cytokines, cytolysis of target cells, suppression by 
metabolic disruption, and suppression by targeting dendritic cells (Figure 1.3). Variations in 
Treg requirements during different model systems as well as between in vitro and in vivo 
requirements have led to an unclear picture for the way in which Tregs suppress. Indeed, in 
most in vivo models detailed information on the interactions leading to Treg mediated 
suppression are poorly defined. That is, the precise anatomical location of suppression, the 
target cells suppressed, and the mechanisms of suppression collectively.
1.2.5.1 Inhibitory cytokines
Inhibitory cytokines such as IL-10 and TGFp have been associated with Treg activity in
many studies. These cytokines have also been the focus of much attention for their role in
generating Tregs extrathymically (described above). The general immunosuppressive effects
of IL-10 and TGFp are well known and generally undisputed. However, their full role in Treg
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Marker / 
molecule
Purported function Expression in Treg 
cells
Expression in 
other T cells
CD25 Receptor for IL-2, may act as 
IL-2 sink on Tregs
Expressed by >80% of 
Tregs
Also expressed on 
activated non- 
regulatory T cells
Foxp3 Transcription factor 
controlling many Treg 
functions and phenotypic 
markers
Expressed by all Tregs Also shown to be 
expressed in 
activated T cells 
(humans only)
CD45RA Marker of naive T cells Demarcates a 
subpopulation of 
resting Tregs (>50%)
Also expressed by 
non-regulatory T 
cells
IL-10 Immunosuppressive cytokine 
expressed by some Tregs
Expressed by <50% of 
Tregs
Also expressed by 
other Foxp3' T cells
TGFp Immunosuppressive cytokine 
expressed by some Tregs
Expressed by <50% 
Tregs
Also expressed by 
other Foxp3‘ T cells
GranzymeB Cytolytic molecule expressed 
by some Tregs
Expressed by <50% 
Tregs
Also expressed by 
cytolytic CD8+ T 
cells
CD39/CD73 Ectonucleotidases involved in 
the generation of extracellular 
adenosine
Expressed by >50% 
Tregs
Also expressed on 
non-regulatory T 
cells and other cells
CTLA-4 Suppression of DC 
maturation and/or function
Expressed by >50% 
Tregs
Also expressed by 
activated T cells
LAG-3 Suppression of DC 
maturation and/or function
Expressed by <20% 
Tregs
Also expressed by 
activated T cells
GITR Member of TNF receptor 
family
Expressed by >80% 
Tregs
Also expressed by 
activated T cells
Table 1.1 Summary of Treg cell markers and their function
Treg cells have been shown to express a number of different markers and molecules which 
contribute to their function and/or delineation. A summary of many of these 
markers/molecules is given in the table above. For each marker/molecule details of the 
purported function, expression in Tregs cells (under normal circumstances) and expression in 
other T cells is given.
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Figure 1.3. Mechanisms of suppression mediated by Treg.
The mechanisms of suppression utilised by Tregs can be divided into four functional groups: 
suppression by inhibitory cytokines; cytolysis of target cells; suppression by metabolic 
disruption; and suppression by targeting dendritic cells.
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biology in vivo is still unresolved. Experiments in vitro suggest that the roles of soluble 
suppressive factors, such as IL-10 and TGFp, in Treg mediated suppression may be limited. 
Indeed, transwell studies where Tregs physically separated from T effectors were unable to 
suppress, have led to the popular view that Tregs inhibit via a cell contact dependent 
mechanism (Takahashi et al. 1998, Thornton and Shevach 1998). Furthermore, a number of 
in vitro experiments have specifically found IL-10 and/or TGFp to be dispensable for Treg 
suppression in mice (Takahashi et al. 1998, Piccirillo et al. 2002, Thornton and Shevach 
1998) and in humans (Dieckmann et al. 2001, Jonuleit et al. 2001).
In contrast, IL-10 has been implicated in Treg activity in numerous in vivo models. These 
include models of allergy and asthma (reviewed in Hawrylowicz and O'Garra 2005, Joetham 
et al. 2007), inflammatory bowel disease (Asseman et al. 1999, Annacker et al. 2003), 
persistent infection (Belkaid et al. 2002), tolerance (Erhardt et al. 2007, Schumacher et al. 
2007), and carcinogenesis (Loser et al. 2007). Whether the IL-10 producing CD4+CD25+ 
(Foxp3+) cells in these experiments are the same as naturally occurring Foxp3+ Tregs remains 
uncertain. However, in an attempt to directly test the role of IL-10 in Foxp3+ Treg mediated 
suppression, Rubtsov et al., (2008) generated mice in which IL-10 was ablated specifically in 
Foxp3+ Tregs. Interestingly, this did not result in systemic autoimmunity but did enhance 
pathology in the colon of older mice and in the lungs and skin of mice with induced 
hypersensitivity. This suggests that IL-10 derived from Foxp3+ Treg is necessary for immune 
homeostasis but may be restricted to the control of inflammatory responses at environmental 
interfaces caused by pathogens or environmental insults.
Significant data also exists to suggest that TGFp produced by Tregs is important in vivo.
Using a mouse model of colitis it was shown that T cells that cannot respond to TGFp escape
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control by Tregs (Fahlen et al. 2005). Similarly, TGFp deficient Foxp3+ Treg cells could not 
prevent the development of colitis, demonstrating an essential role for Treg derived TGFp in 
inhibiting colitis (Li, Wan and Flavell 2007). The production of TGFp by Treg was also 
recently implicated in a model of allergy and asthma (Joetham et al. 2007). Furthermore, 
tumour infiltrating Tregs from patients with head and neck squamous cell carcinoma were 
found to produce TGFp (and IL-10), suggesting these molecules are involved in Treg activity 
during cancer (Strauss et al. 2007). Interestingly, an increasing body of evidence is emerging 
suggesting that membrane bound TGFp plays a role in Treg mediated suppression 
(Nakamura, Kitani and Strober 2001, Ostroukhova et al. 2006, Xia et al. 2007, Green et al.
2003). Moreover, this method of suppression is consistent with the observation that Tregs 
inhibit via cell to cell contact. Taken together, current data suggests that soluble and/or 
membrane bound TGFp is important for the function of regulatory T cells.
Recently, another immunosuppressive cytokine, IL-35, was shown to be required for the 
maximal suppressive activity of Treg in mice (Collison et al. 2007). Unlike IL-10 and TGFp, 
IL-35 was found to be required for Treg activity both in vitro and in vivo. IL-35 is formed by 
the heterodimeric pairing of Ebi3 and IL-12a. The genes for both Ebi3 and IL-12a are 
preferentially up-regulated in mouse Foxp3+ Treg (Gavin et al. 2007), especially Treg that 
are actively suppressing (Collison et al. 2007). Although IL-35 is another addition to the 
mouse Treg suppression portfolio, its full importance including its target cell type and target 
cell function remains to be clarified. Furthermore, a recent report by Bardel et al., (2008) 
showed that human Treg do not express detectable amounts of IL-35, suggesting that it does 
not play a role in Treg mediated suppression in humans.
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7.2.5.2 Suppression by Cytolysis
Typically cytolysis mediated through granzymes is associated with NK cells and cytotoxic 
CD8+ T cells (reviewed in Lieberman 2003). However, a number of studies have found that 
granzyme expression is up-regulated in both mouse and human Tregs, suggesting that 
granzyme mediated cytolysis may be utilised by Tregs (McHugh et al. 2002, Grossman et al.
2004). Consistent with this, target cell killing by human Treg was shown to be mediated 
through Granzyme B and perforin (Grossman et al. 2004). Treg cytolytic activity has also 
been demonstrated with mouse Tregs, indeed, mouse Tregs deficient of granzyme B have 
reduced suppressive activity in vitro (Gondek et al. 2005). Subsequent studies supporting this 
finding showed that Treg can kill B cells in a granzyme B dependent and partially perforin 
dependent manner (Zhao et al. 2006). Also, a more recent study by Cao et al., (2007) showed 
that Treg utilize granzyme B and perforin mediated killing to suppress the ability of NK cells 
and CILs to clear tumours. Other cytolytic mechanisms that have been associated with Treg 
suppressive activity include apoptosis via the TRAIL-DR5 pathway (Ren et al. 2007); 
galectin-1 induced T cell apoptosis (Garin et al. 2007); and lysis of antigen-presenting B cells 
by Fas-FasL interaction (Janssens et al. 2003).
1.2.5.3 Metabolic disruption
It has long been proposed that the expression of CD25 (IL-2 receptor alpha chain) by Tregs
provides them with a competitive advantage for IL-2 consumption over na’ive T cells which
only express CD25 after TCR stimulation (Thornton and Shevach 1998). Evidence exists to
support this theory which may ultimately result in cytokine deprivation-mediated apoptosis of
effector T cells (de la Rosa et al. 2004, Barthlott et al. 2005, Pandiyan et al. 2007). However,
there is also compelling evidence (Fontenot et al. 2005b), including evidence using human
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Treg (Oberle et al, 2007) suggesting that this is not a true mechanism of Treg suppression. In 
particular, Fontenot et al., (2005b) demonstrated that murine Tregs deficient of the IL-2 
receptor alpha chain (CD25) were fully able to suppress in vitro. Clearly, more work is 
needed to determine whether CD25 expression and IL-2 deprivation contribute to Treg 
mediated suppression in vivo.
An interesting advancement in the Treg field has been the discovery that Tregs can inhibit 
target cells via the modulation of intracellular cAMP. An increase in cAMP levels in 
lymphocytes has been associated with inhibition of proliferation and differentiation for many 
years (Bodor et al. 2001, Kammer 1988). The recent evidence implicates Tregs in two 
different mechanisms of altering cAMP in target cells. Bopp et al., (2007) found that Tregs, 
which express high levels of cAMP, can act directly on target cells by delivering cAMP to 
activated target cells via gap junctions. Whereas three papers published in close succession 
collectively demonstrated an indirect mechanism whereby Tregs generated extracellular 
adenosine via the surface expression of the ectonucleotidases CD39 and CD73 (Kobie et al. 
2006, Deaglio et al. 2007, Borsellino et al. 2007). In this alternative mechanism, subsequent 
binding of adenosine to the adenosine A2A receptor on target cells increased intracellular 
cAMP and lead to the suppression of target cell proliferation and cytokine production.
1.2.5.4 Suppression by targeting dendritic cells
As well as targeting effector cells directly, it has been proposed that Tregs may suppress 
dendritic cells (DC) which are required for the activation of T cells. Studies using intravital 
microscopy suggest that Tregs directly interact with DCs (Tang et al. 2006) and are also able 
to reduce the period of interaction between Teff and DCs (Tadokoro et al. 2006). The use of
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CTLA-4 specific antibodies or CTLA-47' deficient Tregs suggests that suppressive 
interactions between Treg and DCs require CTLA-4 (Oderup et al. 2006, Serra et al. 2003) 
which is constitutively expressed by Treg and required for maximal Treg activity in vivo 
(Read, Malmstrom and Powrie 2000). Some data suggests these CTLA-4 dependant Treg 
effects on DCs may result in the induction of IDO mediated catabolism of tryptophan 
(Fallarino et al. 2003), a mechanism thought to be involved in suppressing T cell responses 
and promoting tolerance (Mellor and Munn 2004). Several other papers, including studies 
with human cells, have reported that Tregs can influence the maturation or function of DCs 
(Kryczek et al. 2006, Lewkowich et al. 2005, Houot et al. 2006, Misra et al. 2004), for 
example, the downmodulation of costimulatory molecules such as CD80 and CD86 on DCs 
(Cederbom, Hall and Ivars 2000).
Finally, another molecule that has been implicated in modulating DC function by Tregs is 
lymphocyte activation gene-3 (LAG-3/CD223). LAG-3 is a CD4 homologue which binds to 
MHC class II with higher affinity than CD4. LAG-3 is expressed by Tregs and appears to be 
required for their maximal activity in vitro and in vivo (Huang et al. 2004, Workman and 
Vignali 2005). A recent study by Liang et al., (Liang et al. 2008) showed that Treg inhibit 
DC maturation via LAG-3 interaction with MHC class II expressed on DCs.
Our current understanding of the mechanisms of Treg suppression suggests that Tregs are
capable of inhibiting at multiple levels. Tregs have been shown to inhibit the activation,
proliferation, differentiation and effector function of target cells. Furthermore Tregs appear to
utilise a plethora of molecular mechanisms for inhibition, for example, cell-cell contact
dependant mechanisms, secretion of soluble factors, and competition for cytokines. It is
probable that Tregs utilise alternative inhibitory pathways depending on the nature, context,
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and extent of the response needing to be suppressed. Crucial to our further understanding of 
Tregs will be the elucidation of which mechanisms are used when.
1.2.6 Peripheral homeostasis, activation and trafficking of Tregs
1.2.6.1 Activation
Numerous accessory molecules appear to control the peripheral homeostasis, activation and 
trafficking of Tregs (reviewed in Liston and Rudensky 2007, Wei, Kryczek and Zou 2006). 
Most of these molecules have also been associated with the regulation of normal T cells. In 
conventional T cells, CD28 provides a costimulatory signal for IL-2 production, cell survival 
and proliferation (reviewed in Salomon and Bluestone 2001). Experiments using CD28 
deficient mice showed that CD28 signalling is also required for the generation of Tregs in the 
thymus (discussed above) as well as the peripheral survival of Tregs (Salomon et al. 2000). It 
appears however that CD28 is not completely necessary for Treg function as Tregs from 
CD28 deficient mice were found to be equally suppressive as CD28 sufficient Tregs in vitro 
(Takahashi et al. 2000). As mentioned above, CTLA-4 may also be important for Treg 
activity. In normal T cells CTLA-4 is up-regulated upon activation and can provide a 
negative signal which appears to control the induction of anergy (Greenwald et al. 2001). 
However, in Tregs CTLA-4 is constitutively expressed and appears to be important for the 
maximal suppressive capacity (Read et al. 2000, Takahashi et al. 2000). Two independent 
studies showed that blockade of CTLA-4 abrogated Treg function in in vitro suppression 
assays and in the prevention of colitis in vivo (Read et al. 2000, Takahashi et al. 2000). These 
studies suggested that CTLA-4 engagement is involved in Treg-mediated suppression. Yet, 
on the contrary, a more recent study showed that CTLA-4 cannot be wholly necessary as 
CTLA-4 deficient Tregs are still able to suppress in vitro (Kataoka et al. 2005). GITR
(glucocorticoid-induced tumour necrosis factor receptor family-related gene) is another 
molecule thought to be involved in Treg activation. Tregs constitutively express high levels 
of GITR, whereas high levels of GITR are only found on non regulatory T cells, B cells and 
macrophage following activation (Shimizu et al. 2002, McHugh et al. 2002). Crosslinking 
GITR abrogates Treg mediated suppression in vitro and anti-GITR treatment can elicit 
autoimmune disease in mice (Shimizu et al. 2002).
1.2.6.2 Proliferation
The cytokines IL-2 and TGFp have been associated with Treg proliferation and survival. IL-2 
is essential for Treg growth and survival and may also be involved in Treg function (Furtado 
et al. 2002). Similarly TGFp has been found to stimulate human Tregs to proliferate 
(Yamagiwa et al. 2001). Stimulation of Tregs with a high concentration of lipopolysaccaride 
(LPS) through the toll like receptor (TLR) 4 can induce them to proliferate and prolong their 
survival (Caramalho et al. 2003).
1.2.6.3 Trafficking
It appears that Tregs have unique patterns of expression of adhesion molecules, chemokine
receptors and homing receptors which modulate their retention and migration (Wei et al.
2006). In particular this may be important for the preferential distribution of Tregs to sites
where regulation of immune responses is needed. For example, it has been shown that Tregs
infiltrating ovarian carcinomas express the chemokine receptor CCR4 and migrate towards
CCL22 which is found within the tumour microenvironment. In addition to chemokine
receptor expression, integrin molecules may be important for Treg migration in vivo. For
example, the integrin aEp7 (CD 103) which may identify a more suppressive subset of Tregs
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(Lehmann et al. 2002, Banz et al. 2003), appears to facilitate the homing/retention of Tregs to 
inflamed tissue (Suffia et al. 2005, Huehn et al. 2004).
1.2.7 TCR repertoire of Treg
As mentioned above, it is commonly believed that Treg predominantly recognise self 
antigens. These assumptions come primarily from the autoimmunity observed when Tregs are 
abrogated by either day 3 thymectomy (Nishizuka and Sakakura 1969), Treg deletion (Kim et 
al. 2007) or mutations in Foxp3 (Wildin et al. 2001). Furthermore, experiments with double 
transgenic mice for a TCR and its ligand show that a large proportion of TCR transgenic 
thymocytes become Tregs and that this requires TCR-MHC interactions of relatively high 
affinity (Jordan et al. 2001, Kawahata et al. 2002, Apostolou et al. 2002). However, studies 
showing that Tregs are also able to recognise foreign antigens such as those of the protozoa 
Leishmania (Suffia et al. 2006, Belkaid et al. 2002), bacteria (Cong et al. 2002), transplanted 
organs/grafts (Joffre et al. 2004, Koenen, Fasse and Joosten 2005) and foetal alloantigen 
(Aluvihare and Betz 2006) suggest Treg have a much broader diversity. The key aspects of 
the Treg TCR repertoire that have attracted the most scrutiny are: a) do Tregs have a similar 
level of diversity to conventional T cells; b) do Tregs predominantly or even preferentially 
recognise self antigens; c) to what extent do the TCR repertoires of Treg and Tconv overlap?
1.2.7.1 Diversity o f the Treg TCR repertoire
A number of studies have tried to elucidate whether Treg have as broad a diversity of TCR
specificity as conventional T cells (Tconv). Preliminary analyses to compare the levels of
diversity between Tconv and Treg simply determined the usage of TCR variable segments
VP (and/or Va) on Tconv and Treg cells. A number of groups showed the two cell
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populations have similarly diverse usage of the TCR subsets in both mice (Takahashi et al. 
1998, Romagnoli, Hudrisier and van Meerwijk 2002, Pacholczyk, Kraj and Ignatowicz 2002) 
and humans (Kasow et al. 2004, Fujishima et al. 2005). More detailed analysis of the CDR3 
lengths, a process called spectratyping, also suggested a similar level of diversity in Tregs to 
Tconv (Kasow et al. 2004, Fujishima et al. 2005). Both approaches also suggested there was 
no particular skewing of either repertoire towards a Vp subset or clone. These methods do not 
however determine the identity of individual TCR sequences and thus to compare the true 
TCR usage of T cell populations, sequence analysis of many individual TCR clones must be 
performed by clonotyping.
This technique was carried out by Hsieh et al. (2004) to compare the TCR repertoires of Treg 
and Tconv. They sequenced the Va2 region of TCRa chains associated with a transgenic 
(fixed) TCRP chain. Using this approach they could be confident that identification of the 
same TCRa sequences assured identification of identical TCRs. These studies found that the 
CD4+CD25+ Treg and CD4+CD25' Tconv repertoires were comparably diverse and displayed 
few predominant clones. The diversity of the Treg TCR repertoire was also measured using 
clonotyping by Pacholczyk et al. (Pacholczyk et al. 2006). This report indicated that the Treg 
TCR repertoire was actually more diverse than that of nai've T cells.
1.2.7.2 Recognition o f self
In an attempt to address the issue of whether Treg predominantly recognise self antigen, 
Hsieh et al., (Hsieh et al. 2004) uncoupled the normal anergic state of Tregs in vitro by 
retroviral transduction of non-regulatory T cells with the Treg TCR sequences. With this 
approach they found that these Treg TCR sequences, and not Tconv TCR sequences, induced
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rapid T cell expansion in lymphopenic hosts. This observation suggests that the Treg 
population contains a higher number of TCRs that are self-reactive compared to CD4+CD25‘ 
Tconv. Similar results were obtained when these cells were analysed by limiting dilutions of 
Treg and Tconv (Romagnoli et al. 2002). When stimulated with allogeneic (non-self) or 
syngeneic (self) APCs, the Treg pool contained a significantly higher frequency of self 
reactive T cells than Tconv. A more recent study made T cell hybridomas derived from 
TCRmmiEp mice to investigate the frequency of TCRs directed to self and non-self antigens in 
naive T and Treg cells (Pacholczyk et al. 2007). The TCRmm,Ep mice were obtained by 
crossing transgenic mice expressing the (3 chains of TCRs recognising the self peptide Ea52- 
68 (Ep) (Pacholczyk et al. 2006) with mice expressing a single MHC-peptide complex 
(AbEp) (Ignatowicz, Kappler and Marrack 1996). In TCRmuilEp mice, the TCRs are therefore 
selected in the thymus by the expression of a single MHC-peptide complex (AbEp) resulting 
in a repertoire that is tolerant to AbEp and lacks tolerance to natural, endogenous processed 
peptides. Thus, the AbEp antigen is perceived as self and natural antigens are perceived as 
non-self. Notably, this approach showed that high affinity, self reactive TCRs may indeed be 
more prevalent in the Treg population compared to the Tconv population but are in fact still 
very low in number in both the Treg and Tconv pools. Indeed, both populations were also 
found to recognise foreign MHC-peptide complexes as often.
1.2.7.3 Overlap between the Treg and Tconv repertoires
Another key finding that came from Hsieh and colleagues’ (2004) study was that the Treg 
and Tconv TCR repertoires were generally distinct but overlapping by around 10-25%. A 
much higher level of overlap between the Treg and Tconv repertoires was found in a study 
using the LTD (“limited”) mouse strain which contains a greatly limited TCR repertoire
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(Wong et al. 2007b). The LTD mouse carries an OT-1 TCRp transgene and a TCRa 
minilocus comprising of a single V and two J gene segments, thus TCR variability is vastly 
reduced in these mice but allows for efficient sequence comparisons (Correia-Neves et al.
2001). The results from the comparison of Treg and Tconv cells in LTD mice suggest that 
rarer TCR sequences may comprise overlapping sequences and that if more individual TCR 
sequences were analysed in clonotyping studies a greater degree of overlap may be 
calculated. However, the restriction of the TCR repertoire in LTD mice makes the 
interpretation of this data difficult. A similar study of human peripheral blood T cells 
supported the findings in mice (Fazilleau et al. 2007). Of 2537 analysed TCR sequences, 615 
(24%) were found in both the CD4+CD25hlgh Treg and CD4+CD25' Tconv pools.
1.3. Role for Tregs in tumour development
Given the clear implication for Treg cells in orchestrating self tolerance by preventing 
autoreactive T cells and the fact that tumours are derived from host cells, it is not surprising 
that Tregs have been the subject of much scrutiny by cancer immunologists. It is perceivable 
that T cells reactive to the (self-derived) tumour tissue may be considered as potentially 
harmful autoreactive T cells and therefore inhibited by the actions of Tregs. Thus, when a 
tumour emerges, it may be that the balance between autoimmunity and tolerance favours the 
outgrowth of the tumour by preventing anti-tumour immune responses. Understanding the 
mechanisms involved in controlling this balance is the goal for these scientists and could aid 
the design of therapeutics for cancer (and autoimmune diseases).
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1.3.1 Tumour induced suppressor T cells
A number of studies performed in the lab of Robert North during the 1980s provided much of 
the first compelling evidence for the involvement of suppressive T cells in limiting anti­
tumour immunity. For example, using the Meth A fibrosarcoma cell line, North’s group 
found that tumour development could induce effector T cell activity capable of tumour 
rejection if transferred to recipient T cell deficient mice (Berendt and North 1980, North and 
Bursuker 1984). However, growth of the tumour was also associated with a loss of effector T 
cell activity and the gradual development of suppressive T cell activity which prevents 
tumour rejection (Berendt and North 1980, North and Bursuker 1984). Depletion of this 
suppressive T cell population by cyclophosphamide allowed tumour rejection of established 
tumours (North 1982). Characterisation of these suppressor T cells found them to be 
CD4+CD8‘ and showed that specific depletion of CD4+ cells resulted in CD8 T cell mediated 
tumour rejection (Awwad and North 1988). This group also showed similar findings using 
the P815 mastocytoma cell line (Dye and North 1981, Mills and North 1983). It is likely that 
the CD4+ suppressor T cells North described are the same population of cells now more 
commonly known as CD4+ regulatory T cells (Treg).
1.3.2 Infiltration of Tregs into tumours derived from transplantable tumour cell lines
It has been observed that numerous transplantable tumour cell lines induce the accumulation
of tumour infiltrating Tregs. Needham et al. (2006) used tumour cells derived from the
peritoneal cavity of C57BL/6J mice injected with asbestos fibres. The percentage of Tregs
accumulating in these mesotheliomas increased as the tumour developed. Up to 60% of the
CD4s infiltrating the tumours were found to be CD4+CD25+ Tregs. Similarly, Ghiringhelli et
al. (Ghiringhelli et al. 2005) found that the B16F10 melanoma cell line induced a high
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percentage and overall number of Tregs in draining lymph nodes and tumours of injected 
mice. Staining of the T cells with BrdU showed that the Tregs have a high proliferative status 
at these sites suggesting that this is how Treg accumulate in tumour bearing mice. Other 
transplantable tumour cell lines that have been associated with an accumulation of Treg 
include the colon carcinomas PROb (Ghiringhelli et al. 2004), and CT26 (Zhou et al. 2007), 
and the carcinogen induced fibrosarcoma Meth A (Ko et al. 2005).
1.3.3 CD4+CD25+ Tregs suppress anti-tumour immunity in mice
Following the identification of CD25 as a marker for CD4+ Tregs numerous studies have 
been carried out to try and elucidate whether depletion of these cells enhances tumour 
immunity. Indeed, Onizuka et al. (1999) demonstrated that depletion of CD25+ cells using 
depleting monoclonal antibodies improved the rejection of a range of tumour cell lines. 
Similar to the early findings of Robert North’s group Shimizu et al. (1999) found that this 
rejection was mediated by CD8+ CTLs but also NK like cells. Findings in support of this 
were later reported by a number of other groups (Sutmuller et al. 2001, Chen et al. 2005). It 
has also been found that CD4+ T cells may be involved in tumour rejection and also in 
establishing long term anti-tumour immunity in mice that rejected tumours as a consequence 
of CD25+ cell depletion (Jones et al. 2002, Casares et al. 2003). In addition, Golgher et al. 
(2002) found that long term anti-tumour immunity revealed by Treg depletion was directed 
towards shared tumour antigens and resulted in rejection of tumours from different origins.
The majority of Treg/tumour studies show that it is possible to induce the rejection of 
tumours by depleting CD25+ cells prior to tumour inoculation (Onizuka et al. 1999, Shimizu 
et al. 1999, Sutmuller et al. 2001, Jones et al. 2002). However, the rejection of established
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tumours by manipulation of Tregs, which is more clinically relevant, has proven less 
successful. Ghiringhelli et al. (2004) showed that depletion of Treg using cyclophosphamide 
induced the partial regression of established PROb tumours in rats. Nevertheless, complete 
clearance of the established tumour required a combination of Treg depletion and 
vaccination. Adoptive T cell transfer, whereby anti-tumour T cells are expanded ex vivo and 
re-infused into the patient, represents an alternative clinical strategy for tumour 
immunotherapy. Interestingly, Antony et al. (2005) showed that the cotransfer of CD4+ Th 
cells with anti-tumour CD8 T cells combined with vaccination can improve rejection of 
established tumours in mice. However, this rejection was only possible when the transferred 
CD4+ T cell population was depleted of CD4+CD25+ Tregs. These results suggest that Treg 
depletion may also be necessary for successful adoptive T cell therapy.
1.3.4 Tregs accumulate in MCA induced tumours and prevent tumour rejection
Recently work from our laboratory has suggested that Tregs play an important role in the 
development of MCA induced tumours (Betts et al. 2007). MCA induced fibrosarcomas were 
found to contain a high percentage of CD4+CD25+Foxp3+ Treg. On average, approximately 
50% of the CD4+ tumour infiltrating lymphocytes (TILs) were Tregs. This accumulation was 
also reflected in the tumour draining lymph node, which had significantly more Tregs 
compared to non tumour draining lymph nodes. Furthermore, these Tregs were found to be in 
close proximity to CD8+ T cells and CD4+Foxp3' conventional T cells within the tumour. 
Importantly, depletion of Tregs by administration of anti-CD25 depleting antibodies prior to 
MCA tumour induction resulted in a significant reduction in tumour occurrence. These data 
provide strong evidence that Tregs prevent effective tumour immunity during MCA tumour 
development.
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1.3.5 Do Treg influence immunosurveillance in human tumours?
As mentioned above, it is apparent that any anti-tumour immune responses that exist in 
humans have generally become non effective in clearing tumours in patients with established 
tumours. There is evidence from human cancer patients to suggest that Tregs are involved in 
suppressing these anti-tumour immune responses (reviewed in Betts et al. 2006). The 
evidence supporting this predominantly comes from observational studies comparing the 
frequency of Tregs in cancer patients and in healthy controls. The majority of these studies 
show that the frequency of Treg in the PBMC of cancer patients is significantly elevated 
compared to healthy controls. Furthermore, some studies suggest that the frequency of Treg 
in tumour draining lymph nodes is higher than control lymph nodes from non-cancer patients. 
However, this data is limited because of the difficulty to obtain lymph nodes from healthy 
controls for comparison. Tregs have also been identified amongst the tumour infiltrating 
lymphocytes of cancer patients. An indication of the role for these cells in tumour 
progression is the increased frequency of Tregs observed in some tumours at later stages of 
disease. For example, Curiel et al. (2004) found that stage I ovarian tumours contained less 
Tregs compared to tumours in stages II to IV. Moreover, they found that there was a 
significant correlation between tumour Treg cell content and patient survival.
1.4. Summary
The studies discussed above collectively provide evidence that an anti-tumour
immunosurveillance process exists in mice and in humans. However, it is also apparent that
humans and mice can still develop cancer despite a plethora of anti-tumour mechanisms.
Studies also show that a suppressive T cell subset called regulatory T cells (Treg) play a role
51
in normal homeostasis and in regulating immune responses. Treg cells are a cell type which 
have a role in many disease models and utilise numerous mechanisms of suppression. The 
data discussed above also suggest that effective tumour immunity may be inhibited by the 
action of Treg cells. Moreover, that the accumulation of Treg cells at tumour sites may be a 
mechanism induced by developing tumours in order to escape deletion by the host immune 
system.
Phenotypic andfunctional characterisation o f tumour infiltrating T cells.
For the rational design of anti-tumour therapies, is important to understand the network of 
biological interactions within the tumour microenvironment. A comprehension of the 
phenotypic and functional characteristics of TILs will allow for the clinical efficacy of 
current strategies to be improved and the identification of new potential immuno-therapeutic 
targets. The experiments described in this thesis have utilised a mouse tumour model to 
investigate Treg cells in tumours. Firstly, a phenotypic and functional characterisation of 
tumour infiltrating T cells was carried out (Chapter 3). Specifically, four key questions were 
addressed:
• Do CD4+ and CD8+ cells control tumour development following Treg depletion?
• Do the ratios of Tconv:Treg and CD8:Treg alter in the tumour compared to lymphoid
tissue?
• Do tumour infiltrating Treg cells display a phenotype associated with
immunosuppression?
• Do tumour infiltrating Tconv and CD8+ T cells express activation markers?
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How do Tregs accumulate in tumours?
It has previously been shown that Treg cells accumulate in MCA induced tumours and that 
these Treg cells can prevent anti-tumour responses. It is therefore important to establish the 
mechanism(s) of Treg cell accumulation in tumours. Firstly, this may lead to identifying 
potential therapeutic interventions for the prevention of Treg accumulation. However, an 
understanding of Treg cell accumulation in tumours may also assist in the rational design of 
tumour vaccines. The mechanisms leading to accumulation of Treg cells in tumours were 
investigated (Chapter 4) by addressing the following questions:
• Does conversion of conventional T cells into regulatory T cells account for Treg cell 
enrichment in tumours?
• Does the proliferation of CD4+ T cells preferentially promote the accumulation of 
Treg cells in tumours?
• Does the level of cell death within Treg and Tconv cells favour Treg accumulation in 
tumours?
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Chapter 2 -  Materials and methods
2.1 Mice
Unless stated otherwise, C57BL/6 mice (Charles River or bred in house), aged 8 to 15 weeks, 
were injected with carcinogen (see below). Where indicated, to efficiently discriminate 
between Treg and non Treg cells (Tconv) mice expressing GFP under the control of the 
Foxp3 promoter (Foxp3_GFP) were used (Fontenot et al. 2005c). Where indicated, the 
spleens and inguinal lymph nodes of naive and aged (30-60 weeks) mice were analysed for 
comparison. Mice were isolator-bred and housed in filter-top cages for the duration of the 
experiment.
2.2 Tumour induction
Mice were injected subcutaneously in the left hind leg with 400pg of 3-methylcholanthrene 
(MCA; Sigma-Aldrich) in lOOpl of olive oil under general anaesthetic. Mice were 
subsequently monitored for tumour development at least once a week for up to 1 year. 
Tumour bearing mice were culled when their tumours were between 1cm and 2cm in 
diameter or causing apparent discomfort.
2.3 Depletion of immune cells
Hybridomas secreting CD25- (PC61), CD4- (YTS 191.1.2, YTA 3.1.2), CD8- (YTS 
169.4.2.1, YTS 156.7.7), and rat anti-E. coli feta-galactosidase- (GL113) specific mAbs have 
been described previously (Lowenthal et al. 1985, Cobbold et al. 1984, Qin et al. 1987). 
Depleting antibodies, produced and purified in house as previously described (Jones et al.
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2002), were injected intraperitoneally in 100 to 500pl of sterile PBS at the amounts and times 
stated below (Figure 2.1). For Treg depletion, anti-CD25 Abs (clone PC61, 500pg) were 
given on days -3 and -1 before MCA injection (day 0). Alternatively, rat IgG isotype control 
(GL113, 500pg) was given as a control. CD4+ cells were depleted by injecting a combination 
of two Abs (clones YTS-191 and YTA-3, 100pg of each) twice with a two week interval 
(days 50 and 64). Similarly, CD8+ cells were depleted using a combination of two Abs 
(clones YTS-156 and YTS-196, lOOpg of each) twice with a two week interval (days 50 and 
64). Alternatively, as a control, rat IgG (GL113) was injected.
2.4 Dissection of tissues
Spleen and inguinal lymph nodes were removed from tumour bearing and naive mice. The 
inguinal lymph node from the left (tumour) side of each tumour bearing mouse was removed 
for analysis of a tumour draining lymph node. The inguinal lymph node from the right side of 
the same mouse was taken as a non-draining lymph node. For naYve (control) mice the two 
inguinal lymph nodes (left and right) were pooled. Tumours were resected from tumour 
bearing mice avoiding normal muscle and local lymph nodes. In particular, the popliteal 
lymph node was separated from the tumour mass. However, this lymph node was not used for 
analysis as the draining popliteal lymph node and in particular the non-draining popliteal 
lymph node was relatively small.
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Figure 2.1. Injection program for studying immune factors that control tumour 
development after Treg cell depletion.
C57BL/6 mice were given Treg cell depleting antibody (PC61, 500pg) or a control antibody 
(GL113, 500pg) 3 days and 1 day prior to injection with 400pg of MCA. During tumour 
development (days 50-80) CD4+ or CD8+ cells were depleted with depleting antibodies. Mice 
were monitored daily for tumour outgrowth.
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2.5 Flow cytometry
2.5.1 Preparation of single cell suspensions from tissues
Spleen and lymph nodes were homogenised in a multiwell plate using the back of a syringe 
plunger. Tumours were diced into small pieces (almost to pulp) then forced through a 70pM 
cell strainer (BD Biosciences) using the back of a syringe plunger. Homogenised tissue was 
resuspended in FACS buffer (PBS containing 5mM EDTA and 2% FCS) and passed through 
a 70pM cell strainer. The resulting single cell suspension was washed once by pelleting the 
cells by centrifugation at l,500rpm (-450 x G) for 5 minutes and resuspending in FACS 
buffer. Before antibody staining, spleen and tumour cell pellets were first subjected to lysis of 
red blood cells by resuspending in 5ml of RBC lysis buffer (BioLegend) for 90 seconds at 
room temperature.
2.5.2 Antibody staining
For antibody staining, spleen and lymph node single cell suspensions were plated out into 96 
well, round bottom plates at -0.5 -  1 million cells/well. Enumeration of cells / lymphocytes 
in the tumour cell suspension is problematic due to the high amounts of cell debris and 
connective tissue in the homogenised tumour. Therefore, for FACS staining the tumour was 
simply split into between 1 to 10 wells depending on the size of the tumour cell pellet.
2.5.3 Activation for intracellular cytokine analysis
For analysis of intracellular cytokines by flow cytometry, single cell suspensions (-0.5 to 1.0
million cells per well) were stimulated in a 24 well plate in complete RPMI (RPMI
[Invitrogen] supplemented with 2mM L-glutamine, ImM sodium pyruvate, 50ug/ml
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penicillin streptomycin and 10% foetal calf serum) containing 20 nM phorbol myristate 
acetate (PMA; Sigma-Aldrich) and lpg/ml ionomycin (Sigma-Aldrich). Cells were incubated 
at 37°C for a total of 4 hours. After 1 hour 1 pl/ml of GolgiStop (containing monensin; BD 
Bioisciences) was added to each well.
2.5.4 Antibodies and cell staining
Anti-mouse antibodies for flow cytometric analysis are described in the table below. The 
correct dilutions of the antibodies to give efficient staining were established by titration of the 
antibodies by different members of our lab group. To eliminate dead cells from flow 
cytometric analysis a fixable dead cell staining kit (LIVE/DEAD Aqua; Invitrogen) was used 
prior to antibody staining. For this, cells were washed twice in PBS and 3 to 6pi of diluted 
(1:10; in PBS) live/dead aqua was added directly to the cell pellet. Cells were left to stain at 
room temperature for 15 minutes in the dark then washed twice in FACS buffer. For staining 
of surface markers, 25pi to 50pl of diluted (in FACS buffer) antibody were added to the cells 
and incubated for 10 to 15 minutes at 4°C in the dark. To remove unbound antibodies cells 
were washed three times in FACS buffer. For biotinylated antibodies, cells were additionally 
incubated for 10 to 15 minutes in 25 to 50pl of conjugated streptavidin (SA) diluted to 
0.8pg/ml in FACS buffer and washed a further three times in FACS buffer to remove 
unbound SA. To stain for intracellular antigens cells were firstly fixed and permeabilised by 
incubating for between 40 minutes and 16 hours in Fixation/Permeabilization buffer 
(eBioscience). Subsequent washes and incubations were performed using Permeabilization 
Buffer (eBioscience). Cells were washed once then Fc receptors were blocked for 10 minutes 
at 4°C in the dark using anti-CD 16/32 antibodies diluted to 5pg/ml. Antibodies to 
intracellular antigens were added to the cells and left for 30 minutes at 4°C in the dark. Cells
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Antigen Conjugate Clone Isotype Company Final concent­
ration
Surface
CD3 PeCy5 145-2C11 Hamster IgG eBioscience 2 pg/ml
CD4 FITC RM4.5 Rat IgG2a eBioscience 5 |Ag/ml
CD4 Alexafluor647 RM4.5 Rat IgG2a Caltag 2 pg/ml
CD4 Pacific Blue RM4.5 RatIgG2a BD 2 pg/ml
CD8 PerCpCy5.5 53-6.7 Rat IgG2a eBioscience 2 pg/ml
CD25 Alexafluor488 PC-61.5 Rat IgGl eBioscience 10 pg/ml
CD25 Pe PC-61.5 Rat IgGl eBioscience 4 pg/ml
CD39 Pe 24DMS1 Rat IgG2b eBioscience 2 pg/ml
CD44 FITC IM7 Rat IgG2b BD 5 pg/ml
CD44 APC IM7 Rat IgG2b BD 2 pg/ml
CD62L FITC MEL-14 Rat IgG2a Caltag 10 pg/ml
CD73 Biotin TY/11.8 Rat IgGl eBioscience 5 pg/ml
CD 103 FITC 2E7 Hamster IgG eBioscience 5 pg/ml
CTLA-4 Pe UC10-4F10-11 Hamster IgG BD 2 pg/ml
ICOS Pe 15F9 Hamster IgG eBioscience 2 pg/ml
ICOS Biotin 15F9 Hamster IgG eBioscience 5 pg/ml
GITR Pe DTA-1 Rat IgG2b eBioscience 2 pg/ml
Intracellular
Bcl-2 Pe 3F11 Hamster IgG BD 0.3 pg/ml
Foxp3 Pe FJK-16s Rat IgG2a eBioscience 1 pg/ml
Foxp3 PeCy7 FJK-16S Rat IgG2a eBioscience 1 pg/ml
IFNy FITC XMG1.2 Rat IgGl eBioscience 5 pg/ml
IFNy APC XMG1.2 Rat IgGl BD 2 pg/ml
IL-2 Pe JES6-5H4 Rat IgG2b eBioscience 2 pg/ml
IL-4 Pe 11B11 Rat IgGl eBioscience 2 pg/ml
IL-10 Pe JES5-16E3 Rat IgG2b eBioscience 2 pg/ml
IL-10 APC JES5-16E3 Rat IgG2b eBioscience 2 pg/ml
IL-17 FITC TC11-18H10.1 Rat IgGl Abeam 5 pg/ml
Ki67 FITC B56 Mouse IgGl BD 2 pg/ml
TNFa FITC MP6-XT22 Rat IgGl eBioscience 5 pg/ml
Isotype controls
Isotype Conjugate Company
Hamster IgG FITC - - BD -
Hamster IgG Pe - - eBioscience -
Hamster IgG Biotin - - eBioscience -
Mouse IgGl FITC - - BD -
Rat IgGl Pe - - eBioscience -
Rat IgG2a FITC - - eBioscience -
Rat IgG2b Biotin - - eBioscience -
Rat IgG2b Pe - - eBioscience -
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were washed three times and resuspended in FACS fix (FACS buffer containing -0.1% 
formaldehyde). Where indicated 0.25pg (5pi) of 7-AAD (7-aminoactinomycin D; BD) was 
added to unfixed cells 15 minutes before flow cytometric analysis.
2.5.5 Flow cytometry analysis
For flow cytometric analysis, samples were acquired using either a FACSCalibur or FACS 
Canto II flow cytometer (BD Biosciences) and were analysed using Summit v4.3 software 
(Dako) or FACSDiva software (BD Biosciences).
2.5.6 Gating strategy for identification of CD8+, Tconv and Treg cell populations
To characterise the T lymphocyte populations in tumour bearing mice extensive flow 
cytometric analysis was performed on samples from the spleens, inguinal lymph nodes and 
tumours of tumour bearing mice. For analysis of each sample the same gating strategy was 
adopted. Firstly, the lymphocyte population was gated based on typical lymphocyte forward 
scatter and side scatter patterns (Figure 2.2 step A). Next, dead cells were gated out as these 
can bind antibodies non-specifically. A fixable dye (Live/Dead Aqua, Invitrogen) was used 
for this purpose. Cells with compromised membranes readily stain with the dye and therefore 
have higher fluorescence intensity than cells with intact cell membranes (Figure 2.2 step B). 
The CD4+ and CD8+ T cell populations (previously shown to be CD3+, Appendix Figure Al) 
were gated from the live lymphocyte population based on fluorescent intensity levels from 
CD4 and CD8 specific antibody staining (Figure 2.2 step C). Based on fluorescent intensity 
from Foxp3 specific antibody staining, the CD4+ population was subsequently divided into 
CD4+Foxp3' conventional T cells (Tconv) and CD4+Foxp3+ regulatory T cells (Treg; Figure
2.2 step D). The relative proportions of CD8+, Tconv and Treg cells were determined as 
shown in the example gating strategy and population hierarchy (Figures 2.2 and 2.3).
2.6 Tcell receptor (TCR) clonotyping
Figure 2.4 summarises the clonotyping process which was performed on spleen, non-draining 
lymph node, draining lymph node and tumour samples from MCA-tumour bearing mice.
2.6.1 Cell sorting
Single cell suspensions were sorted using a MoFlo cell sorter (Dako cytomation) operated by 
a core facility (Cental Biotechnology Services; CBS) technician. For mouse 1, lymphocytes 
from spleen and tumour were sorted into two populations based on CD4 and CD25 
expression. CD4+CD25' cells were sorted as conventional T cells (Tconv). Whereas 
CD4+CD25+ cells were sorted as regulatory T cells (Treg.) For subsequent experiments 
(mouse 2, 3 and 4) cells from spleen, inguinal lymph nodes, and tumour were sorted into 
Tconv and Treg based on GFP (Foxp3) expression. Tconv were in the CD4+GFP* gate. Treg 
were CD4+GFP+. Cells were sorted into RNAse free tubes.
2.6.2 RNA extraction
Sorted cells were pelleted by centrifugation at 300 x G for 5 minutes. RNA was extracted 
from pelleted cells using Qiagen RNA easy kit according to the manufacturer’s protocol. 
RNA was eluted from the column using 14pi of RNase free water. The amount of RNA was 
measured with a spectrophotometer (NanoDrop, Thermo Scientific) using 1 to 2pi of the 
eluted RNA.
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Figure 2.2. Gating strategy for identifying Tconv, Treg and CD8+ cell populations
Single cell suspensions were stained with Live/Dead Aqua viability stain and subsequently 
with anti-CD4 PB, anti-CD8 PerCpCy5.5 and anti-Foxp3-PeCy7 mAbs. Lymphocytes were 
defined according to their FSC and SSC (step A). Live lymphocytes were identified as those 
with low fluorescence levels of Live/Dead (step B). Cells were gated into CD8+ lymphocytes 
and CD4+ lymphocytes (step C). CD4+ lymphocytes were further divided into CD4+Foxp3' 
conventional T cells (Tconv) and CD4+Foxp3+ regulatory T cells (Treg) based on their level 
of Foxp3 staining (step D).
Population % of lymphocyte population
Lymphocytes 100.0
-> (Live) lymphocytes 97.2
-> CD8+ cells 22.3
CD4+ cells 35.1
Treg 5.2 (14.9% of 35.1)
Tconv 29.9 (85% of 35.1)
Figure 2.3. Population hierarchy and strategy for determining the frequencies of Tconv, 
Treg and CD8+ cell populations
The relative proportions of the Tconv, Treg and CD8+ T cell populations within the 
lymphocyte population was calculated based on the gating strategy described above and the 
population hierarchy shown. In this example, the CD8+ lymphocyte population makes up 
22.3% of the live lymphocyte gate. However, the CD4+ lymphocyte population, which in this 
example makes up 35.1% of the lymphocytes, is comprised of 14.9% Treg and 85% Tconv. 
Therefore, the Treg population make up 5.2% of the total lymphocytes. Whereas, the Tconv 
population makes up 29.9% of the lymphocyte population.
63
Cell sorting
Tconv Treg
*
RNA extraction
*
cDNA synthesis
*
PCR amplification^ TCR transcripts 
Purification of PCR product 
*  
Cloning into plasmid 
*  
Transformation of competent E. coli 
D N A sejlencing
Figure 2.4. Procedure for TCR clonotyping process.
Tconv and Treg cells were sorted by flow cytometry from single cells suspensions of spleen, 
non-draining lymph node, draining lymph node, and tumour. Immediately after sorting RNA 
was extracted using a column based kit. cDNA was synthesised from 30-200ng of RNA and 
used as a template for amplification of TCR transcripts. The resulting PCR product was 
purified by gel extraction and cloned into a plasmid vector. Cloned vectors were used to 
tranform chemically competent bacteria and plated onto selective LB plates. At least 96 
colonies were picked from each plate and subjected to DNA sequencing of the cloned TCR 
insert.
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2.6.3 cDNA synthesis
cDNA was reverse transcribed from 30 to 200ng of total RNA using superscript III 
(Invitrogen) with 250ng of random oligos. Briefly, RNA and random primers were denatured 
by incubating at 65 °C for 5mins in the presence of lOmM dNTP mix. Next, RT buffer, 0.1M 
DTT, RNaseOUT, and superscript III were added and incubated at 25°C for 5mins, then 50°C 
for 1 hour and finally 70°C for 15mins.
2.6.4 Amplification and purification of TCR transcript
TCR sequences were amplified by PCR using either a TRBV13-2 specific primer (5’- 
GGTGACATTGAGCTGTAAT-3 ’) paired with a common (TRBC) primer (5’- 
CACTGATGTTCTGTGTGACAG-3’) or using a TRBV13-2 specific primer (5’- 
GGTGACATTGAGCTGTAATCAGAC-3’) paired with a TRBJ2-5 specific primer (5’- 
TAACACGAGGAGCCGAGTG-3’). PCR products were separated by agarose gel 
electrophoresis, excised using a clean, sharp knife and subsequently purified from the agarose 
gel using a gel extraction kit (illustra GFX™ PCR DNA and gel band purification kit, GE 
Healthcare) according to the manufacturer’s instructions. The DNA was eluted with lOpl of 
DNase free water.
2.6.5 Cloning and transformation of E. Coli
Purified PCR products were cloned into pCR®2.1-TOPO® plasmid vector by TOPO cloning 
(Invitrogen) according to the manufacturers protocol. The resulting construct was 
transformed into chemically competent E. Coli (TOPIO; Invitrogen) by heat shocking the 
cells at 42°C for 30 seconds. Transformed cells were incubated for only 15 minutes at 37°C
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with shaking before spreading onto pre-warmed selective LB plates (100pg/ml Ampicillin 
with IPTG and X-gal for blue/white screening.) Plates were left overnight (14 to 18 hours) at 
37°C for colonies to form.
2.6.6 Sequencing
High throughput sequencing was performed by a sequencing services company (Beckman 
Coulter Genomics). Briefly, individual white or light blue colonies were picked and 
subsequently expanded in selective media. DNA was prepared from these cultures and 
sequenced with a sequencing primer using an ABI 3730*/ DNA Analyzer. The TRB gene 
usage and CDR3 amino acid composition was established using IMGT/V-QUEST software 
and used to identify individual TCRs.
2.6.7 Statistical analysis
The level of similarity between the different TCR repertoires was measured using the 
Morisita-Hom (MH) similarity index. This unitless index ranging from 0 to 1 takes into 
account the number of shared sequences between two repertoires as well as the contribution 
of those shared sequences to each repertoire. The Estimates software package was used to 
calculate the MH values (Colwell 2005).
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Chapter 3 -  Phenotypic and functional characterisation of 
tumour infiltrating T cells
3.1 Introduction
Previous studies suggest that T lymphocytes prevent tumour outgrowth through immune 
surveillance. However, when cancer arises the host immune response has clearly failed to 
reject the tumour. The accumulation of regulatory T cells may be one process that is 
established in the tumour microenvironment to allow for immune evasion of the tumour. 
Previous studies from our laboratoiy have shown that Treg cells are abundant within 
methylcholanthrene induced tumours and that partial depletion of these cells can reduce 
tumour incidence in mice (Betts et al. 2007). It is therefore reasonable to hypothesize that 
regulatory T cells contribute to the immunosuppressive tumour microenvironment by 
preventing the anti-tumour action of CD4+Tconv and CD8+ T cells. To investigate this 
hypothesis a detailed phenotypic and functional characterisation of CD4+Foxp3" conventional 
(Tconv), CD4+Foxp3+ regulatory (Treg) and CD8+ T cell populations in mice bearing 
chemically induced (MCA) tumours was performed. Specifically, the following questions 
were addressed:
• Do CD4+ and CD8+ cells control tumour development following Treg depletion?
• Do the ratios of Tconv:Treg and CD8:Treg alter in the tumour compared to lymphoid
tissue?
• Do tumour infiltrating Treg cells display a phenotype associated with
immunosupression?
• Do tumour infiltrating Tconv and CD8+ T cells express activation markers?
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The answer to the first question should indicate whether T cells control tumours whilst 
answers to the three subsequent questions should provide insight into whether T cells are 
suppressed by Tregs within the tumour. This information is necessary for understanding the 
relationship between tumours and the immune system and how this may be exploited for 
therapeutic intervention.
3.2 Results
3.2.1 Do CD4+ and CD8+ cells control tumour development following Treg depletion?
Experiments from our laboratory have shown that tumour induction is reduced if Treg cells 
are partially depleted prior to injection of carcinogen (Betts et al. 2007). To deplete Tregs in 
these experiments a CD25-specific antibody (PC61) was administered three days and one day 
before MCA injection. The tumour incidence was significantly reduced from -70% in control 
mice to -40% in mice injected with PC61 (**P=0.001). Whilst approximately 60% of PC61- 
treated animals appear tumour-free, it is possible that tumours are present in the animals but 
that the outgrowth of these tumours are controlled by a T cell response induced as a result of 
Treg depletion. To test this, two groups of mice were set up which received either PC61 Abs 
or control (non-depleting), GL113, Abs at days -3 and -1 prior to injection with MCA. As 
shown in Figure 2.1 (page 55), approximately 7 weeks later, a time-point when tumours are 
not yet visible in either group, the PC61 and GL113 treated mice were injected with depleting 
antibodies against either CD4 or CD8. If either of these T cell subsets were controlling 
tumour outgrowth at this stage, tumours would be expected to grow out more rapidly in T 
cell-depleted animals compared to those receiving the control (non-depleting) Abs (GL113).
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3.2.1.1 Anti-CD4 antibody treatment does not affect tumour control
Mice injected with PC61 (days -3 and -1) were later (days 50 and 64) treated with anti-CD4 
antibodies or control antibodies (Figure 2.1, page 55). Anti-CD4 antibody treatment did not 
alter tumour incidence in comparison to control Ab treatment (Figure 3.1). Thus, following 
PC61 treatment the percentage of tumour free mice after 230 days remained at 40% whether 
CD4+ cells were subsequently depleted or not. This suggests that CD4+ T cells do not control 
tumour growth following Treg depletion. Similarly, no effect of CD4-specific Abs was 
observed in control, Treg-replete animals.
3.2.1.2 Anti-CD8 antibody treatment negates control o f tumour development following 
Treg cell depletion
A second group of mice was given anti-CD8 (or control) antibodies following PC61 
treatment (Figure 2.1, page 55). The treatment of mice with anti-CD8 Abs had a clear effect 
on the overall incidence in mice depleted of Treg cells prior to MCA injection (Figure 3.2). 
Whilst the percentage of mice that remained tumour free following PC61 treatment only was 
40%, the percentage of mice that remained tumour free after being treated with PC61 then 
later with anti-CD8 antibodies was reduced to only 13%, similar to that observed in the 
control group receiving GL113. Using the data from this experiment alone (n=15), the 
difference between the PC61 and anti-CD8 antibody treated mice and those given PC61 then 
control antibodies was approaching statistical significance (P=0.0582). When the results were 
combined with previous data from our laboratory on the survival of mice following PC61 
treatment and compared using a the same statistical test (log rank), depletion of CD8+ cells 
following PC61 Ab treatment significantly altered survival compared to PC61 Ab treatment 
alone (**P=0.0058; Figure 3.3). Overall, these results suggest that CD8+ T cells are important
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Figure 3.1. MCA-induced tumour induction following treatment with PC61 and anti- 
CD4.
Groups of mice (n=15) were injected with either PC61 or GL113 prior to MCA , then 
subsequently with either anti-CD4 Abs or GL113 at days 50 and 64. The tumour incidence 
between experimental groups was analysed using log-rank (Mantel-Cox) tests.
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Figure 3.2. MCA-induced tumour induction following treatment with PC61 and anti- 
CD8.
Groups of mice (n=15) were injected with either PC61 or GL113 prior to MCA , then 
subsequently with either anti-CD8 Abs or GL113 at days 50 and 64. The tumour incidence 
between experimental groups was analysed using log-rank (Mantel-Cox) tests.
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Figure 3.3. MCA-induced tumour induction following treatment with PC61 and anti- 
CD8.
Groups of mice were injected with PC61 prior to MCA , then subsequently with either anti- 
CD8 Abs (n=15) or GL113/no treatment (n=41) at days 50 and 64. The tumour incidence 
between experimental groups was analysed using log-rank (Mantel-Cox) tests.
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for the control of tumour development following depletion of Tregs. CD8+ cells were also 
depleted in mice that were not given PC61. Tumour incidence was not further increased by 
anti-CD8 antibody treatment suggesting that CD8+ T cells are not controlling tumour growth 
in the small number (-13%) of Treg-replete mice that remain tumour free.
3.2.2 Do the ratios of Tconv:Treg and CD8:Treg alter in the tumour compared to 
lymphoid tissue?
3.2.2.1 Analysis o f the Tconv, Treg and CD8+ T cell populations
Mouse models have demonstrated that selective removal of Treg cells from naive animals 
results in catastrophic autoimmune and inflammatory disease (Kim et al. 2007). Thus, Treg 
cells exert potent suppressive effects even under normal homeostatic conditions. As described 
above, Treg cells accumulate in tumours to levels that are significantly higher than in 
lymphoid tissue implying that, within the tumour microenvironment, the impact of Tregs on 
suppression of T cell responses may be even more pronounced at this site. To investigate this 
further, the proportions of different T cell subsets were analysed in the spleens, draining 
lymph nodes (LN), non-draining LNs and tumours of tumour bearing mice and also the 
spleens and LNs of age-matched mice.
A significant (approximately 8 fold; ***P<0.0001) expansion of cells was observed within 
the draining lymph node compared to the non-draining lymph node (Figure 3.4). However, 
the proportions of the different T cell subsets did not remain consistent throughout the 
different compartments of tumour bearing mice. The mean percentage of lymphocytes that 
were Tconv cells in the non-draining lymph nodes of tumour bearing mice was 
approximately 27% (Figure 3.5 A). Interestingly, the mean percentage of lymphocytes that
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Figure 3.4. Total number of lymphocytes in lymph nodes of tumour bearing and naive 
mice.
Single cell suspensions were stained with trypan blue and the number of lymphocytes were 
counted using a haemocytometer. The total number of lymphocytes from draining (D, n=20) 
and non-draining (ND, n=20) inguinal lymph nodes of tumour bearing mice and the total 
number of lymphocytes from inguinal lymph nodes (LN, n=3) of naive age matched mice are 
shown. The total number of cells from the inguinal lymph nodes of naive mice were 
normalised by dividing the value by two as both lymph nodes were combined for counting. A 
paired, non-parametric (Wilcoxon matched) test was used to analyse the difference between 
ND and D lymph nodes of tumour bearing mice.
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Figure 3.5. Proportions of Tconv, Treg and CD8+T cell populations in tumour bearing 
and naive mice.
The proportions of the total lymphocyte population that were made up of Tconv cells (A), 
CD8+ T cells (B) and Treg cells (C) were determined by flow cytometry. Spleens, non­
draining lymph nodes (ND), draining lymph nodes (D) and tumour were analysed from 
tumour bearing mice (n=7). Spleen and pooled inguinal lymph nodes (LN) were analysed 
from nai’ve mice (n=9). Samples within tumour bearing mice were compared using paired T 
tests.
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were Tconv was significantly lower within the draining lymph nodes (approximately 13%) 
compared to the non-draining lymph node. This value for the draining lymph node was 
similar to the average percentage of lymphocytes that were Tconv in the tumours 
(approximately 9%) of tumour bearing mice. Thus it appears that within tumour associated 
tissue the proportion of lymphocytes that are Tconv cells is low.
The pattern with CD8+ T cells was very similar to the pattern of Tconv cells. The mean 
percentage of lymphocytes that were CD8+ T cells was significantly higher in the non­
draining lymph nodes (23.9%) compared to the draining lymph nodes (12.5%; Figure 3.5 B). 
The tumours contained the lowest percentage of CD8+ T lymphocytes (mean 4.8%). Thus, it 
appears that within the tumour and tumour associated lymph node a relatively low proportion 
of the lymphocyte populations are made up of CD8+ T cells.
The changes in proportions of the Tconv and CD8+ T cells were not repeated with the Treg 
cells. The mean percentage of lymphocytes that were Treg cells (Figure 3.5 C) remained 
relatively consistent throughout the spleens, non-draining lymph nodes, draining lymph nodes 
and tumours of tumour bearing mice (means = 3.6% - 5.7%).
It was noticed that in the tumour the T cell populations examined made up a relatively small
proportion of the whole lymphocyte population (approximately 20%; Figure 3.6).
Furthermore, a significant reduction was also seen when comparing the draining lymph node
to the non-draining lymph node (Figure 3.6 B). Thus an accumulation of lymphocytes other
than those analysed appears to occur in the draining lymph node and tumour. A preliminary
analysis of MCA tumour infiltrating lymphocytes indicates that many B220(CD45R)+ cells
and NK1.1+ cells are found within the lymphocyte gate (Appendix Figure A2). Cells
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expressing both CD45R and NK1.1 were also found within the tumour lymphocytes gate. 
Such cells have been previously reported and are proposed to represent a unique subset of 
natural killer cells (Blasius et al. 2007) or dendritic cells (Taieb et al. 2006) which may even 
have anti-tumour activity (Terme et al. 2009).
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Figure 3.6. Proportions of Tconv, Treg and CD8+cell populations in tumour bearing 
and naive mice.
The proportion of Tconv (dark grey bars), Treg (open bars) and CD8+ (light grey bars) cell 
populations within the total lymphocyte population was determined by flow cytometry. 
Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and tumour were 
analysed from tumour bearing mice (n=7). Spleen and pooled inguinal lymph nodes (LN) 
were analysed from naive mice (n=7). Data are presented comparing cell types in individual 
mean (+/-SEM) bars (A) and stacked mean (+/- SEM) bars (B) and pie charts normalised to 
percent of T cell population (C). Samples within tumour bearing mice were compared using 
paired T tests.
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i.2.2.2 Relative proportions o f Tconv, CD8 and Treg cells
The percentages of lymphocytes that were Tconv, CD8 and Treg were evaluated by flow 
cytometric analyses of lymphocytes prepared from spleen, tumours and lymphoid organs and 
used to calculate the ratio of Treg cells to both CD4+ and CD8+ T cells. In the non draining 
lymph nodes, the ratios of Tregs to Tconv cells and CD8+ T cells were approximately 1:6 and 
1:5, respectively (Figure 3.7). However, a difference was observed in tumour draining lymph 
nodes and even more so in the tumour where the ratio of Tregs to Tconv and CD8+ T cells 
changed to approximately 1:2 and 1:1, respectively (Figure 3.7). These data imply that 
tumour infiltrating Tconv cells and CD8+ T cells are more likely to be suppressed by Tregs 
than those in lymphoid tissue. This alteration in the balance of Treg cells to Tconv cells and 
particularly CD8+ T cells may aid the tumour in evading immune mediated destruction.
It is likely that any T cell expected to have an anti-tumour effect would be activated. 
Therefore it was considered relevant to assess the ratio of Tregs to antigen experienced 
(CD44h,gh) T cells. The percentages of the Tconv and CD8+ T cells were altered to account 
only for the proportion of these cells that were CD44hIgh (antigen experienced). On average, 
within the non-draining lymph node only 8.7% of Tconv cells and 11.2 % CD8+ T cells were 
CD44hlgh (Figures 3.8-3.10, discussed below). However, in the tumour, on average, 55.86% 
of Tconv cells and 41.79% of CD8+ T cells were CD44hlgh (Figure 3.9). Within the non­
draining lymph node the ratios of CD44h,ghTconv:Treg and CD44hlghCD8:Treg were both 
-1:2, indicating that Treg cells have a numerical advantage over both CD44hlgh Tconv cells 
and CD44hlgh CD8+ T cells (Figure 3.11). However, within the tumour, the ratio of 
CD44hlghTconv:Treg was approximately 1:1 indicating that Treg cells and CD44hlghTconv 
cells are present in equal proportions (Figure 3.11 A). The trend was not the same for CD8+ T
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Figure 3.7. Ratios of Tconv, Treg and CD8+ T cell populations in tumour bearing and 
naive mice.
The ratio of Tconv/Treg (A, black bars), and CD8+/Treg (B, grey bars) cell populations were 
determined by dividing the calculated proportion of the first population by the second 
population. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and tumours 
were analysed from tumour bearing mice (n=7). Spleens and pooled inguinal lymph nodes 
(LN) were analysed from naive mice (n=7). Sample pairs within tumour bearing mice were 
analysed using paired T tests.
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Figure 3.8. Antibody staining and analysis by flow cytometry of CD44.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for CD44 expression by flow cytometry. Cells were 
stained with anti CD44-FITC (B) or rat IgG2b-FITC isotype control (A) mAbs. 
Representative dot plots of CD8+ T cells, CD4+Foxp3‘ Tconv cells and CD4+Foxp3+ Treg 
cells from each tissue are shown (C).
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Figure 3.9. Percent of Tconv, Treg and CD8+ cells expressing CD44h,gh in tumour 
bearing and naive mice.
The percentage of Tconv (A), CD8+ (B) and Treg (C) cells expressing CD44hlgh was 
determined by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph 
nodes (D) and tumour were analysed from tumour bearing mice (Tconv and Treg cells n=9, 
CD8+cells n=8). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive 
mice (n=3-6). The differences between the means were compared using paired T tests.
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Figure 3.10. Percent of Tconv, Treg and CD8+ cells expressing CD44h,gh in tumour 
bearing and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CD44h,gh was determined by flow cytometry. Spleens, non-draining 
lymph nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour 
bearing mice (Tconv and Treg cells n=9, CD8+cells n=8). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=3-6). The differences between the means were 
compared using paired T tests.
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Figure 3.11. Ratios of antigen experienced (CD44hlgh) Tconv and CD8+T cell to Treg cell 
populations in tumour bearing and naive mice.
The ratio of CD44hlghTconv/Treg (A, black bars), and CD44hlghCD8+/Treg (B, grey bars) cell 
populations were determined by dividing the calculated proportion of the first population by 
the second population. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) 
and tumour were analysed from tumour bearing mice (n=7). Spleen and pooled inguinal 
lymph nodes (LN) were analysed from naive mice (n=3-6). Sample pairs within tumour 
bearing mice were analysed using paired T tests.
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cells in the tumour where the ratio of CD44hlghCD8:Treg remained at approximately 1:2 
(Figure 3.1 IB). Thus, CD44hlgh CD8+ T cells are outnumbered by Treg cells to a similar 
extent in the tumour as in the lymph node. Together these data indicate that Treg cells have a 
numerical advantage over antigen experienced Tconv and CD8 in the lymph node, which 
may contribute to their ability to suppress autoreactive T cells in the periphery. This balance 
is altered in the tumour for antigen experienced Tconv cells which are at equal levels to Treg 
cells, whereas the ratio of antigen experienced CD8+ T cells to Treg cells is similar to that 
observed in the non-draining lymph node. This suggests that Tregs are able to maintain at 
least the same level of suppression over CD8+T cells in the tumour as in the lymph node.
3.2.3 Do tumour infiltrating Treg cells express a phenotype associated with 
immunosuppression?
Recently, many studies have focussed on phenotyping Treg cells in order to identify markers 
that are associated with high suppressive activity. These markers include the activation 
markers CD25, CD44, CTLA-4, ICOS and GITR as well as the integrin, CD 103 and the 
ectonucleotidases, CD39 and CD73. Treg cells from MCA tumour bearing mice were 
assessed for the expression of CD25, CTLA-4, CD 103, CD39 and CD73 and high expression 
levels of ICOS, CD44 and GITR as these are associated with the suppressive phenotype of 
Tregs (Sojka, Huang and Fowell 2008, Sakaguchi 2004, Shevach et al. 2006, Miyara and 
Sakaguchi 2007). An analysis of each of these markers revealed several interesting features 
of tumour infiltrating Treg cells. The percentage of cells expressing CD25, GITRhlgh, CD39, 
and CD73 each remained high in the tumour (Figures 3.12 -  3.23). The percent of Treg cells 
expressing CD44hlgh, ICOShlgh, and CD 103 was approximately 50%, 40% and 30% 
respectively in the spleen and lymph nodes (Figure 3.9 [above] and Figures 3.24 -  3.29).
Significant increases in the percentage of Treg cells expressing CD44hlgh, the percentage of 
Treg cells expressing ICOShlgh, and the percentage of Treg cells expressing CD 103 were seen 
in the tumour. In contrast to this pattern, the percent of Treg cells expressing CTLA-4 was 
significantly lower in the tumour (Figures 3.30 -  3.32). An analysis of cytokine expression by 
intracellular staining revealed Treg cells in tumour bearing mice expressed very little 
detectable IL-4, IL-17 or IFNy (Figure 3.33 and Figure 3.34). In the spleen and lymph nodes 
approximately 10% of Treg cells expressed detectable IL-2, approximately 5% of Treg cells 
expressed detectable IL-10, and approximately 5-10% of Treg cells expressed detectable 
TNFa. Interestingly, in the tumour significantly fewer Treg cells expressed detectable levels 
of each of these cytokines. In summary, these data indicate that most of the markers 
associated with the suppressive phenotype of Treg cells are maintained or bolstered on 
tumour infiltrating Treg cells (Figure 3.35). This suggests tumour infiltrating Treg cell are 
likely to be suppressive within the tumour and that most of the purported mechanisms for 
Treg cell suppression remain possible in these cells.
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Figure 3.12. Antibody staining and analysis by flow cytometry of CD25.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for CD25 expression by flow cytometry. Cells were 
stained with anti CD25-PE (B) or rat IgGl-PE isotype control (A) mAbs. Representative dot 
plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg cells from each tissue 
are shown (C).
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Figure 3.13. Percent of Tconv, Treg and CD8+ cells expressing CD25 in tumour bearing 
and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing CD25 was determined 
by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and 
tumour were analysed from tumour bearing mice (n=10). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=6-8). The differences between the means were 
compared using paired T tests.
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Figure 3.14. Percent of Tconv, Treg and CD8+ cells expressing CD25 in tumour bearing 
and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CD25 was determined by flow cytometry. Spleens, non-draining lymph 
nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour bearing mice 
(n=10). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive mice (n=6- 
8). The differences between the means were compared using paired T tests.
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Figure 3.15. Antibody staining and analysis by flow cytometry of GITR.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for GITR expression by flow cytometry. Cells were 
stained with anti GITR-PE (B) or rat IgG2b-PE isotype control (A) mAbs. Representative dot 
plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg cells from each tissue 
are shown (C).
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Figure 3.16. Percent of Tconv, Treg and CD8+ cells expressing GITRhlgh in tumour 
bearing and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing GITRhlgh was 
determined by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph 
nodes (D) and tumour were analysed from tumour bearing mice (n=7). Spleen and pooled 
inguinal lymph nodes (LN) were analysed from naive mice (n=3-6). The differences between 
the means were compared using paired T tests.
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Figure 3.17. Percent of Tconv, Treg and CD8+ cells expressing GITRhlgh in tumour 
bearing and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing GITRhlgh was determined by flow cytometry. Spleens, non-draining 
lymph nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour 
bearing mice (n=7). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive 
mice (n=3-6). The differences between the means were compared using paired T tests.
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Figure 3.18. Antibody staining and analysis by flow cytometry of CD39.
Single cell suspensions of spleen, non-draining lymph nodeC (ND LN), draining lymph node 
(D LN) and tumour were analysed for CD39 expression by flow cytometry. Cells were 
stained with anti CD39-PE (B) or rat IgG2b-PE isotype control (A) mAbs. Representative dot 
plots of CD8+ T cells, CD4+Foxp3" Tconv cells and CD4+Foxp3+ Treg cells from each tissue 
are shown (C).
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Figure 3.19. Percent of Tconv, Treg and CD8+ cells expressing CD39 in tumour bearing 
and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing CD39 was determined 
by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and 
tumour were analysed from tumour bearing mice (n=6). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=3-6). The differences between the means were 
compared using paired T tests.
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Figure 3.20. Percent of Tconv, Treg and CD8+ cells expressing CD39 in tumour bearing 
and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CD39 was determined by flow cytometry. Spleens, non-draining lymph 
nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour bearing mice 
(n=6). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive mice (n=3-6). 
The differences between the means were compared using paired T tests.
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Figure 3.21. Antibody staining and analysis by flow cytometry of CD73.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for CD73 expression by flow cytometry. Cells were 
stained with anti CD73-biotin (B) or rat IgGl-biotin isotype control (A) mAbs. 
Representative dot plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg 
cells from each tissue are shown (C).
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Figure 3.22. Percent of Tconv, Treg and CD8+ cells expressing CD73 in tumour bearing 
and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing CD73 was determined 
by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and 
tumour were analysed from tumour bearing mice (n=6). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=3-6). The differences between the means were 
compared using paired T tests.
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Figure 3.23. Percent of Tconv, Treg and CD8+ cells expressing CD73 in tumour bearing 
and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CD73 was determined by flow cytometry. Spleens, non-draining lymph 
nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour bearing mice 
(n=6). Spleen and pooled inguinal lymph nodes (LN) were analysed from nai've mice (n=3-6). 
The differences between the means were compared using paired T tests.
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Figure 3.24. Antibody staining and analysis by flow cytometry of ICOS.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for ICOS expression by flow cytometry. Cells were 
stained with anti ICOS-biotin (B) or HamsterlgG-biotin isotype control (A) mAbs. 
Representative dot plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg 
cells from each tissue are shown (C).
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Figure 3.25. Percent of Tconv, Treg and CD8+ cells expressing ICOShlgh in tumour 
bearing and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing ICOShlgh was 
determined by flow cytometry. Spleens (n=5-12), non-draining lymph nodes (ND, n=5-8), 
draining lymph nodes (D, n=5-8) and tumour (n=5-12) were analysed from tumour bearing 
mice . Spleen and pooled inguinal lymph nodes (LN) were analysed from naive mice (n=5-6). 
The differences between the means were compared using paired T tests.
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Figure 3.26. Percent of Tconv, Treg and CD8+ cells expressing ICOShlgh in tumour 
bearing and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing ICOSh,gh was determined by flow cytometry. Spleens (n=5-12), non­
draining lymph nodes (ND n=5-8), draining lymph nodes (D n=5-8) and tumour (n=5-12) 
were analysed from tumour bearing mice . Spleen and pooled inguinal lymph nodes (LN) 
were analysed from naive mice (n=5-6). The differences between the means were compared 
using paired T tests.
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Figure 3.27. Antibody staining and analysis by flow cytometry of CD103.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for CD103 expression by flow cytometry. Cells were 
stained with anti CD103-FITC (B) or Hamster IgG-FITC isotype control (A) mAbs. 
Representative dot plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg 
cells from each tissue are shown (C).
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Figure 3.28. Percent of Tconv, Treg and CD8+ cells expressing CD103 in tumour 
bearing and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing CD103 was 
determined by flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph 
nodes (D) and tumour were analysed from tumour bearing mice (Tconv and Treg n=13, CD8+ 
cells n=5). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive mice 
(n=3-6). The differences between the means were compared using paired T tests.
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Figure 3.29. Percent of Tconv, Treg and CD8+ cells expressing CD103 in tumour 
bearing and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CD103 was determined by flow cytometry. Spleens, non-draining 
lymph nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour 
bearing mice (Tconv and Treg n=13, CD8+cells n=5). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=3-6). The differences between the means were 
compared using paired T tests.
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Figure 3.30. Antibody staining and analysis by flow cytometry of CTLA-4.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for CTLA-4 expression by flow cytometry. Cells were 
stained with anti CTLA-4-PE (B) or Hamster IgG-PE isotype control (A) mAbs. 
Representative dot plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg 
cells from each tissue are shown (C).
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Figure 3.31. Percent of Tconv, Treg and CD8+ cells expressing CTLA-4 in tumour 
bearing and naive mice.
The percentage of Treg (A), Tconv (B) and CD8+ (C) cells expressing CTLA-4 was 
determined by flow cytometry. Spleens, non-draining lymph nodes (N E ) ) ,  draining lymph 
nodes (D) and tumour were analysed from tumour bearing mice (Tconv and Treg n=8, CD8+ 
cells n=7). Spleen and pooled inguinal lymph nodes (LN) were analysed from naive mice 
(n=5-6). The differences between the means were compared using paired T tests.
106
Spleen
Tumourbearing
| Tconv
□  Treg
□  CD8
n
to 6 0 *
a) 40*
Spleen | LN 
Naive
Figure 3.32. Percent of Tconv, Treg and CD8+ cells expressing CTLA-4 in tumour 
bearing and naive mice.
The percentage (mean +/-SEM) of Tconv (black bars), Treg (white bars) and CD8+ (grey 
bars) cells expressing CTLA-4 was determined by flow cytometry. Spleens, non-draining 
lymph nodes (ND), draining lymph nodes (D) and tumour were analysed from tumour 
bearing mice (Tconv and Treg n=8, CD8+cells n=7). Spleen and pooled inguinal lymph 
nodes (LN) were analysed from naive mice (n=5-6). The differences between the means were 
compared using paired T tests.
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Figure 3.33. Percent of Treg cells expressing various cytokines in tumour bearing and 
naive mice.
The percentage of PMA and iomomycin stimulated Treg cells expressing IL-2, IL-4, IL-10, 
IL-17, IFNy, and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=7-12) 
and naive mice (n=3) were analysed, The overall cytokine profile of Treg from spleens (A), 
ND lymph nodes (B), D lymph nodes (C), and tumours (D) of tumour bearing mice and 
spleens (E), and lymph nodes (F) of nai've mice are shown.
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Figure 3.34. Percent of Treg cells expressing various cytokines in tumour bearing mice.
The percentage of PMA and iomomycin stimulated Treg cells expressing IL-2, IL-4, IL-10, 
IL-17, IFNy, and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=7-12) 
were analysed. The expression of IL-2 (A), IL-4 (B), IL-10 (C), IL-17 (D), IFNy (E), and 
TNFa (F) within Treg cells from various locations of tumour bearing mice are compared. The 
mean percentages were compared using unpaired T tests.
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Figure 3.35. Overall phenotype of Treg cells in tumour bearing mice.
The percentage (mean +/-SEM) of Treg cells expressing the markers CD25, CD39, CD44, 
CD73, CD103, CTLA-4, GITR and ICOS were determined by flow cytometry. The overall 
phenotype of these cells from the spleens (A), tumours (B), non-draining (C) and draining 
(D) lymph nodes of tumour bearing mice (n=5-12) are shown.
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3.2.4 Do tumour infiltrating Tconv and CD8+ T cells express activation markers?
Many of the markers described above for phenotyping Treg cells are associated with 
activation of T cells. Tconv and CD8+ T cells were stained with these markers in parallel to 
Tregs. It was therefore possible to gain some insight into the activation status of tumour 
infiltrating Tconv cells and CD8+ T cells. Tconv and CD8+ T cells from tumour bearing mice 
were stained with the following panel of activation markers: CD25, CD44, CTLA-4, GITR 
and ICOS (Figure 3.13, Figure 3.9, Figure 3.31, Figure 3.16 and Figure 3.25). CD44 and 
GITR are thought to be constitutively expressed at low levels in T cells and upregulated 
following TCR activation hence high expression levels of these molecules were examined 
(Pure and Cuff 2001, Nocentini et al. 1997, Shimizu et al. 2002). The expression of all the 
activation markers assessed was elevated significantly on Tconv cells within the tumour 
compared to control nodes implying that the cells are activated and are possibly part of an 
anti-tumour immune response (Figures 3.9 -  3.31).
The increase in expression of all activation markers was not observed however, with CD8+ 
cells. Whilst the percentage of CD8+ T cells expressing CD25, CD44h,gh and GITRh,gh were 
significantly greater in the tumour compared to non-draining lymph nodes (Figure 3.13, 
Figure 3.9,Figure 3.16), CTLA-4 and ICOS expression did not change (Figure 3.31 and 
Figure 3.25). Overall, as for the analysis of Tconv cells, these data imply that significantly 
more CD8+ T cells within the tumour (compared to lymph node) are activated and possibly 
part of an anti-tumour immune response (Figure 3.36 and Figure 3.37).
Cytokine production by the same T cell subsets was assessed by intracellular cytokine 
staining. As shown in Figures 3.38-3.41, very little IL-10, IL-4 or IL-17 was detected in
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both Tconv cells and CD8+ T cells from the lymph node nodes and tumour. Similar levels of 
TNFa were detected in Tconv and CD8+ T cells throughout the tumour bearing mice. 
Interestingly, more IFNy+Tconv cells and IFNy+CD8+ T cells were detected in the tumour 
and tumour draining lymph node compared to the non-draining lymph node (Figure 3.39E 
and 3.4IE), suggesting tumour associated Tconv and CD8+ T cells are activated. However, 
contrary to this, significantly less detectable IL-2 was found in Tconv and CD8+ T cells from 
the tumour compared to the lymph nodes (Figure 3.39A and 3.41A).
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Figure 3.36. Overall phenotype of Tconv cells in tumour bearing mice.
The percentage (mean +/-SEM) of Tconv cells expressing the markers CD25, CD39, CD44, 
CD73, CD103, CTLA-4, GITR and ICOS was determined by flow cytometry. The overall 
phenotype of these cells from the spleens (A), tumours (B), non-draining (C) and draining 
(D) lymph nodes of tumour bearing mice (n=5-12) are shown.
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Figure 3.37. Overall phenotype of CD8+ T cells in tumour bearing mice.
The percentage (mean +/-SEM) of CD8+ T cells expressing the markers CD25, CD39, CD44, 
CD73, CD 103, CTLA-4, GITR and ICOS was determined by flow cytometry. The overall 
phenotype of these cells from the spleens (A), tumours (B), non-draining (C) and draining
(D) lymph nodes of tumour bearing mice (n=5-12) are shown.
114
B.
C.
D.
50V
I
2i*>
40
5 0I
t
I
^ l 30
> 020
S |»
?!0 20
10
Tum ourbearing
Sple«n
IL-2 IL-4 IL-10 IL-17 IFNy T N Fa 
Non draining LN
IL-2 IL-4 IL-10 IL-17 IFNy TNFfl 
Draining LN
IL-2 IL-4 IL-10 IL-17 IFNy TN F a 
Tumour
n
IL-2 IL-4 IL-10 IL-17 IFNy TN Fa
i  r
E.
F.
Naive
_ J L _
50
40i
a
a  I  30
? !> o  20
« 10 * 0
5 1 "!L
Spleen
IL-2 IL-4 IL-10 IL-17 IFNy TN F a 
LN
a
IL-2 IL-4 IL-10 IL-17 IFNy T N F a
Figure 3.38. Percent of Tconv cells expressing various cytokines in tumour bearing and 
naTve mice.
The percentage of PM A and iomomycin stimulated Tconv cells expressing IL-2, IL-4, IL-10, 
IL-17, IFNy, and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=8-13) 
and naive mice (n=3) were analysed, The overall cytokine profile of Tconv from spleen (A), 
ND lymph node (B), D lymph node (C), and tumour (D) of tumour bearing mice and spleens
(E), and lymph nodes (F) of naive mice are shown.
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Figure 3.39. Percent of Tconv expressing various cytokines in tumour bearing mice.
The percentage of PM A and iomomycin stimulated Tconv cells expressing IL-2, IL-4, IL-10, 
IL-17, IFNy. and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=8-13) 
were analysed, The expression of IL-2 (A), IL-4 (B), IL-10 (C), IL-17 (D), IFNy (E), and 
TNFa (F) within Tconv cells from various locations of tumour bearing mice are compared. 
The mean percentages were compared using unpaired T tests.
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Figure 3.40. Percent of CD8+ T cells expressing various cytokines in tumour bearing 
and naive mice.
The percentage of PMA and iomomycin stimulated CD8+ cells expressing IL-2, IL-4, IL-10, 
IL-17, IFNy, and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=5-8) 
and naive mice (n=3) were analysed, The overall cytokine profile of CD8+ cells from spleens 
(A), ND lymph nodes (B), D lymph nodes (C), and tumours (D) of tumour bearing mice and 
spleens (E), and lymph nodes (F) of naive mice are shown.
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Figure 3.41. Percent of CD8+ T cells expressing various cytokines in tumour bearing 
mice.
The percentage of PMA and iomomycin stimulated CD8* T cells expressing IL-2, IL-4, IL- 
10, IL-17, IFNy, and TNFa were determined by flow cytometry. Samples from spleens, non­
draining lymph nodes, draining lymph nodes and tumours of tumour bearing mice (n=5-8) 
Were analysed. The expression of IL-2 (A), IL-4 (B), IL-10 (C), IL-17 (D), IFNy (E), and 
TNFa (F) within CD8+ T cells from various locations of tumour bearing mice are compared. 
The mean percentages were compared using unpaired T tests.
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3.3 Discussion
In this Chapter a phenotypic and functional characterisation of tumour infiltrating T cells was 
performed. The following four questions were addressed:
•  Do CD4+ and CD8+ cells control tumour development following Treg depletion?
• Do the ratios of Tconv:Treg and CD8:Treg alter in the tumour compared to lymphoid
tissue?
• Do tumour infiltrating Treg cells display a phenotype associated with
immunosupression?
•  Do tumour infiltrating Tconv and CD8+ T cells express activation markers?
To address whether CD4+ and CD8+ T cells control tumour development following Treg
depletion, CD4 and CD8 specific Abs were given to mice that were earlier injected with
CD25 specific Abs and MCA. These experiments revealed that CD8+ cells but not CD4+ cells
were vital for the control of tumour development following Treg depletion. The same
question has been addressed in other mouse tumour models. Early experiments by Robert
North and co-workers in the 1980s demonstrated that removal of a CD4+ suppressor T cell
population resulted in spontaneous regression o f the lymphoma cell line L5178Y and that this
rejection was mediated primarily by CD8+ T cells (Awwad and North 1988). Following the
identification of CD25 as a marker for Treg cells Onizuka et al. (1999) reported that
depletion of CD25+ cells resulted in CD8+ (and in some cases CD4+) T cell dependant control
of a variety of tumour cell lines in mice. Subsequently, Shimizu et al. (1999) showed that
tumour specific CD8+ T cell responses (as well as NK-like responses) were generated in mice
inoculated with tumour cells after depletion o f CD25+ cells. A number of groups confirmed
these findings and showed that CD8+ and CD4+ T cell mediated immunity developed in mice
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that rejected tumour cells after depletion of CD25+ cells (Sutmuller et al. 2001, Jones et al. 
2002, Casares et al. 2003, Chen et al. 2005). Together these findings demonstrate that both 
CD8+ and CD4+ T cell responses are important in the control of tumours following Treg 
depletion. The dependence on CD8+ T cells for the control of tumour growth in the 
experiments described in this chapter are therefore consistent with many previous reports 
(Awwad and North 1988, Shimizu et al. 1999, Sutmuller et al. 2001, Casares et al. 2003, 
Chen et al. 2005). However, although it is clear that in tumours a direct anti-tumour effect of 
CD4+ T cells is also important, the experiments in this Chapter indicate this is not the case for 
MCA tumours. The reasons for the differences between various mouse tumour models are not 
clear.
CD8+ and CD4+ cells were also depleted in Treg-replete (control Ab treated) mice. Tumour
incidence was not further increased by anti-CD8 nor anti-CD4 Ab treatment suggesting that
CD8+ and CD4+ T cells are not controlling tumour growth in the -13% of mice that remain
tumour free without Treg depletion. Furthermore the depletion of CD8+ cells following Treg
depletion did not reduce tumour incidence beyond -13%, suggesting that CD8+ cells are not
involved in controlling tumour growth in these mice. These findings suggest that in the
fraction o f mice that remain tumour free, the lack of tumour is not due to an anti-tumour T
cell response. At first this may appear to be in contrast to recent findings from Robert
Schreiber’s laboratory where mice apparently tumour free after 200 days were given a
mixture of Abs against CD4, CD8 and IFNy (Koebel et al. 2007). Following anti-
CD4/CD8/IFNy Ab treatment but not control Ab treatment tumour outgrowth occurred. This
indicated the immune system can restrain cancer growth for extended periods of time. In
apparently tumour free mice occult tumours were kept in a state of equilibrium with the anti-
tumour action of the immune system. However, the outgrowth of tumours did not occur in all
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mice treated with the mixture o f Abs. Only 9 out o f 15 (60%) mice developed palpable 
tumours, thus 40% of mice remained tumour free after anti-CD4/CD8/IFNy Ab treatment. 
Therefore, in similarity to the experiments in this Chapter, the results from Koebel et al. 
indicated that in a large proportion o f mice that remained tumour free the immune system 
was not involved in tumour control. Two possible scenarios could account for the lack of 
tumours in these mice. Firstly, the MCA carcinogen simply did not cause a tumour to arise at 
any point. Alternatively, an unobserved tumour arose and was completely eliminated prior to 
the experimental depletion of the immune system.
Under normal physiological circumstances Treg cells prevent autoimmune and inflammatory
disease (Sakaguchi et al. 1995, Kim et al. 2007). This is thought to involve the suppression of
CIX^Tconv and CD8+ T cells (Thornton and Shevach 1998, Kim et al. 2007, Mempel et al.
2006). The suppressive effect o f Treg cells on Tconv and CD8+ T cells has been shown to be
titratable in vitro (Thornton and Shevach 1998, Fontenot et al. 2005b), therefore an
accumulation o f Tregs within tumour tissue compared to lymphoid tissue may indicate that
the impact of Tregs on suppression o f T cell responses is more pronounced at this site. Using
flow cytometry the proportions o f  TconvrTreg and CD8:Treg were compared in tumour and
lymphoid tissue. Significant differences in the ratios o f Tconv:Treg and CD8:Treg were
found in the tumour compared to the lymph node implying that CD8+ T cells and Tconv are
more likely to be suppressed by Tregs in the tumour than in the lymph node. The difference
between the CD8:Treg ratio was even more prominent when only the antigen experienced
fraction of CD8+ T cells were considered. However, the trend was not the same for Tconv
cells. Together this supports the hypothesis that within the tumour Treg cells become
dominant favouring immunosuppression. In order to fully establish whether tumour
infiltrating Treg cells are suppressive during tumour development more studies are clearly
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necessary. A functional analysis o f these cells, for example an in vitro suppression assay may 
help to further support this hypothesis. Preliminary experiments utilising transgenic mice 
(Foxp3_DTR) expressing the diphtheria toxin receptor on Foxp3+ cells have been carried out 
to specifically deplete Foxp3+ cells in MCA tumour bearing mice. These experiments have 
suggested that Treg depletion can slow tumour growth (my own unpublished data).
As mentioned above the Tconv:Treg ratio and particularly the CD8:Treg ratio were altered in 
the tumour tissue compared to lymphoid tissue. However, an additional observation was 
made which showed an interesting link between the Treg and CD8 cell populations. An 
increase in the proportion o f T cells that were Treg cells was matched by a decrease in the 
proportion o f T cells that were CD8+ T cells. When these two values were plotted against 
each other a clear correlation between the CD8+ T cells and Treg cells was observed 
(***P<0.0001; Figure 3.42A). In contrast, no correlation between Tconv and Treg cells was 
observed (Figure 3.42B). It was noticed that generally tumour tissue (blue circles) contained 
a relatively high proportion o f Treg cells and low proportion o f CD8+ T cells which is in 
contrast to non-draining lymph node (green circles) which generally contained a high 
proportion o f  CD8+ T cells and low proportion o f Treg cells. This finding suggests that a 
reciprocal relationship between Treg cells and CD8+ T cells exists within tumour bearing 
mice. This may be due to Treg cells preventing the expansion o f CD8+ T cells. The findings 
of the depletion experiments above also implicated a relationship between CD8+ T cells and 
Tregs in tumour bearing mice suggesting that Treg cells normally inhibit CD8+ T cells which 
can prevent tumour development.
In agreement with the finding above, Sato et al. (2005) found that the ratio o f CD8+ T 
cells:Treg correlated with survival in epithelial ovarian carcinoma patients. High
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Figure 3.42. Correlation between percentage of Treg cells and other T cells.
The proportion of the T cell pool made up by each subset (Treg, Tconv and and CD8 T 
cells) were determined by flow cytometry. The percentage of the T cell pool made up by Treg 
(y axis) was plotted against the percentage of the T cell pool made up by either Tconv cells 
(A) or CD8+ T cells (B; y axis). Samples from spleens (red), tumours (blue), non-draining 
lymph nodes (green) and draining lymph nodes (black) of tumour bearing mice were plotted. 
The r2 value from the Pearson correlation coefficient was determined.
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intratumoural CD8+ T celhTreg ratio correlated with favourable prognosis. Two recentreports 
also assessed the association between T cells, Tregs and patient outcome in patients with 
colorectal tumours. Sinicrope et al. (2009) revealed that a low intraepithelial CD3+:Foxp3+ 
cell ratio was associated with shorter patient survival time. Furthermore, Salama et al. (2009) 
investigated CD8+ T cells and Foxp3+ T cells in normal and tumour tissue from colorectal 
cancer patients and found that although the ratio of CD8+ T celhTreg showed no significance 
in relation to patient outcome, a high density of CD8+ T cells was associated with good 
patient outcome and a high density of Foxp3+ cells in normal tissue was associated with 
significantly worse outcome. However, they also found that a high density of Foxp3+ cells in 
tumour tissue was actually associated with good patient outcome. Thus although these studies 
suggest Foxp3+ Tregs cells can be associated with poor prognosis, in particular when in 
conjunction with a low CD8+ T cell numbers the precise location and function of the Foxp3+ 
cell infiltration may also be significant in predicting patient outcome. Although in this thesis 
the CD8+ T celhTreg ratio was not compared to outcome or survival time, the correlation 
between CD8+ T cells and Treg cells throughout tumour bearing mice suggests that the 
proportions of these two cell types may alter to establish an immunosuppressive environment 
within tumour bearing mice. In particular, in tumour tissue relatively high Treg numbers are 
associated with low CD8 numbers and therefore potentially an immunosuppressive 
environment.
From the analysis of tumour infiltrating lymphocyte populations it was noticed that a large
proportion of the lymphocyte population was not made up of CD4+ T cells or CD8+ T cells.
Thus other cells expand and dominate the lymphocyte pool in tumours and also tumour-
draining lymph nodes. An initial analysis of tumour bearing mice by flow cytometry with a
panel of Abs against other lymphocyte markers suggested that these cells are made up
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primarily by B cells and also NK cells (Appendix Figure A2). However, their role in MCA 
tumour development remains to be fully understood.
The expression o f numerous markers has been associated with the suppressive capacity of 
Treg cells. To assess whether these markers were upregulated within tumour infiltrating T 
cells a detailed phenotypic analysis of Treg cells from tumour bearing mice was performed. 
This revealed that tumour infiltrating Treg cells display a phenotype associated with 
immunosuppression (Being C D 25\ CD44h,gh, CD 39\ CD73+, CD103\ CTLA-4+, ICOShigh, 
GITRh,gh; Figure 3.35). For most of the markers analysed the percentage of Treg cells 
expressing that marker either remained high in all tissues tested or was significantly higher in 
the tumour compared to the lymph node. Studies where Treg cells are depleted in vivo have 
revealed that Treg cells are continuously suppressing autoimmune and inflammatory 
responses in the periphery (Kim et al. 2007). The findings in this Chapter suggest that within 
the tumour, Treg cells are equal, if not better equipped to suppress immune responses than 
Treg cells in lymphoid tissue. Further investigations are now necessary to identify which of 
these markers are important for the function o f Treg cells in tumours.
Although it is not known which mechanism Treg cells use for suppressing immune responses
within tumours, the results in this Chapter indicate that many of the purported mechanisms
remain possible. CD25 has been linked with Treg activity through its ability to bind to IL-2
and act as an ‘IL-2 sink’ (Thornton and Shevach 1998, de la Rosa et al. 2004, Barthlott et al.
2005, Pandiyan et al. 2007). It has been suggested that constitutive expression of CD25 (IL-
2R) endows Treg cells a competitive advantage over other T cells which have relatively
fewer cells expressing CD25 (Barthlott et al. 2005, de la Rosa et al. 2004). Thus Treg cells
consume IL-2 thereby inhibiting other T cells (de la Rosa et al. 2004, Barthlott et al. 2005,
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Pandiyan et al. 2007). In this Chapter it was demonstrated that within the tumour 
significantly more Treg cells express CD25 compared to Tconv and CD8+ T cells. 
Furthermore, an assessment of the expression of IL-2 by tumour infiltrating T cells indicated 
that compared to lymph node within the tumour low levels of IL-2 are produced by these 
cells (Figure 3.39 and Figure 3.41). This suggests that relatively small amounts of IL-2 may 
be available within the tumour. Furthermore, Treg cells within the tumour may ‘mop up’ the 
limited IL-2 that is available within the tumour preventing Tconv and CD8+ T cells to 
expand. To investigate this possibility further experiments are underway within our 
laboratory to more accurately measure IL-2 levels within the tumour using RT-PCR and 
ELISA (enzyme linked immunoassay). Together these findings also indicate that 
administration of IL-2 could act as a possible treatment strategy by providing enough IL-2 for 
all T cells within the tumour and therefore aiding the expansion of Tconv and CD8+ T cells 
within the tumour. Interestingly, this strategy has already shown modest efficacy in the 
treatment of melanoma, renal carcinoma and other types of cancer (Smith et al. 2008, 
Rosenberg et al. 1998), but this treatment is also associated with significant toxicity.
Extracellular adenosine is a potent immunosuppressor that accumulates during tumour
growth and can inhibit the activity of anti-tumour T cells (Ohta et al. 2006, Pellegatti et al.
2008). Expression of the ectonucleotidases CD39 and CD73 on Treg cells is thought to play a
role in Treg activity through catabolism of adenosine derivatives into adenosine (Kobie et al.
2006, Deaglio et al. 2007, Borsellino et al. 2007). Furthermore, these studies showed that
specific inhibitors of adenosine production can reverse the suppressive effects of Treg cells in
vitro. In this Chapter it was found that the percentage of Treg cells expressing CD39 and the
percentage of Treg cells expressing CD73 were very high (mean >95%) in the tumour. To
further examine whether adenosine catabolism by these enzymes contributes to suppression
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of the immune responses to tumour, inhibitors o f these ectonucleotidases described by other 
groups (Kobie et al. 2006, Deaglio et al. 2007, Borsellino et al. 2007) could be tested in this 
model, initially perhaps in an in vitro suppression assay using Treg cells derived from the 
tumour and ultimately in vivo in tumour bearing mice. Interestingly, within the tumour a large 
percentage (mean >60%) of Tconv and CD8+ T cells also expressed CD39 and CD73. 
Therefore if a suppressive role for CD39 and CD73 was discovered within tumours, their 
expression on tumour infiltrating Tconv and CD8+ T cells may suggest that suppression via 
this mechanism is not restricted to the action Foxp3+Treg cells.
It has been suggested that a distinct subset o f (effector/memory) Treg cells exists that is
discriminated by the expression of CD103. CD103+ Tregs are reported to have a distinct
cytokine profile, be highly proliferative and have a unique ability to home to sites of
inflammation therefore providing a first line o f  defence against harmful inflammatory
reactions (Lehmann et al. 2002, Siewert et al. 2008, Huehn et al. 2004, Suffia et al. 2005).
The expression of CD 103 in T cells is upregulated by TGF0 (Robinson et al. 2001), a
cytokine that can be highly expressed at sites o f inflammation (reviewed in Letterio and
Roberts 1998) and also in MCA tumours (unpublished data from Dr B. Ondondo and Dr E.
Jones). Recent findings indicated that an accumulation of CD103+Treg cells in the tumour
and spleen was responsible for the loss of concomitant immunity in mice bearing the colon
cancer cell line CT-26 (Lin et al. 2009). In this Chapter it was found that the percent of Treg
cells expressing CD 103 was significantly greater within the tumours than in the lymph nodes
suggesting that CD103+Tregs may play a role in preventing anti-tumour immunity. In
contrast to the findings o f Lin et al. the percentage o f Treg cells expressing CD103 was not
significantly altered within the spleen of tumour bearing mice suggesting that these cells do
not lead to a systemic inhibition of anti-tumour immunity in mice with MCA tumours. The
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primary ligand for CD 103 (aEp7 integrin), E-Cadherin has been found to be expressed in 
numerous tumours, although its loss is actually associated with invasive phenotypes 
(Schipper et al. 1991, Umbas et al. 1992, Oka et al. 1993, Mayer et al. 1993, Bringuier et al. 
1993, Gamallo et al. 1993). However, through binding to ligands, such as E-Cadherin, 
CD 103 expression may give cells an ability to be retained within tumour tissue, particularly 
at early stages of tumour development. Given that within MCA tumours the percentage of 
Tconv and CD8+ T cells which express CD103 is approximately 30% (Figure 3.28 B and 
3.28 C), whereas in contrast approximately 70% of Treg cells express CD103 (Figure 3.28 
A), Treg cells may have an added ability to be retained within the tumours compared to 
Tconv and CD8+ T cells. To further support this hypothesis E-Cadherin expression should be 
examined within MCA tumours.
It has previously been shown that Treg cells can express ICOS and that ICOS may be linked 
to the suppressive capacity and proliferation of Treg cells (Ito et al. 2008). ICOShlgh Tregs 
appear to be more suppressive than ICOSlow Tregs suggesting a possible role for ICOS in the 
immunosuppressive function of these cells (Ito et al. 2008, Strauss et al. 2008). Indeed, high 
ICOS levels were shown to be associated with higher Foxp3 expression and ICOS has been 
implicated as being important for the stimulation of IL-10 production by T cells (Ito et al. 
2008, Akbari et al. 2002, Tuettenberg et al. 2009, Strauss et al. 2008). A significantly higher 
percentage of Treg cells were found to be ICOSh,gh in the tumour compared to the lymph 
node. However, no significant difference in IL-10 production was detected in tumour 
infiltrating Tregs compared to Treg cells from the lymph node suggesting tumour infiltrating 
Treg may not suppress via IL-10 and that in this environment an increase in ICOS expression 
is not linked to an increase in IL-10 production.
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Another molecule which was found to be expressed on significantly more Treg cells in the 
tumour than in the lymph node was CD44. CD44 is an adhesion molecule that is expressed 
on most cells (reviewed in Ponta, Sherman and Herrlich 2003). It is commonly used as an 
activation marker for T cells as its expression is upregulated following TCR activation and 
remains highly expressed on memory T cells (Purd and Cuff 2001). It is thought that the 
majority of Treg cells express CD44 at high levels (Fisson et al. 2003). Within the non­
draining lymph node of MCA tumour bearing mice approximately 50% of Treg cells 
expressed CD44hlgh whereas in the tumour ~80% of Treg cells expressed CD44hlgh. Although 
it is commonly used as a marker of T cells which have been activated, the role of CD44 has 
remained elusive. Recent evidence from CD44'/‘ mice showed CD44 played an essential role 
in the survival and memory development of Thl cells (Baaten et al. 2010). CD44 positively 
correlated with Foxp3 expression and suppressive capacity of Treg cells (Liu et al. 2009a). 
There is also evidence to show that an activated (hylanuronic acid binding) form of CD44 
correlates with more suppressive regulatory T cells (Firan et al. 2006). Furthermore, it has 
recently been shown that CD44 costimulation (using antibodies to CD44 or by binding to its 
ligand hyaluronic acid) can promote Foxp3 expression and in certain circumstances the 
production of IL-2, IL-10 and TGFp (Bollyky et al. 2009). Hyaluronic acid (HA) is a 
glucosaminoglycan distributed widely throughout connective tissue and epithelial tissue 
which is thought be required for extracellular matrix formation and facilitating cell 
behaviour, such as cell proliferation, differentiation and migration (reviewed in Laurent and 
Fraser 1992). There is also evidence to suggest a role for HA in tumour progression through 
interactions with cell surface receptors, such as CD44 (Ahrens et al. 2001a, Ahrens et al. 
2001b). Interestingly, it has been demonstrated that MCA tumours contain several types of 
gylcosaminoglycans, of which hyaluronic acid is the major component (Wolanska et al.
1996, Asokan et al. 1989). Furthermore, the amount of glycosaminoglycans increased during
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tumour growth. Clearly the role of HA and its potential role in promoting Treg survival or 
activity requires further experimentation to be verified. Another ligand for CD44, osteopontin 
has been shown to contribute to various cell functions including chemotaxis, cell survival and 
proliferation (reviewed in Mazzali et al. 2002). Analysis of MCA tumours has shown that this 
molecule is abundantly expressed in MCA tumours (Dr B. Ondondo unpublished). 
Osteopontin may therefore provide important survival signals to cells expressing CD44 such 
as Treg cells.
The percentage of Treg cells expressing high levels of GITR was consistently high 
throughout tumour bearing mice. This finding is in agreement with previous reports which 
show constitutively high expression of GITR in Tregs (McHugh et al. 2002, Shimizu et al. 
2002). Removal of GITR+ T cells or administration of GITR-specific Abs produces organ- 
specific autoimmune disease in mice similar to that observed in mice depleted of Tregs 
suggesting that GITR plays a role in Treg cell mediated self tolerance (Itoh et al. 1999). More 
recent studies have shown that administration of Abs against GITR enables immune mediated 
rejection of the melanoma cell line B16 in mice (Ramirez-Montagut et al. 2006) and can 
result in concomitant immunity to B16 tumours (Turk et al. 2004). Furthermore, reports 
indicate that GITR is required for Treg activity in vitro (Itoh et al. 1999, McHugh et al. 2002, 
Tone et al. 2003, Ji et al. 2004). However, the role of GITR interaction in Treg cell mediated 
suppression has not been fully determined. More recent studies suggest GITR ligation can 
induce preferential expansion of Treg cells in vitro and in vivo (Ramirez-Montagut et al. 
2006, Nishioka et al. 2008, Liao et al. 2010, van Olffen et al. 2009), thus GITR may be 
important for the accumulation of Treg cells in tumours. To support this hypothesis the 
presence of the ligand for GITR (GITR-L), which can be found on APCs (Kim et al. 2003, 
Suvas et al. 2005) must be investigated in MCA tumours.
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The expression of CTLA-4 was also analysed in MCA tumour bearing mice. CTLA-4 has 
been reported to be constitutively expressed on Treg cells (Read et al. 2000, Takahashi et al. 
2000). Furthermore, these studies identified that CTLA-4 is an important component of the 
immunosuppressive capacity of Treg cells. In contrast to many of the markers assessed, the 
percentage of Treg cells expressing CTLA-4 was significantly less within the tumour than 
within the lymphoid tissue (Figure 3.31). Therefore, although CTLA-4 expression remains on 
many of the tumour infiltrating Treg cells this finding suggest that CTLA-4 may be 
dispensable for Treg mediated suppression within the tumour. This hypothesis is supported 
by some in vitro studies which show that CTLA-4 is not required for all normal Treg 
activities (Tang et al. 2004, Kataoka et al. 2005). However, Treg-specific deletion of CTLA- 
4 causes spontaneous development of systemic lymphoproliferation and fatal disease in mice 
highlighting its importance in Treg cell development (Wing et al. 2008, Sojka, Hughson and 
Fowell 2009). Furthermore, Treg cells from CTLA-4 deficient mice are unable to control 
pancreatic tissue destruction by autoantigen-specific T cells (Schmidt et al. 2009, Ise et al. 
2010). Collectively these studies show that CTLA-4 is essential for Treg development and 
acquisition of a full suppressive capacity. However, the requirement of CTLA-4 for the 
action of Treg mediated suppression needs further examination.
Most of the markers assessed for investigating the Treg cell phenotype are associated with
activation of conventional T cells. As Abs to both CD4 and CD8 were used in the Ab panels
described above it was possible to also assess the expression of these activation markers on
Tconv and CD8+ T cells from tumour bearing mice. This analysis revealed that many markers
associated with activation were expressed on tumour infiltrating Tconv and CD8+ T cells
suggesting that an increased proportion of Tconv and CD8+ T cells are activated in the
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tumour compared to the lymph node. An increase in the percentage of cells expressing IFNy 
was also observed in the tumour compared to lymph nodes suggesting that Tconv and CD8+ T 
cells are also functionally more active in the tumour than in the lymph nodes. For a more 
complete analysis of the activation status of tumour infiltrating T cells a number of other 
markers could have been measured, for example CD69, CD62L, CD45RA, CD45RO and 
0X40.
It is also interesting to note that despite an 8 fold increase in the number of cells within the 
draining lymph node compared to the non-draining lymph node (Figure 3.4) most of the 
Tconv cells and CD8+ T cells within the draining lymph node were not CD44hlgh (Figure 3.9). 
The reasons for this apparent paradox are not clear. It may be that simply the vasculature of 
the draining lymph node is increased therefore allowing an influx of cells non-specifically 
(Steeber et al. 1987, Herman et al. 1972, Anderson et al, 1975). However, it has also been 
shown that during chronic infection and in tumours exhausted (PD-1+) T cells can show 
markedly lower levels of CD44 expression (Sakuishi et al. 2010, Wherry et al. 2003).
Very few Tconv and CD8+ T cells expressed IL-4, IL-10 or IL-17. These results indicate that 
the T cell response in the tumour is primarily a Thl associated response. This is in agreement 
with numerous reports from other laboratories that show Thl associated cytokine production 
in response to tumours (Zitvogel et al. 1996, Matsui et al. 1999, Nishimura et al. 1999b, 
Egeter et al. 2000).
Although in the tumour numerous activation markers are upregulated on both Tconv and
CD8+ T cells and many of these cells express an antigen experienced phenotype, it is clear
that these cells were not able to effectively control tumour development. This may indicate
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that many of the Tconv and CD8 T cells within the tumour are exhausted, anergic or 
suppressed by tumour infiltrating Treg cells. Indeed, although an increase in the percentage 
of T cells expressing an activated phenotype was observed in the tumour compared to the 
lymph node, it still remained that the majority of tumour infiltrating Tconv and CD8+ T cells 
did not express an activated phenotype. This was particularly noticeable for CD8+ T cells. 
The expression of CTLA-4 and ICOS are two clear examples of this. These two 
costimulatory molecules are reported to be upregulated following activation of T cells 
(Freeman et al. 1992, McAdam et al. 2000, HutlofT et al. 1999, Brunet et al. 1987), however 
>90% of tumour infiltrating CD8+ T cells did not upregulate expression of these markers. 
Similarly, although an increase in the expression of the cytokine IFNy was observed in 
tumour infiltrating T cells versus T cells from lymph node, it remains that the majority of 
tumour infiltrating Tconv and CD8+ T cells do not express any detectable cytokines.
' Furthermore, a significant reduction in the expression of IL-2 was found in tumour
infiltrating Tconv and CD8+ T cells compared to lymph node resident Tconv and CD8+ T 
cells. It has been shown that following T cell activation IL-2 is produced, however co­
stimulation is required for this process (Thompson et al. 1989, reviewed in Linsley and 
Ledbetter 1993). CD28 ligation, for example, is thought to stabilise IL-2 mRNA and also 
activate transcription factors that increase the transcription of IL-2 mRNA (Ragheb, Deen 
and Schwartz 1999, Sanchez-Lockhart et al. 2004). However, antigen recognition in the 
•> absence of co-stimulation inactivates T cells inducing anergy (Harding et al. 1992, Tan et al. 
1993, Chen and Nabavi 1994). The reduction in IL-2 production by tumour infiltrating Tconv
i and CD8 may be due to inefficient T cell stimulation, particularly co-stimulation, leading to
■ ■.*
anergy of these cells and an ineffective immune response. Indeed, a hallmark of anergic T
cells is their inability to produce IL-2 (Maci£n et al. 2002, Jenkins et al. 1987). However,
I* contrary to this, it has been shown that memory responses do not necessarily require
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costimulation for activation (reviewed in Duttagupta et al, 2009). Clearly more work is 
needed to test the reasons for reduced IL-2 production by T cells in tumours.
A significant co-inhibitory molecule which was not investigated in this thesis is Programmed 
Death-1 (PD-1). PD-1 is expressed on the surface of T cells following activation and is 
thought to negatively regulate immune responses (reviewed in Riley 2009). Specifically, 
engagement of PD-1 with its ligands PD-L1 or PD-L2 can inhibit T cell proliferation, 
cytokine production and cytolytic function. Experiments using mice lacking PD-1 or blocking 
antibodies against PD-1 ligands suggest that the induction and maintenance of tolerance 
requires PD-1 (Nishimura et al. 1999a, Nishimura et al. 2001, Okazaki et al. 2003, Ansari et 
al. 2003, Keir et al. 2006). However, the PD-1 :PD-L pathway may also enable the 
persistence of chronic infections and tumour survival (reviewed in Keir et al. 2008). Tumour 
cells may escape anti-tumour immune responses by expressing PD-1 ligands. Indeed, PD-1 
ligands are found on many human cancer tissues (reviewed in Okazaki and Honjo 2007) and 
PD-1 expression is found on tumour infiltrating lymphocytes (Matsuzaki et al. 2010, Sfanos 
et al. 2009, Ahmadzadeh et al. 2009, Fourcade et al. 2009). The expression of PD-1 and its 
ligands in MCA tumours has not yet been investigated, but may be important in modulating 
the immune response generated in these mice.
Another interesting pattern was observed in the expression of CD 103 on CD8+ T cells from
MCA tumour bearing mice. The percentage of CD8+ T cells that expressed CD 103 was found
to be significantly less within tumour compared to lymph node. Although the implications of
this are not clear, CD 103 expression on CD8+ T cells has recently been shown to correlate
with CTL function and retention in tumours (Franciszkiewicz et al. 2009). Studies have also
shown that CD 103 endows peripheral CD8+ cells with a unique capacity to access and
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ultimately destroy graft renal epithelial cells (Feng et al. 2002, El-Asady et al. 2005). 
Furthermore, a recent finding by Webb et al. (2010) suggested that CD 103 marked activated 
and tumour reactive CD8 T cells in high-grade serous ovarian cancer. However, an 
infiltration of these cells was observed in these cancer patients, and in the MCA tumour 
analysed herein indicating that the presence of CD103+ CD8+ T cells is unable to prevent 
tumour outgrowth. Therefore more work is clearly necessary to determine whether CD 103 
expression on CD8+ T cells infiltrating tumours is required for its destruction.
In summary, in this Chapter a phenotypic and functional analysis of T cells from MCA 
tumour bearing mice was performed. This analysis revealed several interesting findings. 
Firstly, it was demonstrated that CD8+ T cells control tumour development following Treg 
depletion. Also, it was found that the ratios of Tconv and particularly CD8+ T cells to Treg 
cells altered significantly within the tumour supporting the hypothesis that an environment 
favouring immunosuppression is established in tumours. Tumour infiltrating Treg cells 
displayed a highly suppressive phenotype and although the expression of numerous activation 
markers was elevated in tumour infiltrating Tconv and CD8+ T cells compared to these cells 
from other locations, for each marker only a small proportion of tumour infiltrating Tconv 
and particularly CD8+ T cells appeared to show expression. Collectively, the data presented 
in this Chapter support the hypothesis that Treg cells accumulate in tumours and gain control 
ofCD8+ T cells, impairing their function and preventing anti-tumour immunity.
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Chapter 4 — Investigation into the mechanisms leading to 
accumulation of regulatory T cells in tumours
4.1 Introduction
One mechanism through which the immune response to tumours might be subverted is by the 
activity of regulatory T cells (Tregs) within the tumour tissue and tumour draining lymph 
nodes. The normal functions of Tregs are to maintain immune homeostasis, prevent 
autoimmunity and limit immunopathology (reviewed in Sakaguchi 2004). However, many 
groups have reported, in studies of both mouse models and patients with cancer, that tumour 
development is often associated with a significant enrichment of Tregs in peripheral blood, 
local lymph nodes and tumour tissue (reviewed in Betts et al. 2006). Using the chemical 
carcinogen 3-methylcholanthrene (MCA), our laboratory previously examined the impact of 
Tregs on tumour immunosurveillance (Betts et al. 2007). Tregs are significantly enriched in 
MCA-induced tumours (fibrosarcomas) compared to lymphoid tissue and even a partial and 
transient depletion of these cells results in a marked reduction in tumour incidence. This 
observation, along with other studies, supports the hypothesis that tumours can utilize Tregs 
for their own advantage by promoting Treg activity (Shimizu et al. 1999, Jones et al. 2002, 
TUrk et al. 2004, Yu et al. 2005). As well as their potential for limiting the effectiveness of 
tumour immunosurveillance, it is likely that Tregs also represent a significant obstacle to 
successful immunotherapy (reviewed in Zou 2006). It is important, therefore, to understand 
foe factors that lead to the enrichment of Tregs during tumour progression to enable the 
development of inhibitory strategies.
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The majority o f Tregs which express the transcription factor Foxp3 (termed naturally
occurring Tregs) are generated in the thymus as a distinct cell lineage (Fazilleau et al. 2007,
Hsieh et al. 2006, Pacholczyk et al. 2006). Foxp3+ Tregs may also be generated in the
periphery through the conversion of conventional Foxp3* T cells (Tconv) into Foxp3+ Tregs;
these have been termed adaptive (or induced) Tregs (reviewed in Bluestone and Abbas 2003).
Experiments using mice with restricted TCR repertoires and limited studies in humans have
suggested that the TCR repertoires of Tregs and Tconv cells are largely distinct, overlapping
by approximately 10 -  20% (Hsieh et al. 2006, Pacholczyk et al. 2006, Scheinberg et al.
2007, Wong et al. 2007b). It has been suggested that Tconv cells with TCRs overlapping with
those of the Treg repertoire represent cells that recognize self-antigens (Hsieh et al. 2006).
Adaptive Tregs that have arisen by conversion of Tconv cells in the periphery may also
contribute to the observed overlap in the TCR repertoires. The role and significance of
adaptive Tregs in vivo, however, is unclear as the majority of the peripheral Treg repertoire is
also represented within the thymic Treg repertoire (Hsieh et al. 2006). Furthermore, TCR
repertoire studies of diabetogenic NOD mice indicated a lack of conversion in autoimmune
disease (Wong, Mathis and Benoist 2007a). However, studies showing that tumours can
facilitate conversion of Tconv cells into Treg cells in vitro (Liu et al. 2007) and, more
recently, in vivo, imply that conversion can potentially contribute to the accumulation of
tumour-infiltrating Tregs (Valzasina et al. 2006, Zhou and Levitsky 2007). In many of these
studies, TGFp has been identified as a key cytokine for the induction of Foxp3. Work from
our laboratory has shown that MCA tumours contain large amounts of TGFP (Dr E. Jones
and Dr B. Ondondo, unpublished, Appendix Figure A3). This finding indicates that the
tumour microenvironment established in MCA tumours may promote the conversion of
Tconv cells into Treg cells. The influence of the tumour environment on Treg proliferation
and survival might also make an important contribution to the enrichment of Tregs within
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TIL populations. It is known that Tregs exhibit a higher turnover than Tconv cells under 
homeostatic conditions and that tumours can license dendritic cells (DCs) to promote the 
proliferation o f Tregs in lymph nodes via TGFp (Ghiringhelli et al. 2005).
Whilst informative, the tumour models described here, often using tumour cell lines and 
tracking the fate of adoptively transferred T cells, omit interactions between the immune 
system and the tumour during the early stages of tumour development; the reciprocal 
influences of the immune system and the tumour during these stages are likely to have a 
significant impact on the nature of their relationship during the period of tumour outgrowth. 
In this Chapter, the MCA tumour induction model, which takes these early interactions into 
account, was used to analyze the TCR repertoires of conventional and regulatory T cells in 
Ofder to assess the contribution o f conversion as well as proliferation and survival to Treg 
enrichment in tumours.
4.2 Results
42.1 Does conversion of conventional T cells into regulatory T cells account for Treg 
eefl enrichment in tumours?
To investigate whether conversion o f conventional CD4+ T cells (Tconv) into Treg cells
contributes to Treg accumulation in tumours the TCR repertoires of the two populations were
compared. As described in Chapter 1 the TCR repertoires of Tconv and Treg cells have been
previously investigated. Experiments using mice with restricted TCR repertoires and limited
studies in humans have suggested that the TCR repertoires of Tregs and Tconv cells are
largely distinct, overlapping by approximately 10 — 20% (Hsieh et al. 2006, Pacholczyk et al.
2006, Fazilleau et al. 2007, Scheinberg et al. 2007). For the studies described in this Chapter,
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it was surmised that if Treg enrichment in tumours is due to the conversion of Tconv cells 
into Treg cells, then the degree of overlap between their TCR repertoires would be 
significantly greater in the tumour compared to other lymphoid tissues where Treg 
enrichment is not observed (Figure 4.1). Thus, the extent of TCR repertoire overlap in Treg 
and Tconv populations isolated from tumour, spleen, non-draining inguinal lymph node and 
draining inguinal lymph node was compared. For this purpose, the CD4+ T cells from 
tumour-bearing mice were purified by flow cytometry.
4.2.2 Similarity between the TRBV13 TCR repertoires of CD4+CD25' T cells and 
CD4+CD25+ T cells
Given that many thousands of unique clonotypes can comprise a single T cell receptor p 
chain variable domain (TRBV) subset it was decided that a single TRBV subset would be 
analysed in detail. Based on previous work from our laboratory performed by Dr Gareth Betts 
it was decided that the TRBV13 (Vp8) subset would be used as this VP gene was well 
represented (approximately 15-20%) within the total Vp TCR repertoires of both Tconv and 
Treg cells from tumour and spleen of tumour bearing mice (Appendix Figure A4 and Figure 
A5). The TRBV 13 chain consists of three further subsets 13-1, 13-2 and 13-3. Initially all 
three were analysed.
For this initial experiment, cells were sorted based on expression of CD25. CD25 has been 
extensively used as a marker for Tregs because the majority of Foxp3+ Treg cells express 
CD25. The advantage of CD25 over Foxp3 as a marker for Tregs is that CD25 is expressed 
on the cell surface allowing for sorting of the cells without permeabilisation. CD4+CD25’ T 
cells and CD4+CD25+ T cells (simply referred to as CD25' and CD25+ T cells hereafter) were
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Figure 4.1. Diagrammatic representation of the hypothesis for studying conversion of 
Tconv into Treg by TCR repertoire analysis
Previous studies have found that the TCR repertoires of Tconv and Treg are generally 
distinct. Approximately 10-20% of the repertoires were found to be overlapping. Therefore in 
non-tumour sites such as the spleen and non-draining lymph node a low level of overlap was 
expected (A) whereas in the tumour (and possibly tumour draining lymph node) if Treg cells 
were accumulating through the conversion of Tconv cells it was surmised that a significant 
increase in the degree of overlap between the Treg repertoire and Tconv repertoire would be 
observed (B).
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sorted from the spleen and tumour of an MCA tumour bearing C57BL/6 (WT) mouse. 
Clonotyping for the three TRBV 13 subsets was performed as described in Materials and 
Methods. In total 873 TCR sequences were analysed for this initial experiment (Table 4.1).
Firstly, the number of overlapping or shared sequences between the TCR repertoires of 
CD25+ and CD25'T cells were analysed for each of the three TRBV13 subsets for the spleen 
and tumour samples. For the TRBV 13-1 subset in the spleen, 1 out of 30 (3.3%) different 
CD25+ TCR clonotypes overlapped with the CD25' TCR repertoire (Figure 4.2A). This one 
TCR clonotype represented 2.2% (2 out of 90) of the spleen CD25+ TCR repertoire analysed. 
Thus the CD25+ and CD25' T cell TCR repertoires were generally distinct within the spleen.
In contrast, in the tumour, more overlapping sequences were observed. Out of 11 different 
TRBV 13-1 CD25+ T cell TCR sequences, 3 (27%) overlapped with the tumour TRBV 13-1 
CD25' T cell TCR repertoire (Figure 4.2B). These represented a large proportion (58%; 28 
out of 48) of the tumour CD25+ T cell TCR repertoire.
The number of overlapping sequences between the CD25+ and CD25‘ T cell repertoires was
also greater within the tumour than in the spleen for the TRBV 13-2 and TRBV 13-3 TCR
subsets (Table 4.2 and Figure 4.3 & Figure 4.4). For the TRBV13-2 subset, in the spleen, 3
out of 50 (6%) different CD25+ TCR clonotypes overlapped with the CD25' TCR repertoire
(Figure 4.3A). These 3 clonotypes made up 13.5% (12 out of 89) of the total spleen CD25+
TRVB13-2 repertoire. In contrast, in the tumour 3 out of 4 (75%) different CD25+ TRBV 13-2
clonotypes were found to be overlapping with the CD25' TCR repertoire (Figure 4.3B). This
made up 48% (46 out of 95) of the tumour CD25+ TRBV 13-2 repertoire. Finally, the
TRBV 13-3 repertoires also showed similar patterns. In the spleen, 3 out of 38 (8%) different
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Experiment 
/ Mouse 
num ber TCR su b se t
Cell
type Spleen ND D Tumour Total
1 TRBV 13-1 CD25" 82 * * 44 126
CD25+ 90 * * 48 138
TRBV 13-2 CD25' 88 * * 84 172
CD25+ 89 * * 95 184
TRBV 13-3 CD25- 90 * * 41 131
CD25+ 79 * * 43 122
Total: 518 * * 355 873
2 TRBV 13-2 Tconv 80 83 82 84 329
Treg 80 88 86 79 333
Total: 160 171 168 163 662
3 TRBV 13-2 Tconv 84 81 78 93 336
Treg 79 92 82 90 343
Total: 163 173 160 183 679
4 TRBV 13-2 / Tconv 51 64 53 40 208
TRBJ 2-5 Treg 55 62 53 63 233
Total: 106 126 106 103 441
Grand total: 947 | 470 434 I 804 2655
Table 4.1. Number of successful traces / sequences analysed.
The number of successful traces that were obtained for the spleens, non-draining lymph 
nodes (ND), draining lymph nodes (D) and tumours from each experiment are given (* = not 
done).
142
A.
B. £
aoa
c
g
§
I
in
OO
10
QO
m
QO
m
QO
50
25
0
25
50
CD25+ n=90(30) Spleen
2.2%
Unique TCR0 CDR3 sequences
CD25- n=82(78)
L  CD25+ n=48(11) Tumour
- 1—■—■—■—■—1—1—»—i__
CD25- n=44(18)
Unique TCRp CDR3 sequences
Figure 4.2. TRBV13-1 TCR repertoires of CD4+CD25‘ and CD4+CD25+cells
T cells were FACS sorted based on their expression of CD4 and CD25 and cells were 
analysed by TCR clonotyping. CDR3 amino acid sequences of the TRBV 13-1 subset were 
determined and used to identify individual TCRs for each T cell subset from the spleen (A), 
tumour (B) of mice given MCA. Each graph displays the different TCR sequences observed 
(x axis) within the CD25+ (filled & above) and CD25' (open & below) repertoires and the 
frequency (y axis) of each sequence within each subset. The total number of TCR sequences 
analyzed is displayed as n=, with the number of unique TCR sequences observed in 
parentheses. The proportion of the CD25+ repertoire that has shared sequences with the 
CD25' repertoire is also shown.
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i
TRBV
subset Tissue
Number of CD25* TCR 
sequences that 
overlap with CD25* 
TCR repertoire
Frequency of I 
overlapping sequences 
within CD25* TCR 
repertoire?
Morisita-
Horn
index
13-1 Spleen 1 out of 30 (3.3%) 2 out of 90 (2.2%) 0.008
Tumour 3 out of 11 (27.3%) 28 out of 48 (58.3%) 0.837
13-2 Spleen 3 out of 50 (6.0%) 12 out of 89 (13.5%) 0.015
Tumour 3 out of 4 (75.0%) 46 out of 95 (48.4%) 0.269
13-3 Spleen 3 out of 38 (7.9%) 3 out of 79 (3.8%) 0.034
Tumour 2 out of 12(16.7%) 13 out of 43 (30.2%) 0.083
Total / 
Average
Spleen 7 out of 118(5.9%) 17 out of 258 (6.6%) 0.019
Tumour 8 out of 27 (29.6%) 87 out of 186 (46.8%) 0.396
Table 4.2. Similarity between CD25+ and CD25' TCR repertoires in mouse 1
The number of CD4 CD25+ TCR sequences that overlap with the CD4+CD25‘ TCR 
repertoire was determined for each TRBV 13 subset for the spleen and tumour. Data are also 
displayed to show the proportion of the CD25+ TCR repertoire that overlapped with the 
CD25* TCR repertoire. The Morisita-Hom similarity index between the CD25* and CD25+ 
TCR repertoires was also determined.
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Figure 4.3. TRBV13-2 TCR repertoires of CD4+CD25 and CD4+CD25+ cells
T cells were FACS sorted based on their expression of CD4 and CD25 and analysed by TCR 
clonotyping. CDR3 amino acid sequences of the TRBV 13-2 subset were determined and used 
to identify individual TCRs for each T cell subset from the spleen (A), tumour (B) of mice 
given MCA. Graphs are displayed as described for Figure legend 4.2.
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Figure 4.4. TRBV13-3 TCR repertoires of CD4+CD25 and CD4+CD25+ cells 
T cells were FACS sorted based on their expression of CD4 and CD25 and analysed by TCR 
clonotyping. CDR3 amino acid sequences of the TRBV 13-3 subset were determined and used 
to identify individual TCRs for each T cell subset from the spleen (A), tumour (B) of mice 
given MCA. Graphs are displayed as described for Figure legend 4.2.
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CD25+ sequences were found to overlap with the CD25' repertoire (Figure 4.4A). These 3 
sequences represented 3.8% (3 out of 79) of the CD25+ TRBV 13-3 repertoire. However, in 
the tumour, more overlap was observed. Out of 12 different clonotypes, 2 (16.7%) 
overlapped (Figure 4.4B). This equated to 30% (13 out of 43) of the CD25+ TRBV13-3 
repertoire in the tumour. On average, in the spleen approximately 6% of the CD25+ TCR 
repertoire overlapped with the CD25' T cell repertoire. In the tumour, on average 
approximately 46% of the CD25+ TCR repertoire overlapped with the CD25' repertoire. This 
difference was statistically significant (*P=0.0473; Figure 4.5A).
To further this analysis the Morisita-Horn (MH) similarity index was used to quantify the 
degree of similarity between each subset. This index is more complex than simply measuring 
the proportion of the CD25+ TCR repertoire that overlaps with the CD25' TCR repertoire. 
The MH index ranges from 0 to 1, representing complete dissimilarity to identical. It takes 
into account the following: a) the number of overlapping TCR sequences; b) how well 
represented those overlapping sequences are; and c) the number and representation of those 
sequences within both repertoires. The MH similarity index between CD25' and CD25+ cells 
was calculated for each tissue (Table 4.2). Across the three TRBV 13 subsets, the TCR 
repertoires of CD25+ and CD25" T cells had an average MH similarity value of 0.396 in the 
tumour and only 0.019 in the spleen (Table 4.2 and Figure 4.5B). Using the values from this 
index the difference was approaching statistical significance, suggesting that the CD25+ and 
CD25’ cells were more similar in the tumour than in the spleen.
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Figure 4.5. Comparison of CD25' and CD25+ cell similarity levels in spleen and tumour
The similarity between CD4+CD25' and CD4+CD25+ T cells was analysed for spleen (•) and 
tumour (■) for the three different TRBV subsets (13-1, 13-2 and 13-3). The percentage of 
CD25+ repertoire that overlaps with the CD25" repertoire (A) or the mean Morisita-Horn 
(MH) similarity value (B) is displayed. The differences between the means were compared 
using paired T tests.
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In summar\. initial data from 1 cells sorted based on CD25 showed that a significantly higher 
percentage of the CD4 CD25’ repertoire overlapped with the CD4+CD25' repertoire in the 
tumour compared to the spleen supporting the hypothesis that conversion of Tconv cells into 
Tregs contributes to the aceumulation of Treg cells in the tumour. This trend was matched 
when a more sophisticated method (MH index) of analysis was applied to the data.
4.2.3 Analysis of the TRBYT3-2 TCR repertoires of Tconv and Treg cells sorted based 
on Foxp3
As mentioned in C hapter 1. the separation of Tregs from Tconv cells using CD25 as a marker 
is not ideal. Not all Foxp3’ Treg cells express C'D25. Therefore, it is likely that the CD25' 
"Tconv" pool of mouse 1 was contaminated with CD25Toxp3+Tregs. Results from Chapter 3 
demonstrate this point (Figure 3.13. page 87). On average, between 7% and 14% of the 
Foxp3"Treg population does not express CD25. Conversely, activated Foxp3'CD4+ non- 
regulatory T cells express CD25. As shown in Chapter 3. on average between 3.5% (non­
draining lymph node) and 31% (tumour) of the Foxp3Tconv populations expressed CD25 
(Figure 3.13). Therefore, it is also likely that very many CD25+Foxp3Tconv cells 
contaminated the CD25" "Treg" pool. Due to the contamination of both cell populations it is 
clear that these data must be interpreted cautiously. This problem is compounded by the fact 
that more CD4*Foxp3'CD25* activated T cells exist in the tumour (mean 31%) compared to 
the spleen (mean 13%) or lymph nodes (3.5-6%). Thus, in the tumour more contamination of 
the CD25 "Treg" pool would occur, and hence an increase in the level of overlap in the 
tumour may refect sampling of more CD25 Foxp3‘ cells. It was imperative to reduce this 
contamination during the FACS process to avoid any skewing of the measurement of 
similarity / overlap. This was especially important since the levels of contamination may be
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greater in the tumour than in the spleen. For this purpose, it was decided that subsequent 
analyses would use mice expressing GFP under the control of the Foxp3 promoter 
(Foxp3_GFP mice) such that lymphocytes could be sorted based on GFP (Foxp3) expression.
The analysis was also further refined to include T cells isolated from the lymph nodes of the 
tumour bearing mouse. Inguinal lymph nodes from the tumour draining and non-tumour 
draining sides of the MCA mouse were taken. This would allow for a direct comparison of 
die two lymph nodes and also provide an additional non-tumour associated site for 
comparison to the tumour.
In the initial experiment described above three TRBV13 subsets were analysed. As the 
patterns of TCR clonotypes observed were similar in terms of diversity and overlap across the 
three different subsets, only one TRBV subset was analysed in further experiments. 
TRBV13-2 was chosen as it gave the highest number of successful sequences for analysis 
(Table 4.1).
Mouse 2 (1st GFP mouse)
The clonotyping experiment was repeated with a second mouse with a number of changes. 
An MCA tumour bearing Foxp3_GFP mouse was used to sort Treg and Tconv cells based on 
Foxp3 expression. CD4+Foxp3+ Tregs and CD4+Foxp3" Tconv cells were sorted from spleen, 
non-draining lymph node, draining lymph nodes and tumour samples. The TRBV 13-2 TCR 
repertoires of each population were determined by clonotyping. In total 662 TCR sequences 
were analysed (Table 4.1).
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As in the previous analyses very little overlap was observed between the Tconv and Treg 
TCR repertoires of splenic T cells (Table 4.3 and Figure 4.6A). Only 1 out of 72 Treg TCR 
clones overlapped with the Tconv repertoire. This represented only 1.3% of the spleen Treg 
repertoire. Very little overlap was observed between the Treg and Tconv TCR repertoires 
from the non draining LN (Figure 4.6B). Only one Treg sequence (representing 1.1%; 1 out 
of 88) overlapped with the Tconv repertoire in the non-draining lymph node. Hence, the TCR 
repertoires of Tconv and Treg cells were mostly distinct.
Interestingly the Treg and Tconv TCR repertoires in the draining lymph node and tumour 
were also generally distinct (Table 4.3). This is in contrast to the result obtained previously 
when the cells were sorted based on CD25. In the draining lymph node only one sequence 
(representing 1.16%, 1 out of 86) of the Treg TCR repertoire was found to overlap with the 
Tconv TCR repertoire (Figure 4.6C). A slight increase in the number of Treg sequences 
overlapping with Tconv sequences was observed in the tumour compared to other locations. 
Out of 38 different Treg TCR clones 3 were overlapping (Figure 4.6D). This represented 
~8% of the Treg clones identified and 14% (11 out of 79 sequences) of the Treg TCR 
repertoire. Although an increase in the degree of overlap between the Treg and Tconv 
repertoires was observed in the tumour in comparison to the other sites, it was apparent that 
in the tumour, the vast majority (85%) of the Treg TCR repertoire was distinct from the 
Tconv TCR repertoire.
To analyse the similarity between the Tconv and Treg TCR repertoires in more depth, the
Morisita-Hom similarity index was calculated for each tissue (Table 4.3). A MH value of
0.01 was calculated for the similarity between the Tconv and Treg cell subsets from the
spleen, and both lymph nodes. A higher MH similarity index of 0.034 was calculated for the
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Number of Treg TCR Frequency of
sequences that overlapping Morisita-
overlap with Tconv sequences within Treg Hom
Tissue TCR repertoire TCR repertoire? index
Spleen 1 out of 72 (1.39%) 1 out of 80 (1.25%) 0.010
1 ND 1 out of 81 (1.23%) 1 out of 88 (1.14%) 0.010
1 D 1 out of 80 (1.25%) 1 out of 86 (1.16%) 0.010
Tumour 3 out of 38 (7.89%) 11 out of 79 (13.92%) 0.034
Table 4.3. Similarity between Treg and Tconv TCR repertoires in mouse 2 
The number of Treg TCR sequences that overlap with the Tconv TCR repertoire was 
determined for the spleen, non-draining lymph node (ND), draining lymph node (D), and 
tumour. Data are also displayed to show the proportion of the Treg TCR repertoire that 
overlapped with the Tconv TCR repertoire. The Morisita-Hom similarity index between the 
Tconv and Treg TCR repertoires was also determined.
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Figure 4.6. TRBV13-2 TCR repertoires of CD4+Foxp3 Tconv and CD4+Foxp3+Treg in 
tumour mice. Tconv (CD4+Foxp3 ) and Treg (CD4+Foxp3+) cells were FACS sorted based 
on Foxp3 expression and analyzed by TCR clonotyping. CDR3 amino acid sequences of the 
TRBV 13-2 subset were determined and used to identify individual TCRs for each T cell 
subset from the spleen (A), tumour (D), non-draining (B) and draining (C) lymph nodes of 
mice given MCA. Graphs are displayed as described for Figure legend 4.2.
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Treg and Tconv TCR repertoires in the tumour. However, this value remained very low 
indicating that very little similarity existed between the Tconv and Treg TCR repertoires.
Therefore, the results from this experiment contrasted with those of the previous experiment. 
The initial experiment suggested that there was a significantly greater overlap between the 
Treg and Tconv TCR repertoires in the tumour compared to the spleen. However, in the 
experiment where Tconv and Treg cells were sorted based on Foxp3, very little of the Treg 
repertoire overlapped with the Tconv repertoire in all tissues examined. It was noticeable that 
the degree of overlap observed in the analysis of T cells from both spleen and in particular, 
tumour, was lower in the later analysis than previously observed when the cells were sorted 
based on CD25. The most likely explanation for these differences between the two 
experiments is that in the initial experiments, (in which cells were sorted based on CD25,) 
contamination of the two T cell pools resulted in an overlap in the two repertoires. The 
reduction in the overlap in the later experiment was therefore as a result of improving the 
purification of Tconv and Treg cells. Furthermore, a much larger change was observed in the 
tumour than in the spleen. This was probably due to the higher level of contamination in the 
tumour compared to the spleen in the initial experiment.
Mouse 3 (2nd GFP mouse)
The experiment was repeated with another set of samples from a different Foxp3_GFP MCA 
tumour bearing mouse. This was a straight repeat of the experiment performed with the 
previous mouse (mouse 2). CD4+Foxp3+ Treg and CD4+Foxp3' Tconv cells were sorted from 
spleen, non-draining lymph node, draining lymph node and tumour. The TRBV 13-2 TCR 
repertoires of each population were determined by clonotyping. In total 679 TCR sequences 
were analysed (Table 4.1).
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In the spleen, out of 68 different TRBV13-2 Treg clonotypes, only 1 overlapped with the 
Tconv repertoire; this accounted for only 1.3% of the Treg TCR repertoire (Figure 4.7A). 
Similarly, none of the 73 different Treg clonotypes overlapped in the non-draining lymph 
node (Figure 4.7B). Thus, in normal lymphoid tissue, the TCR repertoires of Tconv and Treg 
cells were generally distinct. MH values of 0.01 and 0.0 were measured for the spleen and 
non-draining lymph node, respectively (Table 4.4). The lack of overlap between the Tconv 
and Treg TCR repertoires was also reflected in the tumour draining lymph node (Figure 
4.7C), where less than 2.5% (2 out of 82) of the Treg TCR repertoire overlapped with the 
Tconv TCR repertoire. More overlap was observed between the Treg and Tconv TCR 
repertoires in the tumour (Figure 4.7D). Of 77 different Treg clonotypes, 2 overlapped with 
Tconv TCRs. However, this only accounted for around 3.3% of the Treg TCR repertoire. The 
MH values for the draining lymph node and tumour remained less than 0.05 (Table 4.4). 
Hence, although there was slightly more overlap in the TCR repertoires between Tregs and 
Tconv cells in the tumour, the vast majority (>96%) of the Treg repertoire was distinct from 
the Tconv repertoire in all locations.
The Morisita-Hom similarity index was used to measure the similarity between the TCR 
repertoires from all locations and cell populations (Figure 4.8). Using, the average similarity 
from the two analyses of cells sorted based on Foxp3, the levels of similarity between the 
TRBV 13-2 TCR repertoires of Tconv and Treg cells were consistently low (MH < 0.04) 
throughout all four tissues measured. A small increase in the MH values was observed in the 
draining lymph node and tumour but generally the Treg and Tconv TCR repertoires were 
distinct in these tissues as well as the spleen and non-draining lymph node.
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Figure 4.7. TRBV13-2 TCR repertoires of Tconv and Treg in tumour mice. Tconv 
(CD4+Foxp3) and Treg (CD4+Foxp3+) FACS sorted cells were analyzed by TCR 
clonotyping. CDR3 amino acid sequences of the TRBV 13-2 subset were determined and used 
to identify individual TCRs for each T cell subset from the spleen (A), tumour (D), non­
draining (B) and draining (C) lymph nodes of mice given MCA. Graphs are displayed as 
described for Figure legend 4.2.
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0102010201010001020201020102010102010201000001870284
Number of Treg TCR Frequency of
sequences that overlapping sequences
overlap with Tconv within Treg TCR Morisita-
Tissue TCR repertoire repertoire? Horn index
Spleen 1 out of 68 (1.5%) 1 out of 79 (1.3%) 0.010
ND 0 out of 73 (0%) 0 out of 92 (0%) 0.000
D 1 out of 72 (1.4%) 2 out of 82 (2.4%) 0.035
Tumour 2 out of 77 (2.6%) 4 out of 90 (4.4%) 0.044
Table 4.4. Similarity between Treg and Tconv TCR repertoires in mouse 3
The number of Treg TCR sequences that overlap with the Tconv TCR repertoire was 
determined for the spleen, non-draining lymph node (ND), draining lymph node (D), and 
tumour. Data are also displayed to show the proportion of the Treg TCR repertoire that 
overlapped with the Tconv TCR repertoire. The Morisita-Hom similarity index between the 
Tconv and Treg TCR repertoires was also determined.
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Figure 4.8. Morisita-Horn similarity values for comparison of all TRBV13-2 TCR 
repertoires.
Similarity between each TCR repertoire was measured using the Morisita-Hom index. This 
index measures similarity based on the number o f shared sequences between two populations 
as well as how well represented those overlapping sequences are within the two populations. 
A value between 0 (no similarity) and 1 (identical) was calculated by comparing the TCR 
repertoire from each population and coloured according to the scale given. Values used are 
mean similarity taken from two mice and two independent experiments.
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greatest degree of similarity was observed between the Treg repertoires from draining 
iph node and tumour (Figure 4.8). The Treg repertoire from the draining lymph node was 
average ~20% (MH = 0.19) similar to the tumour Treg repertoire. In contrast, the Tconv 
md Treg repertoires from the tumour were only 3.8% (MH = 0.038) similar. The overlap 
between the Treg TCR repertoires from the tumour and tumour draining lymph node was 
^dear for both mice (Figure 4.9).
42.4 Large amount of diversity in TRBV13-2 repertoires
: For the previous two TCR repertoire analyses a single TRBV subset (TRBV 13-2) was 
I examined. A single TRBV subset was chosen in order to reduce the potential clonotypic 
diversity in the TCR repertoires analysed. However, the identification of very many different 
; clonotypes suggested that the diversity in the TCR repertoires was nevertheless still very 
high.
\
* Using data generated from the accumulation of TCR sequences it is possible to estimate the
' number of different clonotypes (diversity, or more accurately termed richness) that would be
!■'
found within each group. The Michaelis-Menten equation (originally designed for measuring
I
enzyme kinetics) can be used to calculate the diversity (richness) of a TCR repertoire in the 
; same way in which species diversity for ecological system can be estimated from a quadrant 
i or sample (Magurran 2004). As the number of TCR sequences analysed (x) increases so too
f
r does the accumulated number of new/unique TCR clones (y; Figure 4.10). However, when an 
'analysed sequence is a repeat of a previously identified clonotype the number of new
|
I clonotypes (y) stays the same. A curve of cumulative number of sequences (x) versus new 
t TCR clones identified (y) therefore follows a non-linear regression (unless all sequences
i
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Figure 4.9. TRBV13-2 TCR repertoires of Treg TCR repertoires from draining lymph 
node and tumour.
The TRBV 13-2 TCR sequences were determined by clonotyping and used to identify 
individual TCRs. The TCR repertoires of Treg cells from tumour and Treg cells from 
draining lymph node were compared for mouse 2 (A)and mouse 3 (B). Different TCR 
sequences observed (x axis) within the tumour Treg (filled & above) and draining lymph 
node Treg (open & below) repertoires and the frequency (y axis) of each sequence within that 
subset are displayed. The total number of TCR sequences analysed is displayed as n=, with 
the number of unique TCR sequences observed in parentheses. The proportion of the tumour 
Treg repertoire that has shared sequences with the draining lymph node Treg repertoire is 
given.
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Figure 4.10 Non-linear regression of accumulation of TCR sequences
The accumulation of sequence data from mouse 2 tumour Treg was plotted. It demonstrates 
that as the cumulative number of sequences increases so too does the number of unique 
sequences. However, each time a repeat sequence is discovered the number of unique 
sequences does not rise. Therefore, (unless all sequences are unique) the graph follows a non­
linear regression.
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analysed are unique). from this non-linear regression the Michaelis-Menten equation can be 
used to estimate the total number of different sequences (Smax) that would be observed if an 
infinite number of sequences were analysed (Figure 4.11).
Using the data generated through the accumulation of TCR sequences and the Michaelis- 
Menten equation, the si/e of the I CR repertoires were first approximated for mouse 2 (Table
4.5 and figure 4.12). I he lowest level of diversity was estimated for the tumour Treg sample 
where 97 clonotypes were predicted to exist in the TRBV 13-2 repertoire. The highest 
diversity was estimated in the draining lymph node Tconv cell sample where 3628 clonotypes 
were predicted. Using this information it is possible to predict how much of the repertoire 
was analysed in the experiment. In the tumour Treg sample, 38 different clonotypes were 
identified. Therefore 39% (38 out of 97) of the estimated clonotpyes were identified (Figure 
4.13). However, in the draining lymph node 79 clonotypes were identified, this equated to 
just 2% (79 out of 3628) of the estimated number of clonoty pes. On average, it was estimated 
that 10% of the possible TRBV 13-2 clonotypes were identified in the TCR repertoire analysis 
of mouse 2 (figure 4.13).
These analyses suggested that a high amount of diversity existed and that many of the TCR 
sequences may have been missed in the initial TRBV 13-2 analysis. Using the Michaelis- 
Menten equation it was estimated that to identify 90% of the predicted 97 clonotypes in the 
tumour a total of 1076 sequences would need to be analysed (Table 4.5). This problem is 
even greater in the draining lymph node. To identify 90% of the clonotypes it was estimated 
that more than 32.000 sequences would need to be analysed.
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Figure 4.11 Extrapolated Michaelis-Menten curve
Using the data plotted in Figure 4.10, GraphPad Prism was used to determine the parameters 
of the Michaelis-Menten equation. Where S(n) = the number of new TCR sequences 
observed after n sequences; Smax = the total number of sequences in the repertoire; and B is 
the amount of sequences required to detect 50% of the Smax. The parameters were used to 
extrapolate the data and generate the graph shown above. These parameters were also used to 
estimate the total size of the TCR repertoire (Smax) and the number of sequences needed to 
identify 90% of the different clonotypes (0.9 x Smax).
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Tissue
Cell
type
Number of 
different TCR 
clonotypes 
identified
Estimated 
number of TCR 
clonotypes
(Sm«)
%of
clonotypes
identified
Number of 
sequences 
required to identify 
90% of clonotypes
Spleen Tconv 77 1977 4% 17,739
Treg 72 531 14% 4,596
ND Tconv 81 1666 5% 14,697
Treg 81 1575 5% 14,616
D Tconv 79 3628 2% 32,814
Treg 80 962 8% 8,530
Tumour Tconv 74 1770 4% 17,397
Treg 38 97 39% 1,076
Table 4.5 Size and diversity estimates for Treg and Tconv TRBV13-2 TCR repertoires in mouse 2
The number of different clonotypes that were identified from TCR repertoire analysis of Tconv and Treg cells isolated from the spleen, non 
draining lymph node (ND), draining lymph node (D) and tumour of tumour bearing mouse 2. From these data the number of clonotypes was 
estimated as well as the number of sequences that would be required to identify 90% of these clonotypes. It was also estimated what percentage 
of the clonotypes were identified in this analysis.
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Figure 4.12 Estimated size of the TRBV13-2 TCR repertoires of Tconv and Treg from 
mouse 2
The accumulated data from TRBV 13-2 TCR repertoire analysis of Tconv (open bars) and 
Treg (filled bars) cells from spleen, non-draining lymph node (ND), draining lymph node (D) 
and tumour was used to plot non-linear regression curves and estimate the size of the TCR 
repertoire using the Michaelis-Menten equation. The estimated the number of clonotypes that 
would be discovered after analysing an infinite number of sequences (Smax) +95% confidence 
intervals are displayed.
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Figure 4.13 Estimated percent of the TRBV13-2 TCR clonotypes identified in mouse 2
From the estimated number of clonotypes predicted and the number of clonotypes actually 
discovered it was estimated what percentage of the possible TRBV 13-2 TCR clonotypes were 
identified within the Tconv (open bars) and Treg (filled black bars) cell repertoires from 
spleen, non-draining lymph node, draining lymph node and tumour. These values were 
averaged to estimate the overall (filled grey bars) percent of the TRBV 13-2 TCR clonotypes 
that was identified.
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The sizes of the TCR repertoires were also estimated for the samples from mouse 3 (Table 
4.6 and Figure 4.14). The highest repertoire size was estimated in the tumour Tconv cell 
sample where 3371 clontoypes were predicted. The lowest was for the non-draining Treg 
repertoire where 297 clonotypes were predicted. It was estimated that throughout all tissues 
on average only 11% of the potential clonotypes were identified (Figure 4.15). In the largest 
estimated sample, the tumour Tconv, more than 31,000 sequences would need to be analysed 
to identify 90% of the total repertoire (Table 4.6). In the smallest, the non-draining Treg 
repertoire, 2387 sequences would need to be analysed to identify 90% of the total repertoire.
The diversity estimates from the TRBV 13-2 repertoires of mouse 2 and mouse 3 indicated 
that the diversity of the TCR repertoires was often very large and that many of the clonotypes 
may have been missed in the analysis. They also suggested that to identify a large majority 
(90%) of the clonotypes extremely large sample sizes (>30,000) are required.
4.2.5 Analysis of the TRBV13-2/TRBJ2-5 repertoires of Tconv and Treg cells
Rather than performing more sequencing in the TRBV13-2 repertoire a different approach 
was taken. The examination of the TRBV 13-2 repertoire was further focused and investigated 
in more detail by performing the sequencing on a single TRBJ subset within the TRBV 13-2 
subfamily. As for the Vp usage analysis, no significant skewing towards any particular jp 
subset was observed within the Treg or Tconv repertoires from the spleen, tumour or lymph 
node (Figure 4.16). Therefore, as above, the relatively common TRBJ2-5 gene was selected 
as a representative subset for the focused analysis.
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Tissue
Cell
type
Number of 
different TCR 
clonotypes 
identified
Estimated 
number of TCR 
clonotypes
(Smax)
%of
clonotypes
identified
Number of 
sequences 
required to identify 
90% of clonotypes
Spleen Tconv 79 1153 7% 10,251
Treg 68 499 14% 4,635
ND Tconv 78 1299 6% 11,556
Treg 73 297 25% 2,387
D Tconv 68 925 7% 9,018
Treg 72 418 17% 3,688
Tumour Tconv 89 3371 3% 31,077
Jreg 77 707 11% 6,509
Table 4.6 Size and diversity estimates for Treg and Tconv TRBV13-2 TCR repertoires in mouse 3
The number of different clonotypes that were identified from TCR repertoire analysis of Tconv and Treg cells isolated from the spleen, non 
draining lymph node (ND), draining lymph node (D) and tumour of tumour bearing mouse 3. From these data the number of clonotypes was 
estimated as well as the number of sequences that would be required to identify 90% of these clonotypes. It was also estimated what percentage 
of the clonotypes were identified in this analysis.
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Figure 4.14 Estimated size of the TRBV13-2 TCR repertoires of Tconv and Treg from 
mouse 3
The accumulated data from TRBV 13-2 TCR repertoire analysis of Tconv (open bars) and 
Treg (filled bars) cells from spleen, non-draining lymph node (ND), draining lymph node (D) 
and tumour was used to plot non-linear regression curves and estimate the size of the TCR 
repertoire using the Michaelis-Menten equation. The estimated the number of clonotypes that 
would be discovered after analysing an infinite number of sequences (Smax) +95% confidence 
intervals are displayed.
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Figure 4.15 Estimated percent of the TRBV13-2 TCR clonotypes identified in mouse 3 
From the estimated number of clonotypes predicted and the number of clonotypes actually 
discovered it was estimated what percentage of the possible TRBV 13-2 TCR clonotypes were 
identified within the Tconv (open bars) and Treg (filled black bars) cell repertoires from 
spleen, non-draining lymph node, draining lymph node and tumour. These values were 
averaged to estimate the overall (filled grey bars) percent of the TRBV13-2 TCR clonotypes 
that was identified.
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Figure 4.16. TRBJ gene usage within Tconv and Treg from tumour bearing mice.
Tconv (CD4+Foxp3 ) and Treg (CD4+Foxp3+) FACS sorted cells were analyzed by TCR 
clonotyping. The TRBJ gene usage for Tconv (open bars) and Treg (filled bars) cells were 
determined for each population from spleen (A), tumour (D), non-draining (B) and draining 
(C) lymph nodes. Data shown are the mean frequencies (+/- SEM) obtained using two mice 
from two independent experiments.
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In agreement with the findings from the TRBV13-2 TCR repertoire analysis, the TRBV13- 
2/TRBJ2-5 TCR repertoires of Tconv and Treg cells were generally non-overlapping within 
all tissues including the tumour (Table 4.7 and Figure 4.17). No shared TCR sequences were 
found within the tumour or the non-draining lymph node. Furthermore, only 1 overlapping 
sequence was found within the spleen and draining lymph node repertoires.
Conversely, when the TRBV13-2/TRBJ2-5 TCR repertoires of Tregs from the draining 
lymph node and Tregs from the tumour were compared, a high degree of overlap was clearly 
observed (Figure 4.18). Out of 17 different clonotypes, 6 (35.3%) were found to be 
overlapping. These 6 overlapping clonotypes made up 33.3% (21 out of 63 sequences) of the 
tumour Treg repertoire. The similarity between the Treg subsets was highlighted when 
analyzed using the Morisita-Hom similarity index (Figure 4.19). The greatest level of 
similarity (MH = 0.16) was observed between the TCR repertoires of the tumour-infiltrating 
Tregs and draining lymph node Tregs. In contrast, the similarity between the Treg and Tconv 
repertoires was less in both the tumour and the draining lymph node (MH = 0.0 and 0.017, 
respectively). These data are in agreement with previous analysis of the whole TRBV13-2 
TCR repertoire.
4.2.6 Size estimates of TRBV13-2/TRBJ2-5 TCR repertoires
The TCR sequence data was used to estimate the size of the TRBV13-2/TRBJ5-5 TCR 
repertoires. Using the Michaelis-Menten equation it was estimated that the largest TRBV 13- 
2/TRBJ2-5 TCR repertoire was the spleen Tconv where 211 different clonotypes were 
predicted (Table 4.8 and Figure 4.20). The tumour Treg repertoire was predicted to be the 
smallest repertoire at 24 different clonotypes. From the spleen Tconv repertoire 42 different
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Number of Treg TCR Frequency of
sequences that overlapping sequences
overlap with Tconv within Treg TCR Morisita-
Tissue TCR repertoire repertoire? Hom index
Spleen 1 out of 33 (3.0%) 7 out of 55 (12.7%) 0.127
ND 0 out of 41 (0.0%) 0 out of 62 (0.0%) 0.000
D 1 out of 33 (3.0%) 2 out of 53 (3.8%) 0.017
Tumour 0 out of 17(0.0%) 0 out of 63 (0.0%) 0.000
Table 4.7. Similarity between Treg and Tconv TCR repertoires in mouse 4
The number of Treg TCR sequences that overlap with the Tconv TCR repertoire was 
determined for the spleen, non-draining lymph node (ND), draining lymph node (D), and 
tumour. Data are also displayed to show the proportion of the Treg TCR repertoire that 
overlapped with the Tconv TCR repertoire. The Morisita-Hom similarity index between the 
Tconv and Treg TCR repertoires was also determined.
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Figure 4.17. TRBJ2-5,TRBV13-2 TCR repertoires of Tconv and Treg in tumour mice.
Tconv (CD4+Foxp3) and Treg (CD4+Foxp3+) FACS sorted cells were analyzed by TCR 
clonotyping. CDR3 amino acid sequences of the TRBV 13-2, TRBJ2-5 subset were 
determined and used to identify individual TCRs for each T cell subset from the spleen (A), 
tumour (D), non-draining (B) and draining (C) lymph nodes of mice given MCA. Graphs are 
displayed as described for Figure legend 4.2.
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Figure 4.18. TRBJ2-5, TRBV13-2 TCR repertoires of Treg TCR repertoires from 
draining lymph node and tumour.
The TRBJ2-5, TRBV13-2 TCR sequences were determined by clonotyping and used to 
identify individual TCRs. The TCR repertoires of Treg from tumour and Treg from draining 
lymph node were compared. Graphs are displayed as described for Figure legend 4.9.
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Figure 4.19. M orisita-Horn similarity values for comparison of all TRBJ2-5, TRBV13-2 
TCR repertoires.
Similarity between each TCR repertoire was measured using the Morisita-Horn index. This 
index measures similarity based on the number of shared sequences between two populations 
as well as how well represented those overlapping sequences are within the two populations. 
A value between 0 (no similarity) and 1 (identical) was calculated by comparing the TCR 
repertoire from each population and coloured according to the scale given.
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Tissue
Cell
type
Number of 
different TCR 
clonotypes 
identified
Estimated 
number of TCR 
clonotypes
(Smax)
%of
clonotypes
identified
Number of 
sequences 
required to identify 
90% of clonotypes
Spleen Tconv 42 211 20% 1765
Treg 33 83 40% 728
ND Tconv 42 118 36% 1064
Treg 41 103 40% 892
D Tconv 38 120 32% 997
Treg 33 121 27% 1311
Tumour Tconv 26 97 27% 1011
Treg 17 24 71% 239
Table 4.8 Size and diversity estimates for Treg and Tconv TRBV13-2/TRBJ2-5 TCR repertoires in mouse 4
The number of different clonotypes that were identified from TCR repertoire analysis of Tconv and Treg cells isolated from the spleen, non 
draining lymph node (ND), draining lymph node (D) and tumour of tumour bearing mouse 4. From these data the number of clonotypes was 
estimated as well as the number of sequences that would be required to identify 90% of these clonotypes. It was also estimated what percentage 
of the clonotypes were identified in this analysis.
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Figure 4.20 Estimated size of the TRBV13-2/TRBJ2-5 TCR repertoires of Tconv and 
Treg from mouse 4
The accumulated data from TRBV13-2/TRBJ5-5 TCR repertoire analysis of Tconv (open 
bars) and Treg (filled bars) cells from spleen, non-draining lymph node (ND), draining lymph 
node (D) and tumour was used to plot non-linear regression curves and estimate the size of 
the TCR repertoire using the Michaelis-Menten equation. The estimated the number of 
clonotypes that would be discovered after analysing an infinite number of sequences (Smax) 
+95% confidence intervals are displayed.
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clonotypes were identified. This equated to —20% (42 out of 211) of the predicted repertoire 
(Figure 4.21). From the smallest repertoire (the tumour Treg repertoire) 17 different 
clonotypes were identified. Therefore, it was predicted that -70% (17 out of 24) of the 
potential TRBV13-2/TRBJ2-5 TCR clonotypes were identified. Throughout the whole mouse 
it was predicted that on average -36% of the potential TRBV13-2/TRBJ2-5 clonotypes were 
identified in the analysis (Figure 4.21). In comparison with the previous two analyses of just 
the TRBV13-2 TCR repertoire (where it was estimated that -10% and -11% of the 
clonotypes were identified) a larger proportion of the potential TCR clonotypes was 
identified (-36%) in the TRBV13-2/TRBJ2-5 analysis. This indicates that the analysis was 
refined so that fewer of the potential TCR clonotypes were missed and hence the chance of 
missing any overlapping clones was also reduced.
4.2.7 Summary of TCR repertoire data
Analysis of the TRBV13-2 and TRBV13-2/TRBJ2-5 TCR repertoires of Tconv and Treg 
cells in tumour bearing mice showed that the Tconv and Treg repertoires were by and large 
distinct from each other. In collaboration with Professor David Price, Dr Kristin Ladell and 
Dr Katherine Wynn of Cardiff University, additional analyses of the TCR repertoires of 
Tconv and Treg cells from MCA tumour bearing mice were made in parallel to the 
experiments described above. Using an unbiased template-switch anchored RT-PCR (Price et 
al. 2005) TCR clonotyping of the total TCR repertoire was performed on CD4+Foxp3'Tconv 
and CD4+Foxp3+Treg cells sorted by flow cytometry. In agreement with the focused TCR 
repertoire analyses, the total TCR repertoires of Tconv and Treg cells were found to be non­
overlapping. No TCR clonotypes from the Treg repertoire were found within the 
corresponding Tconv repertoire from the same location (Figure 4.22).
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Figure 4.21 Estimated percent of the TRBV13-2/TRBJ2-5 TCR clonotypes identified in 
mouse 4
From the estimated number of clonotypes predicted and the number of clonotypes actually 
discovered it was estimated what percentage of the possible TRBV13-2/TRBJ2-5 TCR 
clonotypes were identified within the Tconv (open bars) and Treg (filled black bars) cell 
repertoires from spleen, non-draining lymph node, draining lymph node and tumour. These 
values were averaged to estimate the overall (filled grey bars) percent of the TRBV13- 
2/TRBJ2-5 TCR clonotypes that was identified.
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Figure 4.22. TCR repertoires of Tconv and Treg in tumour mice.
Tconv (CD4+Foxp3 ) and Treg (CD4+Foxp3+) FACS sorted cells from mice bearing MCA 
tumours were analyzed using an unbiased TCR clonotyping method. CDR3 amino acid 
sequences were determined and used to identify individual TCRs for each T cell subset from 
the spleen (A), and non-draining lymph node (B) of mouse A (MA) and the from the spleen 
(C) draining lymph node (D) and tumour (E) of mouse 8 (M8). Graphs are displayed as 
described for Figure legend 4.2.
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The findings from the TCR repertoire analyses of Tconv and Treg cells sorted based on 
Foxp3 expression were compiled. Taken together, on average 4.58% of the tumour 
infiltrating Treg TCR repertoire was found to overlap with the TCR repertoire of tumour 
infiltrating Tconv cells (Figure 4.23). This was more than the average proportion of the Treg 
TCR repertoire (0.285%) that overlapped with the Tconv TCR repertoire in the non-draining 
lymph node. Although this may indicate that an increase in conversion of Tconv cells into 
Tregs occurs within the tumour, this increase was not statistically significant. Moreover, 
greater than 95% of the tumour infiltrating Treg TCR repertoire was found to not overlap 
with the Tconv TCR repertoire (Figure 4.24). This suggests that the vast majority of tumour 
infiltrating Treg cells do not arise through the conversion of Tconv cells. Instead the largest 
degree of overlap was found between the TCR repertoires of Treg cells from the draining 
lymph node and tumour. On average, -20% of the tumour infiltrating Treg repertoire was 
found to overlap with the TCR repertoire of Treg from the draining lymph node (Figure 
4.23). In the most focused (TRBV13-2/TRBJ2-5) TCR repertoire analysis where it was 
estimated that -36%  of the potential clonotypes were identified approximately one third 
(33.3%) of the tumour Treg TCR repertoire overlapped with the draining lymph node Treg 
repertoire (Figure 4.18). Together this suggests that Treg cells within the tumour are more 
likely to have derived from the draining lymph node Treg pool or vice versa than from the 
tumour infiltrating Tconv cell population.
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Figure 4.23 Percent overlap between various TCR repertoires
The mean percent of repertoire (sample) A that overlaps with repertoire (sample) B is given 
(n=4-5). Data from all TCR repertoire analyses on Foxp3 sorted cells from this thesis were 
compiled. Comparisons are displayed as indicated in the table. The differences between the 
mean of two groups were compared using unpaired T tests.
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Figure 4.24 Degree of the Treg TCR repertoire that is found to overlap (and not- 
overlap) with the corresponding Tconv TCR repertoire
The mean (+/-SEM) percentage of the Treg TCR repertoire that was found to be overlapping 
(filled) and not-overlapping (open) with the corresponding Tconv TCR repertoire was 
determined. Data from all analyses on Foxp3 sorted cells from this thesis for spleen, non­
draining lymph node (ND), draining lymph node (D) and tumour were compiled (n=4-5). 
Groups were compared using unpaired T tests.
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4.2.8 Does the proliferation of CD4+ T cells preferentially promote the accumulation of 
Treg cells in tumours?
Originally Tregs were described as being non-proliferative. These conclusions were based on 
the finding that Tregs stimulated through the TCR did not proliferate in vitro. More recently 
it was demonstrated that the addition o f exogenous IL-2, or stimulation with purified DCs 
allowed for the expansion of Tregs in vitro (Thornton and Shevach 1998, Takahashi et al. 
1998, Yamazaki et al. 2003). Furthermore, Gavin et al. (2002) found that upon adoptive 
transfer into lymphopenic hosts both CD4+CD25+ and CD4+CD25' cells proliferate 
extensively. Numerous studies have now confirmed that proliferation of Treg cells is possible 
in vivo and is dependent on both antigen and MHC class-II (Klein, Khazaie and von Boehmer 
2003, Walker et al. 2003a, Cozzo, Larkin and Caton 2003, Gavin et al. 2002). However, the 
proliferative behaviour o f Treg cells under normal and disease states remained to be fully 
determined. Mottet et al. (2003) investigated the proliferation of Tregs in mice with 
experimental colitis and found that Tregs were proliferating in the spleen, and lymph nodes 
of mice with colitis. Interestingly this proliferation was reduced when the inflammatory 
response had subsided, suggesting that Treg cell proliferation is induced by the inflammatory 
response they control. Treg cells were also shown to be more proliferative than Tconv cells in 
the draining lymph node and tumour o f mice with transplanted tumours (Bui et al. 2006). In 
addition, the results of one in vivo human study indicated that Tregs in peripheral blood 
(identified by high levels o f CD25 expression) are highly proliferative (Vukmanovic-Stejic et 
al. 2006). In this study, the authors used deuterium-labelled glucose to label proliferating 
cells with deuterium. They found that the rate o f proliferation was significantly higher in 
Treg cells than in CD4+ memory or naive T cells. This paper also showed that the Treg cells 
appear more prone to apoptosis and have shorter telomere lengths than other CD4 T cells
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suggesting their survival is also impaired. Thus, collectively these data suggest that Treg cells 
have a high rate of turnover in humans in vivo under normal circumstances. Given that the 
proliferation and survival characteristics of Treg cells appeared to vary from Tconv cells 
under normal physiological conditions in humans and in disease states in mice, it seemed 
plausible that these Treg cells may also have altered characteristics within the tumour 
microenvironment which favour their accumulation.
To investigate the proliferative status of Tconv cells and Tregs within tumour-bearing mice,
Ki67 expression was analysed within each of the CD4+ T cell populations. Ki67 is a protein
that is expressed during all active phases of the cell cycle and therefore demarcates cells that
are proliferating (Brown and Gatter 2002). The proportion of CD4+Foxp3' Tconv and
CD4*Foxp3+ Treg cells expressing Ki67 in tumour-bearing mice was analysed by flow
cytometry (Figure 4.25). A higher proportion o f Treg cells compared to Tconv cells were
found to express Ki67 within all of the sites analyzed in both tumour-bearing and naive mice
(Figure 4.26A). The difference between the percentage of Tconv cells expressing Ki67 and
the percentage of Treg cells expressing Ki67 was most significant in the tumour
(***p=0 .0002; Figure 4.26A). For each tissue the numerical difference (differential) between
the proportion of Tconv cells and Treg cells that were Ki67+ was determined (Figure 4.26B).
In the spleen the differential between the percentage of Tconv cells and Treg cells that were
Ki67 was on average -15%. In the tumour the differential between the percentage of Tconv
cells and Treg cells that were Ki67 was significantly (**P = 0.0019) greater where -31%
more Tregs expressed Ki67 over Tconv cells (Figure 4.26B). A similar pattern was also
observed when the draining and the non-draining lymph nodes were compared. The
differential between the proportion of proliferating Tconv cells and Treg cells was —16% in
the non-draining lymph node (Figure 4.26B). The differential between the proportion of
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Figure 4.25. Antibody staining and analysis by flow cytometry of Ki67 
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were analysed for Ki67expression by flow cytometry. Cells were stained 
with anti Ki67-F1TC (B) or Mouse IgGl-FITC isotype control (A) mAbs. Representative dot 
plots of CD8+ T cells, CD4+Foxp3' Tconv cells and CD4+Foxp3+ Treg cells from each tissue 
are shown (C).
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Figure 4.26. Percent of Tconv and Treg cells expressing Ki67 in tumour bearing and 
naive mice
The percentage ofTconv (filled) and Treg (open) cells expressing Ki67 was determined by 
flow cytometry. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and 
tumours were analysed from tumour bearing mice (n=5). Spleen and pooled inguinal lymph 
nodes (ND) were analysed from naTve mice (n=5-6). Data are displayed as (A) percentage of 
cells expressing Ki67 and (B) proliferation differential (percent of Ki67+Treg minus percent 
of Ki67+Tconv). The differences between the means were compared using paired T tests.
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proliferating I corn ce l l s  and I reg c e l l s  w a s  s igni f icant ly greater ( * P = 0 . 0 2 3 1 ) in the draining  
lymph node ( a \ e r a g e  23%).  It is apparent that these increases in the differentials were  
primarily due to signif icant  increases in the percentage of proliferating Tregs within the 
tumour ( 4o°o.  *P 0 . 0 4 9 8 )  and the tumour draining lymph node ( - 3 0 % .  * P ~ 0 .0 3 0 9 )  
compared to normal lym phoid  t is sue  ( 20°«: f i g u r e  4 .2 6 A ) .  Thus. Treg ce l l s  are more  
proliferative than Icons  ce l l s  in all t is sues.  H o w eve r .  Treg ce l l s  in the tumour and to a lesser 
extent in the tumour draining lymph node  are significantly more proliferative. Furthermore,  
this increase in proliferation is I reg cel l  spe c i f ic  as it is not observed w ithin the tumour-  
infiltrating Ic ons  cel l  populat ion.  Ih e s e  data sugge st  that tumour-speci fic  factors lead to 
Treg cell enr ichment  due  to increased I reg cell  proliferation.
4.2.9 Does the level of cell death within Treg and Tconv cells favour Treg cell 
accumulation in tumours?
Previous studies  have  indicated that under normal  ph ys io l og ica l  condi t ions  Treg cel l s are 
more proliferative than Tconv ce l l s  ( Vu km anov  ic -Stej ic  e t al.  200 6) .  However ,  this increase  
in proliferation is a lso  coup led  to a higher  lev el o f  cel l  death compared to T conv cells.  Thus.
an increase in Treg cell  proliferation,  as ob served  in M C A -i n d u c e d  tumours,  might not 
necessarily lead to their accumu lat ion  but may rather reflect higher cell  turnover due to an 
accompany ing e levat ion  in cel l  death.  T o  address  this quest ion,  firstly, the susceptibil ity o f  
tumour-infiltrating Tregs  to cel l  death w a s  a sse sse d  by measuring  expression o f  the anti- 
apoptotic factor. Be 1-2. in T co n v  and I reg populat ions  isolated from tumours and lymphoid  
tissue o f  tumour-bearing mic e  ( f i g u r e  4 .27) .  Part of the analysi s  of Bcl-2 was  carried out by 
Dr Sarah Lauder, a post -doctoral  researcher in our laboratory . Secondly ,  the frequency of
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igure 4.27. Antibody staining and analysis by flow cytometry of Bcl-2
louse splenocytes were stained with anti Bcl-2-Pe (B & D) or Hamster IgG-Pe isotype 
ontrol (A & C) mAbs and analysed by flow cytometry. The percentage of lymphocytes 
within gate (A & B) and the MFI (mean fluorescence intensity; C & D) were determined, 
epresentative plots for the percentage of Tconv cells and Treg cells expressing Bcl-2 are 
lown for spleen and tumour.
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cells which were unable to exclude the cell viability dye 7-aminoactinomycin D (7-AAD) was 
compared in Tconv and Treg cells from tumour bearing mice.
hi agreement with previous findings, it was observed that within normal lymphoid tissue 
(spleen and non-draining lymph node) Treg cells expressed significantly less Bcl-2 than 
Tconv cells. This was found for both the percent o f cells expressing Bcl-2 (Figure 4.28 A) and 
the level (MFI) of Bcl-2 within the whole cell population (Figure 4.28B). In contrast, no 
significant difference in the proportion o f tumour-infiltrating Treg and Tconv cells expressing 
Bcl-2 was found. Furthermore, the mean levels (MFI) of Bcl-2 expression in tumour 
infiltrating Treg and Tconv cells were not significantly different. The draining lymph node 
resembled normal lymphoid tissue in that the percentage of Treg cells expressing Bcl-2 was 
significantly less than the percent of Tconv cells but the difference between the level (MFI) 
of Bcl-2 expression in the Tconv cells and the level of Bcl-2 expression in the Treg cells was 
not significantly different (Figure 4.28B). Overall, these data imply that Tregs within the 
tumour environment are no more prone to cell death by apoptosis than Tconv cells. This is 
particularly interesting as it is in contrast to what is observed in normal lymphoid tissue 
where Treg cells appear more prone to apoptosis than Tconv cells. However, in mammals 
there are at least 12 members of the BCL-2 family, including Bcl-2 itself, which can 
contribute to the induction or inhibition o f apoptosis (reviewed in Youle and Strasser 2008). 
Therefore, although the expression o f Bcl-2 is known to contribute substantially to T 
lymphocyte survival, these data can only indicate cells that are more prone to apoptosis and 
do not demonstrate the actual level of cell death within the cell population (Veis et al. 1993).
To support the findings with Bcl-2 staining and compare the level of cell death in Tconv and 
Treg cell populations, the percentage of dying Tconv and Treg cells was measured by
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Flgire 4.28. Expression of Bcl-2 in Tconv and Treg cells in tumour bearing mice 
Tconv (filled) and Treg (open) cells were stained for Bcl-2 expression and analysed by flow 
cytometry. Spleens, non-draining lymph nodes (ND), draining lymph nodes (D) and tumours 
were analysed from tumour bearing mice (n=4). Spleens and lymph nodes (LN) were 
analysed from naTve mice (n=4-6). Data are displayed as (A) percentage of cells expressing 
Bcl-2 and (B) MFI (mean fluorescence intensity) of cells. The differences between the means 
were compared using paired T tests.
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$ staining with the cell viability marker 7-AAD (Figure 4.29). In agreement with the pattern of
|
Bcl-2 expression shown in Figure 4.28, it was found that significantly higher levels of 7- 
AAD+ Treg cells rather than 7-AAD+ Tconv cells exist in lymph nodes (Figure 4.30). 
However, this was not the case in tumour where, in contrast, the opposite was observed
s
(Figure 4.30). In the tumour, the percentage o f 7-AAD+ Tconv cells was higher than the
I
[ percentage of 7-AAD+ Tregs. In the spleen, the mean percentages of Tconv cell and Treg
r cells that were 7-AAD+ were not significantly different. Taken together, these data suggest
#.
that tumour infiltrating Treg cells have equal if not enhanced survival over tumour infiltrating 
[. Tconv cells. This is particularly interesting given that the difference between these two cell 
[ types is reversed in the lymph nodes of the same mice where fewer Tconv cells appear to be
i
f dying than Treg cells.
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Figure 4.29. Staining and analysis by flow cytometry with 7-AAD
Mouse splenocytes were stained with (B) or without (A) 7-AAD and analysed by flow 
cytometry.
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195
4.3 Discussion
In this Chapter, I have investigated mechanisms leading to the accumulation of regulatory T 
cells in tumours. For this purpose, mice bearing chemically (methylcholanthrene) induced 
tumours were analysed. Two potential mechanisms of accumulation were independently 
tested. Firstly, the contribution of conversion of Tconv cells into Tregs was assessed by TCR 
repertoire analysis. Tconv and Treg cell populations in tumour and normal lymphoid tissue 
were found to have generally non-overlapping TCR repertoires, suggesting that conversion of 
Tconv cells does not account for the accumulation of Treg cells in the tumour. Secondly, 
proliferation and survival of Tconv and Treg cells were compared in tumour bearing mice. 
Tumour infiltrating Treg cells were found to be significantly more proliferative than tumour 
infiltrating Tconv cells as well as Treg cells from other locations. Furthermore, in the tumour, 
in contrast to other tissues, fewer Treg cells than Tconv cells appeared to be dying. This may 
be due to alterations in the levels of anti-apoptotic factors such as Bcl-2.
Initially, the TCR repertoires of Tconv and Treg cells were analysed by sorting the two 
populations based on the expression of CD25. CD4+CD25' and CD4+CD25+ cells were sorted 
as Tconv and Treg cells, respectively. The results from these initial studies suggested that the 
two cell populations had a large degree of overlap in the tumour which was not present in the 
spleen. This would suggest that conversion of Tconv cells into Treg cells was plausible. 
However, a full interpretation of this initial data was difficult because the cells were sorted 
based on CD25. As discussed above, sorting the two populations based on CD25 is imperfect 
and contamination of both the Tconv and Treg cell populations was likely. Firstly, with this 
approach it was likely that CD4+CD25+Foxp3‘ Tconv cells were sorted into the Treg pool and 
secondly, CD4+CD25'Foxp3+Treg cells were sorted into the Tconv pool. It is also clear from
196
the data presented in Chapter 3 that the problem of contamination was likely compounded 
further by the fact that more activated CD4+CD25+Foxp3' Tconv cells are found within the 
tumour compared to the spleen. Thus, the contamination of the two populations was probably 
greater in the tumour than in the spleen and may have led to an increase in the level of 
overlap in the tumour compared to the spleen. Indeed, this appears to be the case, as when 
Tconv and Treg cells were later more stringently sorted based on Foxp3 using the 
Foxp3_GFP reporter mice much less overlap was observed between the two cell populations. 
Thus, it seems most likely that the reduction in the overlap was due to the improved sorting 
criteria.
In later experiments, where cells were sorted based on Foxp3 the degree of overlap between 
the two repertoires was consistently low. The highest degree of overlap between the TCR 
repertoires of Tconv and Treg cells was observed in the tumour of mouse 2 where 13.9% of 
the Treg TRBV13-2 TCR repertoire was found to overlap with the Tconv TCR repertoire. 
Other measurements of the similarity between the TCR repertoires of tumour infiltrating 
Tconv and Treg cells showed less overlap at 3.3% and 0.0%, in mouse 3 and mouse 4, 
respectively. The overlap between the Treg and Tconv TCR repertoires was also consistently 
low within other tissues. Thus it appears that the majority of the Treg repertoire does not 
overlap with the Tconv repertoire in both tumour and normal lymphoid tissue. In the 
TRBV13-2 analyses (but not the TRBJ2-5 analysis) a small increase was observed for the 
degree of overlap between the Tconv and Treg TCR repertoires in the tumour compared to 
the spleen or lymph node which may indicate that an increase in conversion occurs in the 
tumour. However, when all the TCR data were compiled the difference between the spleen or 
lymph node and the tumour was not statistically significant. Furthermore, on average, more
than 95% of the tumour infiltrating Treg TCR repertoire remained non-overlapping with the 
Tconv TCR repertoire.
Based on the hypothesis that a high degree of overlap would be observed if the Treg cells
arose through conversion, these data would suggest that the majority of Treg cells in the
tumour do not arise through conversion of Tconv cells. However, it may be difficult to assess
the level of conversion when looking at one time point. For example, if naive Tconv cells
entering the draining lymph node of tumour, encounter their cognate antigen, become
activated and upregulate Foxp3 immediately, very few of these potentially convertible cells
would exist within the Tconv population at the time of sampling. Thus, when the cells are
sorted late in the development of the tumour, many Tconv cells may have converted into Treg
cells and would therefore not appear in the Tconv repertoire as they have already upregulated
Foxp3. The kinetics of Foxp3 induction have been previously investigated in vitro (Selvaraj
and Geiger 2007). These studies show that the upregulation of Foxp3 in naive CD4+ T cells is
not immediate. It takes between 24 and 48 hours for detectable levels of Foxp3+ cells to
appear in these assays and between 3 to 4 days for more than 50% of the cells to convert.
furthermore, most studies suggest that tumour specific factors, for example an
immunosuppressive cytokine microenvironment, induce the conversion of Tconv cells into
Treg cells. If the conversion of Tconv cells into Treg cells is tumour specific an overlap in the
TCR repertoires of Treg cells from tumour and Tconv cells from the draining lymph node
would be evident. This would be observed even if once entering the tumour Tconv cells are
immediately converted. However, this was not observed. On average less than 1% of the
tumour Treg repertoire overlapped with the draining lymph node Tconv cell TCR repertoire
(Figure 4.23). Instead, the TCR repertoires of Treg cells from tumour were most similar to
the TCR repertoires of Treg cells from the draining lymph node. This was an important
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control in these experiments and supports the hypothesis that Treg cells traffic between the 
two sites and remain unconverted.
Previous investigations based largely on adoptive transfer of Tconv cells, despite showing
that conversion of conventional T cells into Tregs is possible, do not demonstrate the extent
to which conversion might occur in a natural context and whether it accounts for the large
enrichment of Tregs often seen in tumours (Liu et al. 2007, Valzasina et al. 2006, Zhou and
Levitsky 2007). Whilst the data in this thesis do not exclude conversion of Tconv cells as a
mechanism contributing to Treg cell enrichment in tumours, they do demonstrate, in the case
of a spontaneously developing tumour, that the majority of tumour-infiltrating Tregs probably
do not arise through conversion. Accurately measuring the true degree of overlap between
two populations is difficult. This is primarily due to the inherent diversity in the TCR
repertoire. This is particularly true for samples from the spleen and lymph nodes, however, a
large amount of diversity was also detected in the tumour infiltrating T cell populations. This
was, to some extent, not predicted, as expansions of T cells in immune responses to viruses
(for example CMV, EBV and Influenza) tend to be dominated by a limited number of clones
(Day et al. 2007, Miles et al. 2005, Khan et al. 2002, Price et al. 2005, Annels et al. 2000;
and personal communication with Dr Ian Humphreys and Professor David A. Price).
However, very few data on the diversity of T cell responses, particularly CD4+ T cell
responses to whole tumours have been reported. Given the vast diversity in the TCR
repertoires, the limited number (up to 100) of CDR3 sequences analysed may not provide a
true measurement of overlap since additional overlapping sequences may be present in the
fraction of the TCR repertoire not sequenced. A more accurate measurement of the degree of
overlap between two populations would be possible either if the two populations are clearly
dominated by a limited number of clonotypes or with exhaustive sequencing. Given that the
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TCR repertoire may contain many thousands of potential clonotypes, sequencing the required 
number of TCR sequences would be extremely expensive. However, with the advent of deep 
sequencing (Freeman et ah 2009) this may feasibly become cost effective.
In an attempt to overcome the problem posed by the vast diversity of the TCR repertoire, a 
focused analysis of the TCR repertoire was performed whereby a smaller subset of the TCR 
repertoire was analysed. The TRBJ2-5/TRBV13-2 subset was analysed instead of the whole 
TRBV13-2 subset. Using this approach, the ~50-100 analysed sequences covered a larger 
proportion of the TRBJ2-5/TRVJ13-2 repertoire since the potential diversity was reduced 
compared to the whole TRBV13-2 repertoire. Thus, a more in depth analysis of one particular 
subset was achieved. The diversity in this repertoire appeared reduced as fewer single 
sequences and more repetitive sequences were found. Indeed, it was estimated that 
approximately 36% of the potential TCR clonotypes was identified with this focused 
analysis, compared to approximately 10% in the previous TRBV13-2 analyses. Ultimately, 
the results of this focused analysis were very similar to the previous findings of the thesis. 
The Tconv and Treg TCR repertoires in the tumour were generally non-overlapping, 
supporting the view that the majority of tumour infiltrating Treg cells do not arise through the 
conversion of Tconv cells. However, even with this focused analysis, the repertoires were 
still diverse particularly in the spleen and lymph node. Furthermore, the TCR repertoire 
analysed using this method represents a limited sampling of the extensive TCR repertoire. 
Interestingly, the degree of overlap between the TCR repertoires of Tregs from the draining 
lymph node and Tregs from the tumour was higher with the TRBJ2-5/TRVB13-2 specific 
analysis in comparison to simply the TRJV13-2 analysis. This supports the notion that the in 
depth analysis improved the capacity to find any potential overlap between two repertoires.
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The degree of overlap between the TCR repertoires of Tconv and Treg cells has been 
previously investigated (Hsieh et al. 2004, Pacholczyk et al. 2006). Using mice with a fixed 
VP chain, Hsieh et a l (2004) found that the TRAV14 repertoires of CD4+CD25+ and 
CD4+CD25' cells overlapped by approximately 10-20%. Pacholczyk and colleagues (2006) 
compared the TCR repertoires of CD4+CD25+Foxp3+ and CD4+CD25 Foxp3' cells in 
transgenic (TCRmini) mice which express a single TCRp chain and a TCRa chain that allows 
for rearrangement of only a single Va (Va2.9) segment to one of two Ja (Ja26 and Ja2) 
segments and found that the TCR repertoires of these cells overlapped by 10-20%. 
Furthermore, they found that the highest degree of overlap was between the repertoires of 
TCRs found on thymocytes and peripheral T cells belonging to the same group of cells (70- 
80% for Foxp3‘ cells and 65% for Foxp3+ cells) suggesting that these cells are distinct 
populations both in the thymus and in the periphery (Pacholczyk et al. 2006). In this thesis, 
the degree of overlap between the TCR repertoires of the Treg and Tconv cell populations 
was lower than that reported by other groups which had used TCR-transgenic mice (Hsieh et 
al. 2004, Pacholczyk et al. 2006). This disparity is expected given the curtailed TCR 
repertoires found within these mice. In these models, a limited number of TCR structural 
combinations pass thymic selection resulting in a restriction in peripheral diversity and, 
accordingly, an increased chance of identify recurring overlapping clonotypes. The T cell 
dynamics during a natural tumour response in a TCR intact animal is considerably more 
complex considering the full 2xl06 (and 25x106 in humans) receptor pool available in mice 
(Arstila et al. 1999, Casrouge et al. 2000). In this thesis, non-TCR-transgenic mice were used 
to investigate whether the degree of repertoire overlap between the two T cell populations 
was significantly different in cells isolated from the tumour compared to lymphoid tissue.
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The analysis of the Tconv and Treg TCR repertoires was further scrutinised by Lathrop et al. 
(Lathrop et al. 2008). In this paper, the requirement for TCR engagement for Foxp3 
Hpregulation was considered when analysing the repertoires of the two cell types. The Tconv 
fccil population was analysed separately as CD44high (antigen experienced) and CD44low 
(naive) cells. In similarity to the reports mentioned above which analysed the whole Tconv 
pool (Hsieh et al. 2004, Pacholczyk et al. 2006), Lathrop et a l (2008) found that the TCR
§
repertoires of CD44h,gh Tconv and Treg cells were generally non-overlapping. The analysis of 
|H» TCR repertoires of Tconv and Treg cells in MCA tumour bearing could be improved by
I comparing the TCR repertoires of CD44hlghTconv and Treg cells. However, since the
1. . .  . . . . .
| majority (approximately 60%) of tumour infiltrating Tconv cells were found to be CD44
f
f (Figure 3.9 page 81) it seems unlikely that the similarity between TCR repertoires of Tconv 
and Treg cells from the tumour will change dramatically when further categorised based upon 
CD44 expression. In contrast, the percentage of Tconv cells that were CD44hlgh within the 
lymphoid tissues (spleen, draining and non-draining lymph nodes) was found to be only 
approximately 10-30% (Figure 3.9 page 81) thus a change in the similarity between the 
lymphoid Tconv TCR repertoire and other TCR repertoires may be seen. In particular the 
TCR repertoires of Tconv cells from the draining lymph node and tumour may be more 
similar when only antigen experienced, CD44hlgh Tconv cells are considered.
The findings in this Chapter are also similar to those of a study which analysed the degree of
conversion in self antigen-specific T cells in the context of a mouse model of type I diabetes
(Wong et al. 2007a). The TCRs of Treg and Tconv cells isolated from the pancreas and
pancreas-draining lymph nodes of BDC2.5/NOD TCR transgenic mice were distinct, thereby
indicating no role for conversion in response to a pancreatic autoantigen. Similarly, a more
recent study into the TCR repertoire and specificity of T cells in experimental allergic
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encephalomyelitis (EAE) concluded that, despite sharing autoantigen specificity, effector T 
cells and Treg cells had largely distinct TCR repertoires, similarly suggesting that conversion 
between these two populations was minor (Liu et al. 2009b). Thus, the combined results of 
these studies imply that tolerance in the context of autoimmunity and tumour immunity is 
achieved without substantial conversion of conventional T cells into Tregs.
In contrast, a role for conversion may exist in preventing immune responses to some foreign 
antigens such as those of commensal bacteria in the gut (induced tolerance). In the intestine, 
Ihe immune system must resist infection from occasional pathogens whilst maintaining 
tolerance to commensal flora and dietary antigens. The generation of Tregs by conversion 
from Tconv cells has been suggested as an important mechanism for establishing this 
tolerance to persistent antigens in the gut (Coombes et al. 2007). Interestingly, recent data 
suggests that the Foxp3 locus contains a dedicated (non-coding) region (CNS1) that controls 
the induction of Foxp3 in the periphery (Zheng et al. 2010). Although mice lacking CNS1 
had no defect in thymic production of Treg, cells from CNS1-deficient (but not CNS1- 
sufficient) mice were unable to induce Foxp3 and therefore generate Treg cells in gut- 
associated lymphoid tissues.
Using the accumulated data from TCR repertoire analyses it was possible to estimate the
sizes of the TCR repertoires of Tconv and Treg cells from tumour bearing mice. The
Michaelis-Menten equation was used for estimating the size of the TCR repertoires as it is
relatively simple to use and can be calculated using the statistical software package, Prism
(Graphpad). Numerous methods have also been used to estimate T cell diversity. Summary
statistics such as Simpson’s diversity and Shannon’s entropy indexes have been used as
measures of diversity in TCR repertoires (Ferreira et al. 2009, Venturi et al. 2007). However,
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*fhcse indexes provide limited information about the size of the TCR repertoire from which 
the sample was taken. One approach is to use a method which assumes that all clonotypes are 
equally represented within a sample. The MLE (maximum likelihood estimation) method is 
based on this assumption and been used to estimate the TCR repertoire diversity for various 
data sets (Casrouge et al. 2000, Barth et al. 1985, Hsieh et al. 2004). However, TCR 
repertoire samples usually show significant skewing therefore the assumption of this test is 
often not applicable. The abundance-coverage and incidence-coverage estimators take into 
account some heterogeneity in the clonality of a population and are therefore probably the 
most robust methods (Pacholczyk et al. 2006, Hsieh et al. 2004). Nevertheless, it is clear that 
none of these methods are considered ideal and new methods for estimating TCR diversity 
have been suggested (Venturi et al. 2007, Sepulveda, Paulino and Cameiro 2010).
To confirm the validity of the method used in this thesis (Michaelis-Menten) the size
estimates generated for each mouse were compared to the size estimates generated using the
abundance coverage estimator (ACE). Using the software package, Estimates (Colwell
2005), the ACE method was applied to estimate the diversity of the TCR repertoires of Tconv
and Treg cells from the spleen, lymph nodes and tumour of mouse 2 , mouse 3 and mouse 4.
A significant correlation (R2=0.7543, ***P=<0.0001) between the size estimates generated
using the two methods was found (Figure 4.31), indicating that the Michaelis-Menten and
ACE methods are comparable for estimating the size of the TCR repertoires. Although it has
been suggested that the Michaelis-Menten method is likely to underestimate the total size of
the repertoire (Magurran 2004), this was not consistent with the findings from the comparison
of the two methods. Overall, the size estimates made using the Michaelis-Menten method
may not be completely accurate, however, they provided a good estimate of the number of
TCR clonotypes that would be found within each repertoire and also the number of sequences
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Figure 4.31. Size estimates of TCR repertoires using Michaelis-Menten and ACE 
methods
The sizes (estimated number of clonotypes) of the TCR repertoires of Tconv and Treg cells 
from tumour bearing mouse 2 (A), mouse 3 (B) and mouse 4 (C) were estimated using the 
Michaelis-Menten (open bars) and ACE (filled bars) methods. The ACE method was applied 
using the statistical software package Estimates. Samples from spleens, non-draining lymph 
nodes (ND), draining lymph nodes (D) and tumours were analysed. The correlation between 
the size estimates generated using the two methods was also plotted and the Pearson’s r2 
value determined (D).
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that would be required to identify for example 90% of those clonotypes. The diversity 
estimates indicated that in the TRBV13-2 analyses only approximately 10% of the clonotypes 
were identified and when the TCR repertoire analysis was focused onto the TRBJ2- 
5/TRBV13-2 sequences approximately 36% of the potential clonotypes were identified. This 
finding supports the reasoning for focusing the TCR repertoire analysis using TRBJ2-5 and 
TRBV13-2 specific primers.
An interesting pattern that appeared from these size estimates was that the size of the Treg 
cell TCR repertoire was often smaller than the size of the Tconv cell TCR repertoire. The 
restriction of the Treg TCR repertoire was most consistently noticed within the tumour. The 
sizes of the Tconv and Treg TCR repertoires were found to be most similar within the non­
draining lymph node. This is in agreement with previously published data that suggests that 
the TCR repertoires of Treg cells and Tconv cells in naive mice are equally diverse (Hsieh et 
al. 2004, Pacholczyk et al. 2006). It has been suggested that high Treg TCR diversity ensures 
that self tolerance can be established and maintained. In support of this model, Ferreira et al. 
(2009) showed that the Treg TCR repertoire of non-obese diabetic mice was markedly 
restricted. Interestingly, a recent study by Adeegbe et al. (2010) demonstrated that when a 
severe breakdown in immune tolerance is induced (mice lacking IL-2R(3), control of 
autoimmunity is achieved by only a fraction of the Treg repertoire. However, individual mice 
exhibited unique patterns of skewing of the Treg TCR repertoire suggesting that a large 
diversity is necessary to ensure that self tolerance is readily established towards the random 
autoimmune cell(s) generated in each individual. The restriction of the Treg TCR diversity 
observed in MCA tumours may therefore resemble the response required to control 
autoimmunity.
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Due to the small size of the Treg TCR repertoire in the tumour in each of the analyses in this 
Chapter a relatively large proportion of the potential TCR clonotypes were identified. In mice 
2, 3 and 4 the average percentage of the potential Treg and Tconv TCR clonotypes that were 
actually identified was estimated to be 10%, 11% and 36%, respectively. However, it was 
estimated that in mice 2, 3 and 4 approximately 39%, 11% and 69% of the potential tumour 
Treg TCR clonotypes were identified, respectively. Therefore, it was estimated that the 
proportion of the potential tumour Treg TCR repertoire identified was often above average. 
This indicates that within the tumour the likelihood of identifying any potentially overlapping 
sequences was greater than within other locations where fewer of the potential clonotypes 
were identified. Furthermore, this strengthens the finding that very little of the tumour Treg 
TCR repertoire is overlapping with the Tconv TCR repertoire and therefore conversion of 
Tconv cells into Treg cells is unlikely to account for the accumulation of Treg cells within the 
tumour. Instead, it seems most likely that tumour infiltrating Treg cells derive from naturally 
occurring Treg cells. This finding is in agreement with Bui et al. (2006) who demonstrated 
that following adoptive transfer of Thy 1.2 CD4+CD25+ T cells into Thy 1.1 Treg depleted 
mice, the CD25+CD4+ cells within TILs derived mostly from the adoptively transferred 
Thy 1.2 naturally occurring CD4+CD25+ Tregs.
To examine the mechanisms that underlie Treg cell enrichment in tumours, the proliferation
and survival of Tregs and Tconv cells in TILs and lymphoid tissues were compared. The
expression of Ki67, a marker of proliferating cells, was analysed by flow cytometry. The
analysis of this molecule which is present during all active phases of the cell cycle has been
extensively used in the analysis of tumours in clinical laboratories (Scholzen and Gerdes
2000). It has also become widely used by immunologists using flow cytometry to analyse the
proliferating fraction of cell populations. The analysis of Ki67 provided a snap shot of the
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proliferative status of cells within tumour bearing mice. Tumour infiltrating Treg cells were 
found to be significantly more proliferative than tumour infiltrating Tconv cells as well as 
Treg cells from other locations.
A more traditional method for measuring proliferation is the use of Bromodeoxyuridine 
(BrdU). BrdU is incorporated into the DNA of cells as they divide, and hence can indicate 
any cell that has divided. By injecting BrdU directly into the mouse, Tconv and Treg cells 
that have recently divided would become stained. Since Ki67 is upregulated during all active 
phases of the cell cycle and BrdU is only incorporated following the S phase, Ki67 provides a 
more comprehensive measurement of the current proliferative state of a cell. However, it has 
also been suggested that Ki67 can be expressed in cells that are arrested in the cell cycle and 
therefore not actively proliferating (van Oijen et al. 1998). Therefore, to confirm the results 
of staining with Ki67, BrdU incorporation in tumour bearing mice is currently being 
examined in our laboratory. The incorporation of BrdU was previously used to compare the 
proliferation of CD4+CD25+ and CD4+CD25' cells from TILs and draining lymph node of 
mice with transplanted MCA sarcoma cell lines (Bui et al. 2006). These studies suggest that 
CD25+ Treg cells are more proliferative than CD25* Tconv cells in both the tumour and 
tumour draining lymph node. Furthermore, tumour infiltrating CD25+ cells were more 
proliferative than CD25+ cells from the draining lymph node. However, in this study Bui et 
al. (2006) did not separate these cells based on Foxp3 expression making a full interpretation 
of these data difficult.
Previous studies of Treg cell turnover have shown that Treg cells are more proliferative than
Tconv cells but are also more prone to cell death (Vukmanovic-Stejic et al. 2006). Given
these findings, attempts were made to measure the level of cell death within Tconv and Treg
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cells from tumour bearing mice. Firstly, the anti-apoptotic factor Bcl-2 was assessed by flow 
cytometry. In agreement with previous studies, in normal lymphoid tissue the level (MFI) of 
Bcl-2 expression and the percent of cells expressing Bcl-2 were found to be significantly 
lower in Treg cells than Tconv cells. However, within the tumour, both the percent of cells 
expressing Bcl-2 and the level of Bcl-2 were similar in the Tconv and Treg cell populations 
suggesting that in the tumour, Treg and Tconv cell turnover are similar. Since there are at 
least 12 members of the BCL-2 family which can contribute to induction or inhibition of cell 
death another method of measuring cell death was also investigated to support the findings of 
the Bcl-2 staining (Youle and Strasser 2008). For this purpose, Tconv and Treg cells were 
stained directly ex vivo with the cell viability dye 7-AAD. In the lymph node, a significantly 
higher percentage of the Treg cells were 7-AAD+ compared to Tconv cells, suggesting more 
Treg cells were dying than Tconv cells. However, in the tumour the opposite was observed, 
more Tconv cells than Treg cells were 7-AAD+ suggesting that Treg cells are less prone to 
die than Tconv cells in the tumour. This may reflect the nature of antigens, costimulation or 
cytokines found within the tumour microenvironment which favour Treg cell survival.
Accurately measuring cell death in vivo and ex vivo is considered difficult. Firstly, it is
thought that the intrinsic mechanisms for the removal of dead/dying cells are rapid (Kerr,
Wyllie and Currie 1972, Pamaik, Raff and Scholes 2000, Savill et al. 2002), therefore dying
cells are difficult to observe. Furthermore, once dissected from the mouse, it is thought that
the dynamics of cell death and regulation of cell death markers can alter in cells particularly
following extensive handling in the laboratory (Carbonari, Cibati and Fiorilli 1995,
Darzynkiewicz et al. 1997, Listman et al. 1998, Mattes 2007). Despite these caveats, staining
for cell death with Bcl-2 and 7-AAD was found to be quite consistent and the differences
between various groups reached statistical significance. Furthermore, the levels of these
210
markers were compared between the two different cell types which were stained together. 
Thus the Tconv and Treg cells that were compared were treated in exactly the same manner. 
Therefore, although the exact amount of cell death within the tissues may not be correct, and 
therefore comparisons between the various tissues cannot be accurately made, it is likely that 
the difference between the two cell types from the same location is authentic. To confirm 
these findings, work is currently underway within our laboratory to measure the level of 
Caspase-3 within tumour infiltrating Tconv and Treg cells by immunohistochemistry. Using 
this method, only minor disruption of the tissue occurs, and the time between dissection from 
the mouse and fixation is minimal allowing very little time for changes in the expression of 
markers for cell death, such as Caspase-3.
In summary, the results in this Chapter have shown that the conversion of Tconv cells into 
Treg cells is unlikely to account for the accumulation of Treg cells within the tumour tissue. 
However, Treg cells were found to proliferate more than Tconv cells in all sites examined 
and this difference was most significant in the tumour. Furthermore, in contrast to lymphoid 
tissue, the tumour microenvironment was seen to offer Treg cells protection against apoptosis 
as fewer dying Treg than Tconv cells were observed in the tumour. It is therefore reasonable 
to conclude that the enrichment of Tregs within the CD4+ TIL population is due to the tumour 
environment preferentially promoting proliferation and survival of Tregs. The causes for this 
are as yet unknown. This may reflect the nature of the antigens expressed by tumour cells. 
The antigens recognised by Treg cells remain largely unknown, however, there is some 
evidence to suggest that compared to Tconv cells, Treg cells preferentially recognize self­
antigens (Hsieh et al. 2004, Pacholczyk et al. 2006). Most antigens expressed by cancer cells 
and recognised by the immune system are non-mutated self antigens (reviewed in Houghton
and Guevara-Patiflo 2004), thus Tregs may receive stronger antigen-driven signals than
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conventional T cells in the tumour environment. The stimulation of Treg cells may further 
support Treg proliferation and survival through the secretion of cytokines such as IL-2 and 
TGFp.
The highly proliferative status of tumour infiltrating Treg cells and lack of overlap in the 
Treg and Tconv TCR repertoires suggest that the accumulation of Treg cells in the tumour is 
through the expansion of naturally occurring T cells. A restriction in the diversity of the 
tumour Treg TCR repertoire was noted. This restriction is in agreement with the suggestion 
that these cells are expanding. Nevertheless, it is clear that the diversity of the tumour 
infiltrating Treg population remains large, suggesting many Treg cell clones are stimulated to 
expand. There was no evidence that a restriction in the Tconv TCR repertoire occurs in 
tumour bearing mice. This suggests that the strong stimulation of particular Tconv cell clones 
does not occur, and may also signify that a robust anti-tumour immune response is not 
generated in these mice. In agreement with this hypothesis, the proportion of Tconv cells 
expressing Ki67 in the tumour was similar to the proportion of Tconv cells expressing Ki67 
in lymphoid tissue. However, it was demonstrated in Chapter 3 that the immune response to 
MCA tumours is primarily associated with the effects of CD8+ T cells rather than CD4+ T 
cells. An analysis of the TCR repertoire of tumour infiltrating CD8+ T cells may therefore be 
more indicative of the anti-tumour immune response generated in MCA tumours. Early data 
generated from our laboratory suggest that the TCR repertoire of CD8+ T cells isolated from 
MCA tumours is also diverse.
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Chapter 5 — Final Discussion
For this thesis I have investigated the accumulation, phenotype and function of CD4+ Foxp3+ 
regulatory T cells in chemically induced (MCA) mouse tumours. The results of these 
experiments indicate that control of tumour growth following Treg cell depletion is 
dependent on CD8+ cells. In tumour bearing mice the ratio of Treg cells to conventional 
CD4+ T (Tconv) cells and particularly CD8+ T cells altered within tumour tissue to favour 
immune suppression. Furthermore, tumour infiltrating Treg cells displayed a phenotype 
associated with immunosuppression whereas only a small fraction of tumour infiltrating 
Tconv and CD8+ T cells appeared activated. Together these findings support the hypothesis 
that Treg cells accumulate within tumours and gain control of T cells preventing anti-tumour 
immunity. To investigate how Treg cells accumulate within MCA tumours a detailed analysis 
of the TCR repertoires of Tconv cells and Treg cells from tumour bearing mice was 
performed. Little overlap between the repertoires of these cells was found suggesting that the 
majority of tumour infiltrating Treg cells do not arise through the conversion of Tconv cells. 
Instead, it was found that the proliferation and survival characteristics of tumour infiltrating 
Treg cells favoured their accumulation over Tconv cells. These findings support the rational 
for inhibition of Treg cells in the treatment of cancer (reviewed in Curiel 2008, and Zou
2006). They also indicate that it is necessary to investigate tumour specific factors which 
' cause their preferential proliferation and survival as this may enable manipulation of these 
cells for therapy.
The role of the immune system in preventing tumour growth in humans has been
controversial (reviewed in Dunn et al. 2002). It has been demonstrated that tumour reactive T
cells can be isolated from the tumours and blood of patients with cancer (Lee et al. 1999,
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Germeau et al. 2005, Coulie et al. 1992, Mazzocchi et al. 1994). However, the reasons for the 
inability of tumour reactive immune cells to eliminate tumours in cancer patients remain to be 
folly determined. The findings from this thesis and many other studies suggest that Treg cells 
can limit the immune response to tumours (reviewed in Betts et al. 2006). It has also been 
shown that many other mechanisms of immune suppression exist in tumours (reviewed in 
Rabinovich, Gabrilovich and Sotomayor 2007). The recruitment of myeloid derived 
suppressor cells (MDSC) to tumours may contribute to hampering an effective anti-tumour 
immune response (reviewed in Seraftni, Borrello and Bronte 2006, and Kusmartsev and 
Gabrilovich 2006). These cells suppress cellular immune responses primarily through the 
production arginase-1 and nitric oxide synthase 2A (reviewed in Gabrilovich and Nagaraj 
2009). Tumour cells may also secrete soluble factors with direct immunosuppressive effects 
such as IL-10, TGFbeta, and IDO or express receptors/ligands with immune inhibitory effects 
(reviewed in Kim et al. 2006b, Raffaghello et al. 2004, Teicher 2007, Uyttenhove et al. 2003, 
reviewed in Muller and Prendergast 2007). In addition, tumours can evade immune detection 
through downmodulation of the protein machinery involved in antigen processing and 
presentation such as MHC and TAP (reviewed in Seliger, Maeurer and Ferrone 2000, Algarra 
et al. 2004, Vitale et al. 1998, Kaklamanis et al. 1995, Cromme et al. 1994). Therefore, 
evidence suggests that tumours can evade immune detection and elimination through the 
induction of multiple mechanisms which lead to local immune suppression and the outgrowth 
of non-immunogenic cancer cells. This poses a significant obstacle to generating effective 
immunotherapy to cancer. To overcome the immune suppressive environment within tumours 
and generate a successful immune response to cancerous cells may require the inhibition of 
several mechanisms. Indeed preliminary experiments using Foxp3_DTR mice have shown 
that in a number of subjects the complete removal of Treg cells in MCA tumour bearing mice 
does not induce any obvious signs of tumour control (my own unpublished observation).
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One approach to cancer immunotherapy which shows promise is cancer vaccination 
(reviewed in Emens 2008). Cancer vaccines are designed to awaken the immune system to 
the presence of cancer by presenting it with antigens associated with tumour cells. To date, a 
limited number of cancer vaccines have been approved for use (Goldman and DeFrancesco 
2009). Numerous other cancer vaccines have failed to show clinical efficacy (Goldman and 
DeFrancesco 2009). It is hoped that a more comprehensive understanding of tumour 
immunology will allow for the design of more successful cancer vaccine approaches. The 
discovery and characterisation of tumour antigens which can generate robust immune 
responses forms a vital part of this understanding. Many of the antigens used in cancer 
vaccines are tumour-associated antigens: antigens expressed by tumours but also expressed 
by other tissues at lower levels. Since these are self antigens, tolerance to these antigens has 
been previously established by the host. This may have contributed to the failure of many 
previous trials. Breaking the tolerance to these antigens, but also avoiding detrimental 
autoimmune disease may be necessary for the success of the cancer vaccine. Depletion or 
inhibition of Treg cells may aid the reversal of tolerance although the side effect of 
autoimmunity may also remain. Alternatively, to avoid the induction of autoimmunity, 
vaccination with tumour-specific antigens (antigens expressed only by tumour cells) may also 
improve immunotherapy. These antigens normally consist of mutated self proteins, but may 
be considered as immunologically foreign. Unfortunately, however, expression of the same 
tumour-specific antigen by the tumours of many patients appears to be rare (Parmiani et al.
2007). This makes the design of a vaccine to such antigens less attractive as only a fraction of 
patients may respond to treatment. Furthermore, it still remains that the body has already 
been exposed to the antigen so it is likely that the immune system has become tolerant to the 
antigen targeted. Therefore, breaking tolerance to tumour-specific antigens may also be 
required for the success of cancer vaccines which target them.
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In order to generate the best therapeutic outcomes in cancer patients it appears that 
combinatorial therapies will be required. Results from James Allison’s lab demonstrate that 
CTLA-4 blockade in combination with a vaccine consisting of irradiated tumour transduced 
to express the cytokine GM-CSF (Gvax) can eradicate established tumours in mice (van Elsas 
et al. 2001, van Elsas, Hurwitz and Allison 1999, Hurwitz et al. 1998). Interestingly, this 
therapy causes priming of effector T cells through Gvax and removal of inhibitory effects by 
CTLA-4 blockade which synergise to increase the intratumour frequency and activity of 
effector T cells resulting in tumour rejection (Quezada et al. 2006). In humans, anti-CTLA-4 
treatment also resulted in an increase in anti-tumour immunity when given to patients 
previously vaccinated with Gvax (Hodi et al. 2003). Furthermore, anti-CTLA-4 treatment in 
conjunction with vaccination with tumour-antigen derived peptide also resulted in tumour 
regression in patients with metastatic melanoma (Phan et al. 2003). However, this treatment 
was also associated with the induction of autoimmunity in a number of patients indicating the 
importance of CTLA-4 in regulating tolerance to self antigens (Phan et al. 2003).
Adoptive cell therapy (ACT) represents another potential approach for immunotherapy of 
cancer (reviewed in June 2007a, June 2007b). This involves the infusion of anti-tumour 
lymphocytes, often in large numbers, to cancer patients. The latest studies in humans have 
shown impressive response rates (Dudley et al. 2008). More recent ACT regimes have 
combined ACT with the administration of irradiaton, lymphodepleting agents, vaccines or 
growth factors that aid the in vivo impact of the transferred cells (Dudley et al. 2008, 
reviewed in Rosenberg and Dudley 2009). The immunosuppressive effect of Treg cells is 
thought to hamper the effectiveness of adoptively transferred anti-tumour cells (Antony and 
Restifo 2005). Animal studies suggest that a major effect of lymphodepletion is the removal 
of suppressive cells such as Treg cells (Klebanoff et al. 2005).
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Of major importance for the success of immunotherapeutics such as ACT and cancer 
vaccination is the determination of which antigens are recognised by tumour infiltrating Treg 
cells and tumour infiltrating Tconv/CD8+ T cells. There is evidence to show that vaccination 
of tumour antigens may expand populations of Treg cells (Nishikawa et al. 2005, 
Chakraborty et al. 2004, Wang et al. 2004, Zhou, Drake and Levitsky 2006). Therefore 
careful selection of antigens and/or epitopes for vaccination is required to avoid simultaneous 
induction of Treg cells. Epitope mapping of tumour infiltrating T cells including Treg cells 
will uncover these details. However, as the results of Chapter 4 demonstrate the diversity of 
the T cell repertoires of tumour infiltrating Treg cells and in particular Tconv cells may be 
large. Consequently it is likely that numerous epitopes and antigens which stimulate tumour 
infiltrating T cells exist in tumours making comprehensive epitope mapping demanding. 
Clearly, the TCR repertoires of T cells infiltrating human tumours must be determined to 
know if the large diversity observed in MCA tumours also exists in other tumours. The 
results of Chapter 4 indicate that the TCR repertoires of tumour infiltrating Tconv cells and 
Treg cells are distinct, suggesting that they recognise different epitopes. This would suggest 
that careful selection of epitopes for vaccination or in vitro stimulation of cells for ACT will 
allow for expansion of Tconv cells and not concurrent stimulation of Treg cells. In 
accordance with the findings in this thesis, a recent study of T cell responses in patients with 
colorectal carcinoma demonstrated that Treg and Tconv cells tend to recognise distinct 
antigens (Bonertz et al. 2009). However, in contrast Vence et al. (2007) demonstrated that 
patients with metastatic melanoma contain Treg cells that recognize tumour antigens known 
to also stimulate Tconv cells and CD8+ T cells. This finding was further corroborated by 
recent findings which showed that two tumour antigen derived peptides known to stimulate 
CD4+ Th cells could also stimulate Tregs (Fourcade et al. 2010). Collectively, these studies
i n
demonstrate the complexity of immune responses to tumours and highlight the necessity for 
further investigation of multiple cancer types.
In this thesis, the TCR repertoire of CD8+ T cells was not determined. These cells were 
identified as being important for anti-tumour immune responses (following Treg cell 
depletion). It would therefore be interesting to determine the TCR repertoire of tumour 
infiltrating CD8+ T cells. Of particular interest would be the diversity of the TCR repertoire 
of tumour infiltrating CD8+ T cells. A large diversity in the TCR repertoire of tumour 
infiltrating Tconv cells was observed in this thesis. This suggests that the expansion of 
particular Tconv clones was not induced in tumours. This is also corroborated by the finding 
that the majority of tumour infiltrating Tconv and CD8+ T cells display no signs of activation 
and that the majority of tumour infiltrating Tconv are not proliferating. Several reasons for 
this may exist. Firstly, the diverse TCR repertoire may reflect low avidity interactions 
between the T cells and target resulting in poor stimulation (Price et al. 2005). Alternatively, 
the milieu of costimulatory factors and cytokines within the tumour may result in suboptimal 
stimulation and a lack of clonal expansion (Smith-Garvin, Koretzky and Jordan 2009). Clonal 
expansion of anti-tumoural Tconv and CD8+ T cells may allow for tumour regression. 
Therefore it is necessary to determine the factors which prevent this expansion. The 
suppressive effects of Treg cells may contribute to preventing the proliferation of anti-tumour 
T cells and thus therapeutic removal of Treg cells may allow for clonal expansion of T cells 
and subsequently tumour regression.
It is evident that the phenotype of Treg cells overlaps significantly with that of other tumour
infiltrating T cells, in particular Tconv cells (presumably following their activation). This
presents a major problem for therapeutic targeting of Treg cells. Any approach to deplete
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Treg cells through targeting the surface markers described herein are likely to also cause 
simultaneous depletion of activated anti-tumour Tconv and CD8+ T cells. Therefore the 
identification of Treg cell specific surface molecules which allow for their exclusive 
depletion remains paramount for this approach to be successful. Current treatments which 
target Treg cells through the CD25 receptor, such as ONTAK (Barnett et al. 2005), may not 
show significant efficacy due to this problem. An alternative approach which may circumvent 
this is to limit the preferential accumulation of Treg cells within tumours, for example, by 
targeting tumour specific factors which cause their preferential proliferation and survival. The 
particular antigens, cytokines or costimulatory factors found within the tumour environment 
which mediate this remain to be determined.
In this thesis, two potential mechanisms for Treg cell accumulation in MCA tumours were 
investigated, namely conversion of Tconv cells into Treg cells and preferential 
proliferation/survival of Treg cells. An additional mechanism of accumulation which was not 
investigated in this thesis was the preferential recruitment and/or retention of Treg cells in 
tumours. For this purpose the expression patterns of chemokines and chemokine receptors on 
T cells in MCA tumour bearing mice could be examined. High expression levels of 
chemokine receptors may allow Treg cells to accumulate and be retained within tumour 
tissue more readily. Two independent studies, one of B-cell non-Hodgkin lymphoma the 
other of ovarian carcinoma, have found that that tumours can produce the chemokine CCL22 
which attracts CCR4+ Treg cells into tumour tissue (Curiel et al. 2004, Yang et al. 2006). 
Furthermore, Curiel et al. (2004) utilised NOD/SCID mice to demonstrate that the in vivo 
migration of human Treg cells to transplanted human ovarian tumours was dependant on 
CCL22. The potential role for CCL22 and CCR4 expression should be investigated in the 
recruitment of Treg cells into MCA tumours and more importantly, other human tumours.
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As mentioned above, mice specifically depleted of Treg cells succumb to severe autoimmune 
disease within 7-14 days (Kim et al. 2007). Therefore, any approach to remove Treg cells is 
likely to be met by the induction of autoimmunity. To prevent autoimmune disease partial 
Treg cell depletion may be more efficacious. Alternatively, this may be better achieved 
through tumour specific ablation of Treg cells. However, the development of tumour specific 
targeting drugs represents another significant obstacle to successful cancer treatment. Finally, 
it is thought that tumours develop through a Darwinian-like process - selecting less 
immunogenic variants over time (reviewed in Dunn et al. 2004). Therefore, the late stage 
tumours targeted in cancer vaccinations and ACT approaches may not be susceptible to 
immunotherapy as they have selected for variants which are no longer recognisable by the 
immune system. Thus, the window of opportunity for successful immunotherapy may be 
early in tumour development which may be significantly earlier than the time of tumour 
discovery and treatment.
In conclusion, over the last few decades great strides in understanding tumour immunology 
have allowed for the development of immunotherapies for the treatment of cancer. These 
therapies have shown real promise, but have been met by significant obstacles limiting their 
clinical effectiveness. The suppressive effect of regulatory T cells appears to represent one 
such obstacle. Further studies are necessary to elucidate the interactions between the immune 
system and cancer and to continue the improvements in immunotherapeutic strategies. I 
remain cautiously optimistic that the immune system will one day be utilised for the 
treatment of significant numbers of cancer patients.
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Figure Al. Staining of lymphocytes from tumour bearing mouse with anti-CD3 and 
anti-CD4 antibodies.
The percercentage of lymphocytes expressing CD3 and CD4 were deteremined by flow 
cytometry. Single cell suspensions from the spleens, draining lymph node (D), non-draining 
lymph node (ND) and tumours of a tumour bearing mouse were stained with conjugated 
antibodies against CD3 and CD4 and analysed using a flow cytometer.
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Figure A2. Expression of CD45R (B220) and NK1.1 on lymphocytes in tumour bearing 
mouse.
Single cell suspensions of spleen, non-draining lymph node (ND LN), draining lymph node 
(D LN) and tumour were stained with anti-CD4, anti-CD8, anti-CD45R(B220) and anti- 
NK1.1 antibodies and analysed by flow cytometry. Lymphocytes (gated based on FSC/SSC) 
were further categorised into CD4+ single positive, CD8+ single positive, and CD4 CD8‘ 
populations. The percentage of cells expressing CD45R(B220) and NK1.1 within these 
populations were determined.
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Figure A3. TGFp containing MCA-induced tumours
Serial sections of spleen (A) and tumour tissue (B) from mice bearing MCA induced tumours 
were stained with TGFp (grey) and Foxp3 (brown) -specific antibodies.
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Figure A5. TRBV usage by CD4+FOXP3+ Treg cells from spleen and tumour.
Splenocytes and single cell suspensions of tumour tissue were stained with anti-CD4, - 
FOXP3 and a series of anti-TCRvp antibodies specific to TRBV 2, 13-1/2, 13-3, 15 and 16. 
The percentage of CD4+Foxp3+ Treg cells that expressed TRBV 2 (A), 13-1/2 (B), 13-3 (C), 
15 (D) and 16 (E) is shown for spleen and tumour.
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Figure A6. TRBV and TRBJ usage of CD4FOXP3+ Treg and CD4+FOXP3 Tconv 
usage in tumour bearing mice.
T conv (C D 4+Foxp3') and Treg (C D 4 +Foxp3+) ce lls  w ere sorted from single cell suspensions 
o f  sp leen, non draining lymph node and tum our tissu e. TCR repertoire analysis was 
perform ed using 5 ’RACE. Graphs sh ow  the T R B V  (A , C, & E) and TRBJ (B , D, & F) usage 
from the TCR sequence data obtained from T con v (open bars) and Treg (filled bars).
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